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Chapter 1
Hearing is very important in everyday life. Humans depend on their hearing in
a number of respects, such as for communication, socializing, learning, listen-
ing and to be warned for approaching danger. So when hearing is lost, it can
have a disabling effect on a person’s life. It has been estimated that in the
Netherlands > 1 million people have an average hearing loss of at least 35 dB
at the frequencies involved in speech perception (1, 2, and 4 kHz). In general,
two types of hearing loss can be distinguished: conductive and sensorineural
hearing loss. Conductive hearing loss is due to a blockage of the anatomical
cascade that conducts the sound waves from the outer to the inner ear.
Examples are middle ear infections, perforation of the eardrum, and otosclero-
sis, a disorder in which the stapes may become immobile because of exces-
sive growth of the bone. The other type of hearing loss is called
“sensorineural” and refers to damage of the cochlea and/or auditory nerve.
Sensorineural hearing loss can be induced by aging (presbycusis), loud music
or noise, viral or bacterial infections and drugs (such as aminoglycoside antibi-
otics or the anti-cancer drug cisplatin). 
In this thesis will be investigated whether the side effects of cisplatin upon the
auditory system can be reduced or even prevented.
The peripheral auditory system
The peripheral auditory system can be subdivided into three parts: the outer,
middle, and inner ear. The outer ear consists of the auricle and the external
auditory canal and plays a role in sound localization, partly by frequency-selec-
tive modification of the sound wave, while it is transferred to the tympanic
membrane (eardrum). Subsequently, these acoustic vibrations progress along
the tympanic cavity (= middle ear) via the cascade of three tiny ossicles: the
malleus (hammer), the incus (anvil) and the stapes (stirrup). Since there will
be an energy loss when sound is transferred directly from air to the fluid in the
cochlea, the ossicles amplify the sound and transfer the sound-induced vibra-
tions via the stapes to the oval window, efficiently converting the sound waves
into vibrations of the cochlear fluids.
The cochlea, which together with the vestibular apparatus comprises the inner
ear (Fig. 1A) is responsible for the transduction of the sound-induced vibra-
tions into electrochemical impulses in the auditory nerve. The cochlea con-
sists of a fluid-filled spiraling tube that progressively diminishes in diameter
towards the apex. In a cross section of the cochlea (Fig. 1B) the tube seems to
consist of three scalae: the scala vestibuli, the scala tympani, and the scala
media. 
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At its base, the scala vestibuli is sealed off by the oval window membrane, to
which the stapes is connected. The scala tympani is closed at its base by
another thin elastic membrane: the round window membrane. The scala tym-
pani and the scala vestibuli are in open connection at the apex of the cochlea
by an opening known as the helicotrema. In between these two compart-
ments lies the scala media, which is separated from the scala vestibuli by
Reissner’s membrane and from the scala tympani by the basilar membrane.
On top of the latter is situated the organ of Corti, which contains ±16000
receptor cells (hair cells).
The scala tympani and scala vestibuli contain perilymph, which is like normal
extracellular fluid in composition and is at or near ground potential. The scala
media contains endolymph, which is more like intracellular fluid with high lev-
els of K+ and low levels of Na+. K+ provides the major charge carrier for sen-
sory transduction in the hair cells (Wangemann, 2002). The electrolyte
composition and potential of the endolymph (+ 80 mV) is regulated by an
energy-consuming mechanism involving multiple ion transport processes in
12
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Figure 1: A. The structure of the human inner ear, containing the vestibular apparatus and the cochlea. B. 
Cross section of the cochlea that shows the arrangement of the three scalae: the scala tympani (ST), scala vestibuli
(SV) and scala media (SM). The stria vascularis (StV) is situated on he lateral wall of the scala media. SGN: Spiral
ganglion cells; BM: basilar membrane; RM Reissner’s membrane. C. Detailed structure of the organ of Corti, which
contains the receptor cells: outer hair cells (OHCs) and inner hair cells (IHCs). TM: tectorial membrane. 
the stria vascularis located in the lateral wall of the cochlea. The stria vascu-
laris is a complex, multilayered structure, containing three layers of different
cell types. Facing the endolymphatic space is a luminal layer of marginal cells,
which are characterized by the presence of numerous basolateral membranes
that are rich in mitochondria. The middle layer of the stria vascularis is com-
posed of the capillaries and intermediate cells. Facing the spiral ligament there
is a layer of multiple flat, basal cells. 
The sensory epithelium of the inner ear, the organ of Corti, (Fig. 1C) is posi-
tioned on top of the basilar membrane. It contains two types of hair cells: the
outer hair cells (OHCs) and the inner hair cells (IHCs). The OHCs are arranged
in three rows and the IHCs in a single row. Both types contain a bundle of hair-
like structures, the so-called stereocilia, on the surface facing the scala media.
The tops of the stereocilia of the OHCs are inserted into holes in the tectorial
membrane. When a sound-induced vibration reaches the cochlea, the basilar
membrane moves up and down because of differences in the fluid pressure
between the scala vestibuli and the scala tympani. This movement of the basil-
ar membrane is accompanied by a shearing motion between the organ of
Corti and the tectorial membrane, causing the stereocilia to bend. In response
to these movements the hair cells generate a stream of electrical signals that
code the frequency, intensity and duration of the sound. The electrical signals
are generated in both IHCs and OHCs, but the neural information predomi-
nantly originates from the IHCs, which receive 90-95% of the afferent nerve
fibers (Spoendlin, 1972). The signals are transported through the eighth cranial
nerve (vestibulocochlear nerve) to the brain. The OHCs are responsible for the
sensitivity and frequency selectivity of the cochlea. It is thought that OHCs can
generate forces, by actively contracting and relaxing, enhancing the basilar
membrane motion (Brownell et al., 1985). 
Several factors, such as noise, bacteria, viruses, aging, drugs and other chemi-
cal agents, may cause hearing loss (ototoxicity). Some of the clinically applied
ototoxic agents, such as aminoglycosides and cisplatin, have such a critical
role in the treatment of serious, life-threatening diseases that the ototoxic risk
can considered to be of less importance. 
Cisplatin
The biological activity of cis-diamminedichloroplatinum (II) or cisplatin (Fig. 2)
was discovered in 1965 by Rosenberg and co-workers during their studies to
the effects of an electric current on bacterial growth. They noticed that an
electrical field caused inhibition of Escherichia coli cell division (Rosenberg et
13
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al., 1965). Further investigation indicated that the active agents responsible for
this effect were platinum salts, which were produced at the electrode during
electrolysis (Rosenberg et al., 1967). Several platinum complexes were tested
for their biological activity and some of them, including cisplatin, suppressed
cell division and induced filamentous growth of bacteria (Howle and Gale,
1970), which was known to be an indicator of DNA damage. 
Therefore, it was plausible to assume that cisplatin would also interfere with
cell division in eukaryotes and subsequent studies revealed that cisplatin treat-
ment indeed results in arrested growth of tumors. Surprisingly, the trans-iso-
mer of cisplatin had no effect on tumor growth (Rosenberg et al., 1969).
The first clinical trials with cisplatin
started in the 1970s. Nowadays, cis-
platin is a widely used antineoplastic
agent. Cisplatin-based combination
chemotherapy displays significant
efficacy in the treatment of testis
tumors, ovarian carcinoma, squa-
mous cell carcinoma of the head and
neck, and non-small-cell carcinoma
of the lung. This anti-tumor effect is
due to a covalent binding between
the platinum atom and genomic or
mitochondrial DNA. Once cisplatin
enters the cell the chlorine atoms are
replaced by water, resulting in the formation of a positively charged aquated
species that can react easily with nitrogen or sulphur atoms in intracellular
macromolecules to form protein-, RNA-, or DNA-adducts. If there is another
potentially reactive site nearby, cisplatin can react further to form intra- and
inter-strand crosslinks (Kartalou and Essigmann, 2001), eventually leading to
apoptotic (programmed) cell death of tumor cells. The clinical use of cisplatin,
however, is limited by dose-dependent side effects, such as renal dysfunction,
peripheral neuropathies, hearing loss, nausea, vomiting, and myelosuppres-
sion. Severe nephrotoxicity was the most important dose limiting finding in
early clinical trials. With forced diuresis, this side effect has become more
manageable, leaving peripheral neuropathies and ototoxicity as the major side
effects of concern. 
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Figure 2: chemical structure of cisplatin
Cisplatin-induced sensory peripheral neuropathy
Peripheral neuropathy is one of the most commonly encountered side effects
of cisplatin. It is dose dependent and may occur upon exposure to amounts as 
low as 150 mg/m2 (Kopelman et al., 1988; Laurell and Borg, 1988). The extent
of the neurotoxic effects is closely related to the total cumulative drug dose
and dosage schedule, but it also depends on the concentration of the single
dose administered. Significant neurotoxicity will always occur when patients
receive more than 300 mg/m2 cisplatin (Walsh et al., 1982; Cersosimo, 1989).
The first clinical signs indicating cisplatin-induced peripheral neuropathy are
numbness, tingling, loss of ankle jerks and painful paresthesia in the hands
and feet. With further treatment loss of vibration sense, reduction in sensibility
to touch or pain and decrease in position sense of the affected areas may
develop (Thompson et al., 1984; Cersosimo, 1989). No damage to the motor
system has been observed. The neurotoxic effect of cisplatin is limited to the
sensory system (Roelofs et al., 1984; Thompson et al., 1984). Cisplatin-induced
sensory neuropathy shows a typical delayed time-course, which often reaches
its maximum 1-4 months after the last cycle of cisplatin chemotherapy
(Hovestadt et al., 1992). Neurophysiological studies have demonstrated that
cisplatin causes decreased amplitudes of the sensory nerve action potential,
slowing down of sensory nerve conduction velocity and prolongation of sen-
sory nerve latency (Cersosimo, 1989). Histological studies have shown sensory
root ganglia disruption, loss of large myelinated fibers, axonal degeneration
and degeneration of myelin sheaths (Roelofs et al., 1984; Thompson et al.,
1984; Gregg et al., 1992). In animal studies, the electrophysiological and patho-
physiological pattern of cisplatin-induced peripheral neuropathy is similar to
that seen in patients. Cisplatin largely affects sensory nerve structure and func-
tion. Preferential toxicity is found for large-diameter neurons and propriocep-
tive sensory modalities, while motor nerves are spared (Muller et al., 1990;
Apfel et al., 1992; Cavaletti et al., 1994; Cece et al., 1995). 
Cisplatin-induced ototoxicity
Clinical studies
The ototoxic effect caused by cisplatin in humans is characterized by a 
bilateral, high-frequency sensorineural hearing loss (changes in thresholds at 4
to 8 kHz), usually associated with tinnitus. After prolonged drug use, hearing
loss can progress to the speech frequency range, which is from 1-4 kHz 
(De Oliviera, 1989; Schweitzer, 1993). The incidence of cisplatin-induced 
ototoxicity ranges from 11 to 91%, depending on the mode of drug administra-
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tion, dosage per treatment and cumulative dose (De Oliviera, 1989; Waters et
al., 1991). Also, age and pre-existing hearing loss can influence the severity of
cisplatin ototoxicity (Fausti et al., 1984). Bolus injections of 60 mg/m2, adminis-
tered once a week, have been shown to cause significant threshold differ-
ences after 6-12 months of treatment (Aguilar-Markulis et al., 1981). At
cumulative doses of 270 mg/m2 the first significant changes in auditory thresh-
old appear, especially at the high frequencies (Schaefer et al., 1985). At doses
of more than 450 mg/m2, 88% of the patients show a high-frequency hearing
loss (> 4 kHz) (McHaney et al., 1983). Only sporadically (incomplete) recovery
of cisplatin-induced hearing loss has been reported (Aguilar-Markulis et al.,
1981; Vermorken et al., 1983; Melamed et al., 1985; Laurell and Jungnelius,
1990). Histopathological studies in humans have shown loss of OHCs and IHCs
in the basal turn of the cochlea, degeneration of the stria vascularis, significant
decrease in the number of spiral ganglion cells, and damage to the cuticular
plate (Wright and Schaefer, 1982; Strauss et al., 1983; Hinojosa et al., 1995;
Hoistad et al., 1998). 
Experimental studies 
In vitro cisplatin-models generally concern the toxicity of cisplatin with respect
to isolated cochlear OHCs (Saito et al., 1991, 1996; Sha et al., 2001; Devarajan
et al., 2002) and cochlear explants (Clerici et al., 1996; Zheng and Gao, 1996;
Kopke et al., 1997; Liu et al., 1998). However, most of the studies about the oto-
toxic effects of cisplatin have been performed in vivo in rodents: e.g., hamsters
(Melamed et al., 2000; Kaltenbach et al., 2002), chinchillas (Ford et al., 1997;
Tsukasaki et al., 2000), gerbils (Sie et al., 1997, 1999; Alam et al., 2000), rats
(Laurell et al., 1995, 1997; Meech et al., 1998; Hatzopoulos et al., 1999, 2001,
2002), guinea pigs (Tange, 1984; Schweitzer et al., 1986; Kohn et al., 1988;
Laurell and Engström, 1989, Laurell and Bagger-Sjöbäck 1991b; Schweitzer,
1993; Saito et al., 1994a, b; 1997a, b; Kohn et al., 1997; De Groot et al., 1997;
Cardinaal et al., 2000a-c; Klis et al., 2000, 2002), and sporadically in other mam-
mals such as dogs (Sockalingam et al., 2002) and rhesus monkeys (Stadnicki
et al., 1975). In these studies cisplatin was administered by intraperitoneal
injection at doses ranging from 0.75 to 4 mg/kg given repeatedly one to five
times per week for a total of 1-8 weeks or as a single dose of 5-18 mg/kg by
intraperitoneal injection or intravenous infusion. 
The estimation of the onset of ototoxicity has been performed by measuring
the auditory brain stem response (ABR), electrocochleography (ECochG) or
by measuring the otoacoustic emissions (OAE). In animals the electrophysio-
logical and pathophysiological pattern of cisplatin-induced ototoxicity is simi-
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lar to that seen in patients. Cisplatin induces a dose-related permanent sen-
sorineural hearing loss starting at the high frequencies. Pathophysiological
studies in guinea pigs have shown that chronic cisplatin administration leads
to loss of OHCs, and at high doses also to loss of IHCs, with those in the basal
turn more severely affected than the ones in the middle and apical turns
(Nakai et al., 1982; Tange, 1984, Hoeve et al., 1988; Saito and Aran, 1994b;
Cardinaal et al., 2000a). Laurell and Bagger-Sjöbäck (1991a) have shown that
the morphological changes in the cochlea of guinea pigs after cisplatin expo-
sure occur in three stages. The first stage includes disturbance of the support-
ing cells surrounding the OHCs. The second stage was characterized by
degeneration of the OHCs; one of the first signs is loss of stereocilia and intra-
cellular vacuolation. The IHCs usually remain intact until all the OHCs have
degenerated. In the final stage collapse of the entire organ of Corti occurs. The
effects of cisplatin are not limited to the hair cells. Boheim and Bichler (1985)
have shown that cisplatin destroys the efferent auditory nerve fibers near the
OHCs. Others have found histological changes in the spiral ganglion cells of
guinea pigs, consisting of vacuolation of their cytoplasm (Cardinaal et al.,
2000b) and cell shrinkage (Van Ruijven et al., personal communication).
Furthermore, damage to the stria vascularis was observed in several studies in
rats and guinea pigs (Kohn et al., 1988, 1997; Meech et al., 1998; Campbell et
al., 1999; Cardinaal et al., 2000a, b). This damage consisted of blebbing and
vacuolation of the marginal cells and atrophy of the intermediate cells.
Besides these morphological changes, a smaller than normal endocochlear
potential (EP) was observed after administration of cisplatin to chinchillas
(Ford et al., 1997) and guinea pigs (Komune et al., 1981; Konishi et al., 1983;
Laurell and Engström 1989; Klis et al., 2000, 2002). 
A number of animal studies (Stadnicki et al., 1975; Nakai et al., 1982; Stengs et
al., 1997; Cardinaal et al., 2000b; Klis et al., 2000, 2002) demonstrated that sev-
eral of the cisplatin-induced ototoxic effects (OHC damage, increase of hear-
ing threshold, decease of EP) recover after cessation of the cisplatin treatment.
Summarizing, cisplatin seems to have at least three targets in the cochlea, the
organ of Corti, the stria vascularis and the spiral ganglion cells. Presently, the
relation between the respective effects on these targets, e.g., whether one is
causally related to the other and how these targets are involved in recovery, is
unknown.
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Protection against cisplatin-induced side effects
Several attempts have been made to prevent cisplatin-induced side effects,
e.g. by changing the dose, the method of administration or even by replacing
cisplatin with a non-toxic analogue (e.g. carboplatin). However, these efforts
proved to be unsatisfactory. Thus, another approach was investigated to over-
come the toxic effects of cisplatin: pharmacological intervention. Several
classes of compounds, such as neurotrophins and sulphur-containing com-
pounds, have been found to protect against cisplatin-induced neuro- and oto-
toxicity. In this section the most significant results from experiments with
different classes of compounds that protect against cisplatin-induced ototoxic-
ity will be reviewed.
Fosfomycin
The first agent tested for its possible protection against cisplatin ototoxicity
was fosfomycin. Both Ohtani et al. (1985) and Schweitzer et al. (1986, 1993)
showed that significantly less OHC loss occurs when animals are treated with
1 mg/kg/day cisplatin in combination with 300 mg/kg/day fosfomycin.
However, these results could not be reproduced in later studies performed by
Church et al. (1995) and Kaltenbach et al. (1997), in which higher doses of cis-
platin (3 mg/kg/day, once every other day) were used in combination with fos-
fomycin co-treatment. These seemingly contradictory results could be
explained by the observation of Ohtani et al. (1985) that at high concentrations
of cisplatin (5 mg/kg/day) fosfomycin has no protective effect. 
Sulphur-containing compounds
The application of sulphur-containing compounds was based on the hypothe-
sis that damage caused by cisplatin is due to formation of free radicals, which
interfere with the antioxidant defense system, resulting in oxidative stress
(Rybak et al., 1995, Ravi et al., 1995). Severe oxidative stress produces major
disruption of cell metabolism, resulting in cell death (Evans and Halliwell,
1999). Several compounds that may reduce free radical formation, have been
described, e.g. sodium thiosulfate (STS), diethyldithiocarbamate (DDTC), 4-
methylthiobenzoic acid (MTBA), L- and D-methionine, lipoic acid, and salicyl-
ate. In 1985, it was shown that sodium thiosulfate, already known to prevent
cisplatin nephrotoxicity, prevents from neurotoxicity when administered
simultaneously with cisplatin in patients (Markman et al., 1985). This com-
pound also seemed to protect guinea pigs from cisplatin-induced hearing loss
(Otto et al., 1988; Church et al., 1995; Kaltenbach et al., 1997; Saito et al.,
1997a). However, it has been shown that STS reacts with cisplatin to form
18
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covalently bound complexes, thus hampering cisplatin’s anti-tumor activity
(Howell et al., 1982). Therefore, recent experiments have focused on the
direct application of STS into the inner ear in order to selectively bind cisplatin
in the cochlea (Wang et al., 2002). Another protective agent is the sulphur-con-
taining amino acid methionine. Both the naturally occurring L-methionine and
its synthetic analog D-methionine have been tested for their otoprotective
properties. Campbell et al. (1996, 1999) have showed excellent protection by
D-methionine from cisplatin ototoxicity in rats. Unfortunately, also L- and D-
methionine lowered the systemic exposure to cisplatin (Reser et al., 1999;
Ekborn et al., 2002; Vrana and Brabec, 2002). Therefore, topical administration
of L- or D-methionine directly onto the round window membrane has been
studied (Li et al., 2001; Korver et al., 2002). With this approach both com-
pounds completely protect the inner ear from cisplatin-induced ototoxicity.
Other sulphur-containing compounds that provide protection against cisplatin
ototoxicity after systemic application are diethyldithiocarbamate (Church et
al., 1995; Kaltenbach et al., 1997; Rybak et al., 1995; Walker et al., 1994), 4-
methylthiobenzoic acid (Rybak et al., 1997; Kamimura et al., 1999), salicylate
(Li et al., 2002) and lipoic acid (Rybak et al., 1999a-c). However, excessive
amounts of these compounds are necessary to realize a protective effect
against cisplatin ototoxicity; the concentration of the sulphur-containing com-
pounds exceeds the cisplatin dose by 5 to 100 times (e.g., 300 mg/kg D-methio-
nine versus 8 mg/kg cisplatin). At these concentrations the sulphur-containing
compounds are known to react directly with cisplatin resulting in a lowered
cytotoxic effect of the drug (Ekborn et al., 2002).
Neurotrophic factors
In 1992 a group of neuropeptides was shown to have protective effects on cis-
platin neuropathy (Apfel et al., 1992). These neurotrophic factors are, among
others, nerve growth factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4/5
(NT-4/5), brain-derived neurotrophic factor (BDNF), and glial-derived neu-
rotrophic factor (GDNF). Each of them signals through a specific high-affinity
Trk receptor (Gao, 1999). NGF specifically acts on TrkA, BDNF and NT-4/5 on
TrkB, and NT-3 selectively activates TrkC (Gao, 1999). All of the neurotrophins
also bind to the NGF low-affinity receptor p75 (Chao, 1994). Three of these
receptors, i.e., TrkB, TrkC, and p75 have been identified in spiral ganglion and
hair cells (Ylikosky et al., 1993; Pirvola et al., 1994). Recent experiments have
reported that rats and patients treated with cisplatin show a significant reduc-
tion in the level of circulating NGF (De Santis, 2000; Cavaletti et al., 2002).
Since NGF suppresses the generation of reaction oxygen species (ROS)
19
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(Dugan et al., 1997), reduction of NGF could result in an increased generation
of ROS, eventually leading to peripheral neuropathy or ototoxicity. Most of the
experiments with growth factors have been performed in vitro with organo-
typic culture of cochlear explants or vestibular neuro-epithelia. BDNF and NT-
4/5 were found to delay further degeneration of spiral ganglion cells. This
protective effect, although somewhat smaller, was also observed when NT-3
was administered to spiral ganglion cells (Zheng et al., 1995, 1996). However,
no attenuation of cisplatin-induced hair cell loss was observed with these
compounds (Zheng and Gao, 1996). The results of studies performed with
NGF are rather conflicting. Some authors have reported that NGF protects spi-
ral ganglion cells from cisplatin-induced toxicity (Malgrange et al., 1994), while
others consider NGF to be ineffective (Zheng et al., 1995, 1996). Kuang et al.
(1999) recently showed that locally delivered GDNF protects guinea pig
cochleas when it was administered in combination with systemically applied
cisplatin. This is the only study known to show protection in vivo by one of the
above co-treatments at a dose in the µg-range, suggesting a specific mecha-
nism against ototoxicity at the hair cell level. Recently, another group of pep-
tides known as melanocortins has been demonstrated to protect against
cisplatin-induced ototoxicity in vivo at this dose range. 
Melanocortins
Already in 1987, it was reported that the class of peptides known as
melanocortins, is able to protect against cisplatin-induced neurotoxicity.
Melanocortins are derived from the pituitary peptide AdrenoCorticoTropic 
hormone (ACTH) and include α−Melanocyte Stimulating Hormone (α−MSH),
the ACTH(4-9) analog ORG 2766 and the synthetic cyclic peptide melanotan-II
(MT-II) (Fig. 3). In vitro experiments with neurons from the dorsal root ganglia
(DRG) showed that both α−MSH and ORG 2766 prevent the outgrowth-inhibi-
ting action of cisplatin. However, they do not increase survival of DRG neurons
nor do they appear to have any effect upon the death of supporting cells (Bär
et al., 1993; Hol et al., 1994a; Windebank et al., 1994).
In vivo experiments in rats showed a decrease in the sensory nerve conduc-
tion velocity (SNCV) as well as the number of thick myelinated fibers after
treatment with cisplatin. Concurrent treatment with MT-II prevents the
decrease of SNCV (Ter Laak et al., 2003), while ORG 2766 prevents both the
decrease in SNCV (De Koning et al., 1987; Gerritsen van der Hoop et al., 1988;
Hamers et al., 1991a, 1993a) and the decrease in number of thick fibers
(Gerritsen van der Hoop et al., 1994).
A clinical trial, in which patients with ovarian carcinomas were concomitantly
treated with cisplatin and ORG 2766, showed that ORG 2766 prevented part 
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of the cisplatin-induced decrease of the vibration perception threshold (VPT)
(Gerritsen van der Hoop et al., 1990). Unfortunately, 4 months after cessation
of the cisplatin treatment the majority of patients still had abnormal VPT values
and showed a continued increase of clinical complaints (numbness, loss 
of strength, pain, etc.). Nevertheless, these effects were less pronounced 
in patients previously treated with ORG 2766 (Hovestadt et al., 1992). 
In a more recent clinical study, in which more patients were included, this 
protective effect of ORG 2766 could not be reproduced; It was observed that
ORG 2766 causes an increase in the onset and degree of neuropathies
(Roberts et al., 1997). 
Since the melanocortins α−MSH, ORG 2766, and MT-II showed promising neu-
roprotective effects in animal studies, we decided to test for the possible oto-
protective action of these neuropeptides. Hamers et al. (1994) and Stengs et al.
(1998b) showed a partially protective effect of 75 µg/kg/day ORG 2766 upon
cisplatin-induced ototoxicity in guinea pigs as shown from changes in ECochG
thresholds. Major threshold shifts were observed in all saline co-treated ani-
mals but not in all ORG 2766 co-treated animals after 8 daily doses of 2.0 mg
cisplatin/kg (Hamers et al., 1994). Animals treated with ORG 2766 that showed
21
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Figure 3: Structures of MT-II, ORG 2766 and α−MSH
no protection, tended to have slightly worse CAP input-output curves than the
saline co-treated ones, but OHC survival was significantly better in these ‘non-
responders’ than in saline-treated controls (De Groot et al., 1997). Heijmen et
al. (1999) demonstrated that treatment of albino guinea pigs with daily injec-
tions of cisplatin (2 mg/kg/day i.p. for 8 days) and concomitant injections of 
α−MSH (75 µg/kg/day s.c. for 9 days) results in a considerable number of ani-
mals with preserved hearing after cessation of cisplatin treatment. This was
not found in the cisplatin/saline treated group. 
Thus, these experiments have demonstrated that ACTH-derived neuropeptides
(melanocortins) are able to protect against cisplatin-induced ototoxicity.
However, the mechanism by which these neuropeptides exert their otoprotec-
tive effect is not yet known. Their protective effect cannot be due to a direct
interaction between the melanocortins and cisplatin, since both α−MSH and
ORG 2766 were administered in much smaller doses than cisplatin. The actual
target might be the intermediate cells in the stria vascularis. Meyer zum
Gottesberge (2000) has suggested that these intermediate cells, which are
actually melanocytes (Hilding and Ginzberg, 1977), are under α−MSH control.
α−MSH may act as an emergency system in the regulation of inner ear home-
ostasis and function. ACTH-derived neuropeptides, such as α−MSH, are known
to strongly bind to G-protein-coupled melanocortin (MC) receptors (Mountjoy
et al., 1992). Therefore, α−MSH and ORG 2766 may exert their protective action
by activating a MC-like receptor in the intermediate cells, thus preventing cis-
platin from damaging the stria vascularis. Although the epidermal melanocytes
have been shown to contain a MC-receptor that specifically binds to α−MSH
(Tsatmali et al., 2002), the presence of such a MC-receptor has yet to be
demonstrated in the inner ear. Moreover, none of the known MC-receptors
binds to ORG 2766. So the actual mechanism of action in the prevention of cis-
platin-induced ototoxicity of the ACTH-derived neuropeptides is still unclear.
Methods for studying ototoxicity
In this thesis we are mostly interested in the prevention of cisplatin-induced
ototoxicity. Cisplatin causes structural damage and functional loss in several
tissues of the cochlea and the auditory nerve. In order to study these effects
experimentally we have used two approaches: electrocochleography and his-
tology.
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Electrocochleography
Electrocochleography (ECochG) is a method to record the stimulus-related
potentials of the cochlea and auditory nerve (Ruth et al., 1988). The response
that is measured with ECochG occurs within the first 2-3 ms after an abrupt
stimulus, and includes the following components (Fig. 4): 
- The cochlear microphonics (CM), which is a stimulus-related alternating
current (AC) potential that closely mimics the frequency of the stimulus. It
is primarily generated by the OHCs, and it represents the displacement of
the basilar membrane in response to an acoustic stimulus (Sellick et al.,
1982). When the electrode is placed on the round window membrane the
recordings reflect the activity of the OHCs in the basal turn. 
- The summating potential (SP), a positive or negative stimulus-related
direct current (DC) potential that reflects the time-related displacement of
the cochlear partition. It is generated mostly by the IHCs, although a signifi-
cant contribution is made by the OHCs (Durrant et al., 1998). 
- The compound action potential (CAP), which is a transient response that is
generated by peripheral eighth cranial nerve. It represents the summed
response of the synchronous firing of thousands of auditory nerve fibers
(Goldstein and Kiang, 1958; Ferraro et al., 1983). The amplitude of the CAP
reflects the number of nerve fibers that are firing simultaneously
Figure 4: Principles of an ECochG measurement. All recordings were performed at the round window. Traces
obtained on stimuli with 180ο phase difference are averaged separately. Adding these averages cancels CM so that
CAP and SP are clearly distinguished. Subtracting these averages removes CAP and SP while the CM remains.
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Histology
Another method to investigate cisplatin-induced cochlear damage is by study-
ing the histopathological effects of the various functional entities of the
cochlea, e.g. outer hair cells (OHCs), inner hair cells (IHCs), spiral ganglion
cells and stria vascularis. In this thesis the quantitative analysis of OHCs and
IHCs was performed in midmodiolar sections. The cochlea is divided into two
halves after which 1 µm thick slices (sections) are taken from the cut surface
(Fig. 5).
In these sections the number of hair cells were counted at seven different
locations along the basilar membrane (2 transections for the basal turn; 2 tran-
sections for the middle turn and 3 transections for the apical turn). 
Figure 5: Principle of midmodiolar sectioning
The number of hair cells missing, relative to the expected 3 OHCs per transec-
tion, is a measure of cochlear damage. This hair-cell damage can be com-
pared and correlated to the impairments found in the electrophysiological
data.
Outline of the thesis
As outlined in the previous paragraphs, many advances have been made in the
management of cisplatin-induced side effects. However, the neurotoxic and
ototoxic side effects can not be treated effectively without hampering the cyto-
toxic action of cisplatin. Since ACTH-derived neuropeptides have shown to be
effective as neuroprotective compounds that do not interfere with the anti-
neoplastic properties of cisplatin, our group has tested these peptides for their
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possible otoprotective action. In previous studies, in which the drugs were
administered during a fixed number of days, it was shown that both α−MSH
and ORG 2766 have a beneficial effect on cisplatin-induced ototoxicity.
However, since only part of the animals was protected, further optimization of
the melanocortin treatment was considered to be necessary. Furthermore, the
mechanism underlying the action of melanocortins had to be investigated. 
This thesis is based on a longitudinal animal model in which an implanted
electrode allows repeated measurements of cochlear sensitivity. In the first
part the compounds are administrated systemically, in the second part we
focus on a cochlear model in which the compounds can be delivered directly
into the cochlea via a mini-osmotic pump system.
In the first study (Chapter 2) the longitudinal animal model is used to investi-
gate the otoprotective effects of the new and more potent melanocortin-recep-
tor agonist melanotan-II (MT-II). This synthetic melanocortin has been
effective in the protection of cisplatin-induced peripheral neuropathy (Ter
Laak et al., 2003). The objective of the study was to investigate whether MT-II
is able to delay the occurrence of cisplatin-induced ototoxicity and to effect
subsequent recovery. Animals were implanted with a permanent electrode
and treated daily with cisplatin and MT-II until a 40 dB CAP threshold shift at 8
kHz occurred. Subsequently, cisplatin treatment was stopped and CAP recov-
ery was studied for another 2 weeks. 
A subsequent study was performed to test the protective effects of the
melanocortin peptides α−MSH and ORG 2766 in the same longitudinal animal
model (Chapter 3). We investigated whether these peptides delay the occur-
rence of the cisplatin-induced shift in auditory threshold, and whether they
effect the subsequent recovery of the cochlear action potential (CAP) and
endocochlear potential (EP). Both peptides showed significant ameliorating
effects on the recovery of the CAP.
Since it was suggested that this recovery might be due to reversible strial fail-
ure and EP recovery, in the third study (Chapter 4) we have investigated the
time course of EP recovery and whether the recovery of the EP is influenced
by α−MSH co-treatment. In an experimental set-up similar to that of the sec-
ond study, the EP and CAP were measured 1, 2, or 3 days after the criterion
threshold shift at 8 kHz was reached. 
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To gain more insight into the mechanism underlying α−MSH action, the sec-
ond objective of this thesis, we switched to the cochlear model in which
effects of cisplatin and melanocortins could be studied without the possibly
confounding influence of systemic administration. In the fourth study 
(Chapter 5) this animal model was used; cisplatin was administered directly
into the cochlea via a mini-osmotic pump system while α−MSH or saline were
administered daily by systemic injection. This approach decreased interanimal
variability, which made it easier to quantify the efficacy of systemic α−MSH co-
treatment. Furthermore, since cisplatin was delivered directly to the cochlea,
any ameliorating effects of α−MSH would indicate that treatment with α−MSH
probably involves a cochlear target.
To complement the previous study a mirror experiment was performed in the
fifth study (Chapter 6). Guinea pigs that were implanted with a permanent
electrode and a mini-osmotic pump, pumping either saline or α−MSH, were
co-treated systemically with cisplatin until the 40 dB threshold shift at 8 kHz
was reached. Then, cisplatin treatment was stopped, but intracochlear perfu-
sion and electrocochleography were continued for 10 days to evaluate possi-
ble effects of local α−MSH treatment on recovery. 
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Summary
Cisplatin, an important chemotherapeutic agent, has severe dose-limiting side
effects including peripheral neurotoxicity and ototoxicity. Peripheral neurotoxi-
city can be delayed or prevented by simultaneous treatment with a class of
neuropeptides known as melanocortins. Examples are ORG 2766, 
α−melanocyte stimulating hormone (α−MSH) and melanotan-II (MT-II). In albi-
no guinea pigs, our group has found that ORG 2766 and α−MSH can also
reduce cisplatin-induced ototoxicity. In this study we investigated the possibly
protective effects of MT-II upon cisplatin ototoxicity.
Guinea pigs, equipped with a permanent round window electrode for electro-
cochleography, were treated with cisplatin (1.5 mg/kg/day i.p.) and simultane-
ously with MT-II (30 or 3 µg/kg/day s.c.) or saline until a 40 dB suppression of
the compound action potential (CAP) threshold (3 µV criterion) at 8 kHz
occurred. This 40 dB criterion was reached after 5 to 18 days. Thereafter, the
treatment was stopped, but electrocochleography was continued for another
four weeks.
The number of days in which the 40 dB criterion threshold shift was reached
in the MT-II co-treated group did not differ from the period in the saline group.
Ten days after the end of the treatment a spontaneous recovery of the CAP
was observed in all groups and at all frequencies, although it was more pro-
nounced at lower frequencies. Also with respect to recovery, no differences
were found between the saline and the MT-II co-treated group. Thus, in con-
trast with the otoprotective properties of other melanocortins, MT-II has no
protective properties against cisplatin-induced ototoxicity, at least not with the
doses applied here.
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Introduction
Cisplatin (cis-diamminedichloroplatinum (II)), an important chemotherapeu-
tic drug, is used in the treatment of different types of malignancies such as
ovarian and testicular carcinoma and in cases of cancer of the head, neck,
bladder and lung. Unfortunately, cisplatin has severe dose-limiting side effects
including nephrotoxicity, peripheral neuropathy and ototoxicity.
The ototoxic effect of cisplatin is characterized by a bilateral, high frequency
sensorineural hearing loss, usually associated with tinnitus (De Oliviera, 1989;
Schweitzer, 1993). Laurell and Bagger-Sjöbäck (1991a) showed that the mor-
phological changes in the cochlea of guinea pigs after cisplatin exposure
occur in three stages. The first stage included disturbance of the supporting
cells surrounding the outer hair cells (OHCs). The second stage was character-
ized by degeneration of the OHCs, which previously had been shown to
progress from base to apex (Nakai et al., 1982); One of the first signs was the
loss of stereocilia and intracellular vacuolization. The inner hair cells (IHCs)
usually remained intact until all the OHCs had degenerated. In the final stage
the entire organ of Corti had collapsed. Other studies, in rats and guinea pigs
(Kohn et al., 1997; Meech et al., 1998; Campbell et al., 1999; Cardinaal et al.,
2000a,b), focused on damage to the stria vascularis. This damage consisted of
blebbing and vacuolization of the marginal cells and atrophy of the intermedi-
ate cells. The stria vascularis gives rise to the endocochlear potential (EP). In
line with the morphological damage to the stria, a smaller than normal EP was
observed after administration of cisplatin to guinea pigs (Klis et al., 2000,
2002). Summarizing, cisplatin seems to have at least two targets in the
cochlea: the organ of Corti and the stria vascularis. Presently, the relation
between the respective effects on these targets, e.g. whether one is causally
related to the other, is unknown.
Several compounds that are known for their nephroprotective and neuropro-
tective effects also seem to be able to protect the inner ear from cisplatin toxi-
city. These compounds include anti-oxidants, e.g. D-methionine (Reser et al.,
1999; Campbell et al., 1999), 4-methylthiobenzoic acid (Kamimura et al., 1999;
Rybak et al., 1999a) and diethyldithiocarbamate (Kaltenbach et al., 1997;
Rybak et al., 1999a). The application of these compounds is based on the
demonstration that reactive oxygen species generation is increased in the
cochlea after administration of cisplatin (Clerici et al., 1996; Kopke et al.,
1997). Another group of protective compounds is a class of neuropeptides
known as the melanocortins. Melanocortins are compounds related to the
mother compounds α−Melanocyte Stimulating Hormone (α−MSH) and
AdrenoCorticoTropic Hormone (ACTH). α−MSH and the synthetic ACTH(4-9)
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analog ORG 2766 have shown to enhance recovery after peripheral nerve trau-
ma at both histological and functional levels (Bijlsma et al., 1984; De Koning et
al., 1986; Van der Zee et al., 1991), and ORG 2766 specifically has shown to pre-
vent the development of cisplatin-induced neuropathy both in animals (De
Koning et al., 1987;  Hamers et al, 1993a) and in humans (Gerritsen van der
Hoop et al., 1990). Our group showed that, in guinea pigs, these peptides can
also provide protection against cisplatin ototoxicity (Hamers et al., 1994; De
Groot et al., 1997; Stengs et al., 1998b; Heijmen et al., 1999; Smoorenburg et al.,
1999; Cardinaal et al., 2000c).
Melanotan-II (MT-II) is a cyclic melanocortin (MC) with very high affinity for
the MC1-, MC4- and MC5-receptor (Schiöth et al., 1997; Yang et al., 1997;
Hadley et al., 1998; Haskell-Luevano et al., 2000). The compound has already
been administered to humans and showed little side effects (Wessels et al.,
2000). In vitro experiments showed that MT-II is a ten times more potent ago-
nist for the human MC1-receptor than α−MSH (Yang et al., 1997; Haskell-
Luevano et al., 2000). The MC1-receptor is found in melanocytes in the skin;
MC4- and MC5-receptors have been localized in the nervous system.
Concerning the inner ear, it has been suggested that a receptor for α−MSH,
probably the MC1-receptor, is present in the intermediate cells (which are
melanocytes) of the stria vascularis (Meyer zum Gottesberge, 2000). MT-II has
proven to be effective in the prevention of cisplatin-induced peripheral neu-
ropathy in rats; Ter Laak et al. (2003) showed that MT-II ameliorates cisplatin-
induced neuropathy after subcutaneous administration at 1.0 µg/kg.
The present study was designed to investigate the possibly protective effect of
MT-II on cisplatin ototoxicity in guinea pigs that were equipped with a perma-
nent round window electrode. This animal model allowed us to track putative
effects of MT-II before, during and after cisplatin-treatment. The post-treatment
measurements are important with regard to recovery. Our group has shown
that cisplatin-induced ototoxicity is partly reversible in guinea pigs (Stengs et
al., 1997; Klis et al., 2000, 2002), i.e. the cochlea has the ability to recover from
cisplatin insults. MT-II might enhance this recovery.
Materials and methods
Animals and experimental design
Thirty-two female albino guinea pigs (strain: Dunkin-Hartley, Harlan
Laboratories, Horst, The Netherlands; weight 350-650 g), equipped with a per-
manent round window electrode were treated with cisplatin and one of three
co-treatments. These co-treatments consisted of either MT-II in saline 
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(3 µg/kg/day; n=9 or 30 µg/kg/day; n=11) or approximately equal volumes of
plain saline (n=12). The animals were housed, four together, in macrolon
cages and had free access to food and water. They were maintained on a
12:12 h dark/light cycle. The animals were treated daily with cisplatin and the
relevant co-treatment until the electrocochleogram showed a 40 dB reduction
of the Compound Action Potential (CAP) threshold at 8 kHz stimulation. This
threshold, more appropriately called iso-response level, was defined as the
sound level required to evoke a CAP of 3 µV. One day after 40 dB reduction of
the CAP threshold was reached, an additional last dose of MT-II or saline was
given without administration of cisplatin. After the end of the cisplatin treat-
ment electrocochleography was continued for four weeks to evaluate the pos-
sible effects of MT-II on the expected recovery. 
The care and use of the animals reported in this study were approved by the
Animal Care and Use Committee of the University of Utrecht (DEC-UMC
#91035).
Drugs
Cisplatin (Platosin®; Pharmachemie B.V., Haarlem, The Netherlands) was
diluted with physiological saline (pH 7.4) to a final concentration of 0.1 mg/ml.
It was administered intraperitoneally at a daily dose of 1.5 mg/kg body
weight/day. This dose was based upon the previous experiments with cisplatin
by Stengs et al. (1998a, b) and Heijmen et al. (1999). The high dilution was
chosen to stimulate diuresis and thus to minimize renal effects. Melanotan-II
(MT-II; Ac-Nle-cyclic-[Asp-His-D-Phe-Arg-Trp-Lys]NH2; Bachem, Bubendorf,
Switzerland) was dissolved in saline. MT-II was administered subcutaneously
in a daily dose of 3 or 30 µg/kg body weight/day. The argument for these doses
is as follows. Ter Laak et al. (2003) found protection against cisplatin neurotox-
icity at 1.0 µg/kg MT-II, not at 0.1 µg/kg. α−MSH protection against cisplatin
neurotoxicity works best between 7.5 and 75 µg/kg/day (Van der Zee et al.,
1991). MT-II has a 10 times greater affinity for the MC1-receptor than α−MSH.
Thus, 3 µg/kg/day is right in the middle of the predicted effective dose window
for MT-II (0.75-7.5 µg/kg/day). We also did not want to risk too low a concen-
tration (see effect of  0.1 µg/kg/day in neuroprotective studies). Thus, in order
not to miss the protective effect we also chose a concentration 10 times higher
(30 µg/kg/day).
Surgical techniques
Prior to surgery the animals were injected with an antibiotic (chloramphenicol
sodium succinate; 60 mg/kg) and then anaesthetized with 50 mg/kg ketamine
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(Parke Davis, Hoofddorp, The Netherlands) and 1 ml/kg Thalamonal (a mix-
ture of fentanyl and droperidol: 0.05/2.5 mg/ml; Janssen Pharmaceutica,
Tilburg, The Netherlands). Local anaesthetic (lidocaine 1%; Adrenaline
1:100.000; 0.3 ml) was used in areas to be incised. Under sterile conditions the
bulla of the right ear was opened retro-aurically and the skull was exposed
around the bregma. The round window electrode was made of insulated
stainless-steel wire (diameter 0.175 mm including teflon insulation; Advent,
Halesworth, UK) with a 0.5 mm diameter gold ball micro-welded (Unitek 80F;
Unitek Equipment, Monrovia, CA, USA) to the exposed and flattened tip. The
wire was soldered to a Berg 22-26 gold terminal that fitted into a Berg 2x3
mini-latch housing (Farnell, Maarssen, The Netherlands). Stainless-steel
screws were inserted through the skull and connected to the mini-latch hous-
ing via two silver wires also connected to a gold terminal. The electrode was
positioned on the round window and secured to the bulla with polymaleinate
glass-ionomer cement (Ketac-Cem Aplicap, ESPE dental supplies, Utrecht, The
Netherlands). The mini-latch housing was connected to the skull with dental
acrylic cement, which also covered and insulated the stainless-steel screws
and the electrodes. The wound was closed in two layers with vicryl.
Electrocochleography
Measurements were performed differentially with the round window elec-
trode as the active electrode and two screws on the skull as reference and
ground electrodes, respectively. Trains of tone bursts of 2, 4, 8, and 16 kHz
were used as stimuli. The tone bursts were constructed with cosine-shaped
rise-and-fall times of 1 ms (1.5 ms at 2 kHz) and had a duration of 8 ms. The
sound stimuli were produced in an open field configuration with a Fame
tweeter (Staffhorst Electronics, Utrecht, The Netherlands) positioned at 10 cm
from the pinna. Consecutive tone bursts were presented with alternating
polarity at 99 ms intervals in order to avoid synchronization with the mains 
frequency of 50 Hz. The responses were amplified (EG&G Instruments model
5113 amplifier, Te Lintelo Systems, Zevenaar, The Netherlands), bandpass 
filtered between 1 Hz and 30 kHz, AD converted and stored on disk for off-line
analysis. CAP and Summating Potentials (SP) were obtained by adding the
responses evoked by tone bursts of opposite polarity, Cochlear Microphonics
(CM) by subtracting these responses. The CAP was measured relative to the
SP and not relative to the baseline of the recording since, in principle, the CAP
is superimposed on the SP. The CM was measured as the peak-to-peak ampli-
tude in the middle of the sinusoidal response. Electrocochleography was con-
tinued until four weeks after the end of the treatment. Animals that did not
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have a normal threshold at 8 kHz (defined as a threshold at less than 25 dB
SPL stimulus level) or that showed signs of otitis media, during surgery or
when they were sacrificed, were excluded from this study. Statistical analysis
was performed by means of analysis of variance (ANOVA), using STATISTICA
software. 
Results
General findings
In the follow-up after cisplatin-treatment, four animals were lost because of a
failing electrical connection (2 in each MT-II co-treated group). Fatalities did
not occur, neither during treatment nor in the four weeks post-treatment 
survival period. Most animals treated with cisplatin, in combination with MT-II
or plain saline, showed loss of weight (Table 1). 
Table 1: Mean change in body weight ± s.d. at the end of the cisplatin-treatment 
Co-treatment Number of animals Change of bodyweight     
Grams %  
MT-II 30 µg/kg/day N=11 -8   ± 14 (range -31 to +12) -1.8 ± 3.3
MT-II 3 µg/kg/day N=9 -20 ± 25 (range -57 to +8) -3.7 ± 4.6
Saline N=12 -17 ± 30 (range -87 to +30) -3.6 ± 7.2  
When the cisplatin-treatment was terminated the animals started gaining
weight again at their normal rate. ANOVA showed a significant effect of time
(F(2,42)=270, P<0.001), but no interaction with co-treatment (F(2,42)=0.62,
P=0.93). This indicates that weight changed significantly over time, which is
trivial, but that weight changes during and after cisplatin-treatment was similar
in all three groups. Thus, weight changes cannot account for possible effects
the MT-II co-treatment. 
Cisplatin effects on CAP thresholds in relation to co-treatment
During the first days of treatment no dramatic change in CAP threshold was
observed. As previously reported (Klis et al., 2000) a threshold shift occurred
rather suddenly after several days of treatment (cf., Fig. 3). The number of days
necessary to evoke a threshold shift of ≥ 40 dB at 8 kHz was 5 to 18 days of
treatment (Fig. 1).
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Figure 1: The time necessary to evoke a hearing loss of ≥ 40 dB in the 3 µV iso-response level (CAP threshold) at 8
kHz for the MT-II 30 µg/kg/day (black bar), MT-II 3 µg/kg/day (grey bar) and the saline (white bar) co-treated
groups.
Figure 1 suggests that there is no effect of co-treatment with MT-II on the num-
ber of days necessary to reach criterion loss. ANOVA confirmed this lack of
effect of co-treatment (F(2,29)=0.12, P=0.89), even when excluding the atypical
animal in the control group (F(2,28)=0.07, P=0.93), which required 18 injec-
tions to reach criterion threshold shift. Maximum CAP threshold shifts
occurred either at the day cisplatin administration was terminated or 1 to 2
days later (cf., Fig. 3). Maximum threshold shift in dB as a function of frequency
is shown in Figure 2 for the three treatments. The hearing loss occurred in a
broad frequency range, although it clearly increased as a function of frequency.
ANOVA showed a significant main effect of frequency (F(2,12)=40.3, P<0.001),
but not of co-treatment (F(2,12)=0.04, P=0.96).
37
Protective effect of melanotan-II
Figure 2: Maximal Compound Action Potential (CAP) threshold shift at the end of the cisplatin-treatment as a func-
tion of stimulus frequency for () MT-II 30 µg/kg/day (n=11), () MT-II 3 µg/kg/day (n=9) and () saline (n=12)
co-treated groups.
Recovery of CAP thresholds in relation to co-treatment
Pronounced recovery of the CAP threshold was observed in all three groups
after cessation of the cisplatin-treatment. This recovery was observed at all fre-
quencies, although it was more pronounced at the lower frequencies. Every
individual animal showed recovery; there were no signs of a dichotomous dis-
tribution in any of the three groups. The recovery started to level off at about 10
days post-treatment. Figure 3 shows the build-up and recovery of the CAP
threshold as a percentage of the loss in dB at the time cisplatin-treatment was
stopped (day 0). The measurements beyond 15 days post-treatment are not
shown; they did not show any further systematic shift. Note the previously
mentioned sudden onset of the hearing loss in Figure 3. 
Statistical analysis (ANOVA) of the data starting at day 0 showed significant
effects of time (≡recovery; F(2,45)=14.7, P<0.001) and frequency (F(2,45)=3.76,
P=0.032). Co-treatment was not a significant main factor and there was no sig-
nificant interaction between co-treatment and either frequency or time, indi-
cating a lack of effect of MT-II co-treatment on threshold recovery. Recovery
can also be expressed in terms of post-treatment growth of CAP amplitude at a
fixed stimulus level (Klis et al., 2000). 
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Figure 3: Build-up and recovery at 2, 4, 8, and 16 kHz (+ SEM) of the CAP threshold for () MT-II 30 µg/kg/day
(n=9), () MT-II 3 µg/kg/day (n=7 ) and () saline (n=12) co-treated groups. The horizontal black bar repre-
sents the last 5 days of cisplatin-treatment. Day 0 represents the day that the treatment was stopped. 100% of initial
loss in dB corresponds to the threshold shift at the time of cessation of cisplatin-treatment (average values in dB
SPL are given in Fig. 2), 0% corresponds to the pre-treatment baseline.
We tested the effects of co-treatment on recovery of CAP-amplitudes at several
stimulus levels and at all frequencies (2-16 kHz). This alternative approach
also showed no significant effect of co-treatment (data not shown).
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Recovery of CM in relation to co-treatment
The CM were also affected by cisplatin-treatment. As an example, Figure 4
shows the CM amplitude at 16 kHz, 66 dB SPL. This CM was lost at the same
day the CAP criterion threshold shift was reached. At 16 kHz, the CM ampli-
tude hardly recovers. 
However, statistical analysis (ANOVA) of the 16 kHz CM data starting at day 0
showed a significant effect of time (≡recovery; F(2,45)=2.78, P<0.001). Once
again, co-treatment was not a significant main factor and there was no signifi-
cant interaction between co-treatment and time, indicating a lack of effect of
MT-II co-treatment on recovery. The same results were found at all other 
frequencies (2-8 kHz; not shown).
Figure 4: Build-up and recovery at 16 kHz, 66 dB SPL of the CM amplitude (+ SEM) for () MT-II 30 µg/kg/day
(n=9), () MT-II 3 µg/kg/day (n=7) and () saline (n=12). The horizontal black bar represents the last 5 days of
cisplatin-treatment. Day 0 represents the day that the treatment was stopped. 100%  of initial loss in µV corresponds
to the shift at the time of cessation of cisplatin. 0% corresponds to the pre-treatment baseline.
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Discussion
Cisplatin ototoxicity 
The chronic recording technique applied in this study allowed us to monitor
cochlear sensitivity changes before, during and after cisplatin-treatment, with
or without MT-II co-treatment, on a day-to-day basis. The effects of cisplatin
alone on the CAP as a measure of cochlear sensitivity, were in accordance
with previous results (Klis et al., 2000, 2002). 
We observed that a physiological threshold shift occurred rather suddenly
after several days of cisplatin administration. Further, we found that the num-
ber of injections necessary to evoke criterion threshold shift varied substan-
tially between animals (Fig. 1). In the present study the number of days
(=injections) necessary to reach the criterion threshold shift varied from 5 to
18 days, although the latter value is clearly an unexplained outlier. Hearing loss
occurred over a broad frequency range (Fig. 2), although it was significantly
larger at the higher frequencies. The marked recovery after cessation of cis-
platin-treatment (Figs. 3, 4) was also found previously (Klis et al., 2000, 2002).
Typically, recovery of CAP threshold was more prominent at lower frequencies
(Fig. 3). Recovery of CM at all frequencies and CAP at high frequencies was far
less pronounced. (Figs. 3, 4). It has to be kept in mind that the CM, recorded at
the round window, derives from hair cells in the immediate vicinity of the
round window, irrespective of stimulus frequency (Dallos, 1973). On the other
hand, the CAP derives from its characteristic frequency location. Klis et al.
(2000, 2002) hypothesized that the occurrence of hearing loss over a relatively
broad frequency range and the subsequent recovery from cisplatin-evoked
loss might be related to loss and recovery of the strial integrity, reflected in the
EP. The less prominent recovery of the CM at all frequencies and the similarly
less prominent recovery of the CAP at higher frequencies could be explained
by simultaneously occurring permanent loss of OHCs in the basal cochlear
turn near the electrode. We propose that similar events occurred in the pres-
ent experiment.
MT-II does not change the characteristics of cisplatin intoxication and recovery
The main issue in this study was whether MT-II, a potent melanocortin with
high affinity for the MC1-receptor, would be capable of protecting against cis-
platin-induced ototoxicity. The rationale for this hypothesis was based on two
sets of experimental observations. The first set of observations consisted of
positive results from our laboratory with the related compounds ORG 2766 and
α−MSH. Both compounds have shown to protect against cisplatin ototoxicity in
various experiments (Hamers et al., 1994; De Groot et al., 1997; Stengs et al.,
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1998b; Heijmen et al., 1999; Smoorenburg et al., 1999). The second observa-
tion, which led to the present experiment, was the effect of MT-II on cisplatin-
induced peripheral neuropathy in rats. MT-II was found to protect against
cisplatin-induced neuropathy (Ter Laak et al., 2003), a property which MT-II
shares with ORG 2766 (Hamers et al., 1993a). Evidently, we did not find pro-
tecting effects of MT-II. At the two concentrations applied the compound had
no effect on the number of cisplatin injections necessary to evoke criterion
hearing loss (Fig. 1). Further, MT-II did not enhance recovery (Figs. 3, 4). One
might assume that the compound would have had an effect at another dose.
Melanocortins are known to have an inverted U-shaped or bell-shaped dose
effect curve (De Koning et al., 1986). In other words low and high doses are
inactive and only the intermediate dose results in enhanced recovery. Ter Laak
et al. (2003) found that MT-II had protective effects on cisplatin-induced neu-
ropathy at 1.0 µg/kg/day, but not at 0.1 µg/kg/day. We chose 3 and 30 µg/kg/day
because MT-II, according to in vitro results, shows a ten times higher affinity
for the human MC1-receptor than α−MSH (Yang et al, 1997). The latter com-
pound and ORG 2766 are effective at daily doses of 75 µg/kg/day (Hamers et
al., 1994; Stengs et al.,1998b; Heijmen et al., 1999; Smoorenburg et al., 1999).
Thus, chances are small that we missed a possible protective effect of MT-II.
Also, pharmacokinetic studies performed in the rat showed a half life of MT-II
of 1.5 hours (Ugwu et al., 1994) compared to α−MSH, which has a half life of 7
minutes (Wilson and Harry, 1980). Considering these properties of MT-II we
assumed that this compound should have the same or maybe even a larger
effect if the effect of α−MSH is MC1-receptor mediated.
Another explanation for the lack of protecting effects could be that the com-
pound simply does not reach its target. Although we do not know the exact tar-
get of the melanocortins, it is highly likely that the target is located in the inner
ear. The actual target might be the intermediate cells in the stria vascularis,
which presumably express receptors for melanocortins (Meyer zum
Gottesberge, 2000). If so, the lack of effect of MT-II could be due to earlier bind-
ing of the compound to MC-receptors in the rest of the body. For instance, MT-II
is believed to be more efficiently bound to MC4 and MC5-receptors in the brain
than α−MSH because of its lower molecular weight and more lipophilic char-
acter (Yang et al., 1997; Schiöth et al. 1997). So MT-II could be intercepted on
its way to the cochlea, whereas α−MSH would not be intercepted and would
therefore reach the cochlea more efficiently. Experiments with local adminis-
tration of melanocortins in the inner ear might shed more light on the issues
discussed above. Finally, the ameliorating effects of α−MSH and ORG 2766 co-
treatment on cisplatin-induced ototoxicity, found in previous studies, might be
mediated by a mechanism that does not involve MC-receptors. 
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Conclusion
The potent melanocortin, melanotan-II, did not prevent cisplatin-induced 
ototoxicity in guinea pigs, at least not in the concentrations applied here. Also,
no MT-II-induced enhancement of recovery of cochlear sensitivity after 
cisplatin-treatment was observed. In both these aspects, MT-II differs from its
parent compound, α−melanocyte stimulating hormone and therefore appears
less promising for future clinical applications. 
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Summary
Cisplatin, an important chemotherapeutic agent, has severe dose-limiting side
effects, including peripheral neuropathy and ototoxicity. Peripheral neuropathy
can be delayed or prevented by simultaneous treatment with a class of neu-
ropeptides known as melanocortins. Examples are α−melanocyte stimulating
hormone (α−MSH) and the non-melanotropic ACTH/MSH(4-9) analog ORG
2766. Here, we investigated whether these peptides delay the occurrence of
the cisplatin-induced shift in auditory threshold, and whether they affect the
subsequent recovery of cochlear potentials. Chronically implanted round win-
dow electrodes were used to obtain daily recordings of auditory nerve com-
pound action potentials (CAP) and cochlear microphonics (CM) at
frequencies ranging from 2 to 16 kHz. Cisplatin (1.5 mg/kg i.p.) plus α−MSH 
(75 µg/kg s.c.), ORG 2766 (75 µg/kg s.c.), or saline were injected daily until a 40
dB CAP threshold shift at 8 kHz was reached. Endocochlear potential (EP) was
measured either 1-2 days or 28 days later, followed by histological analysis of
the cochlea. Peptide co-treatment did not consistently delay the threshold
shift. However, the CAP threshold recovered faster and to a greater extent,
with the potency order being α−MSH>ORG 2766>saline. Significant recovery
at the two highest frequencies was seen in the α−MSH-treated animals only.
CAP amplitude at high sound pressures, which depends more on nerve func-
tion than on outer hair cell (OHC) function, decreased severely in all groups
but recovered significantly in the α−MSH and completely in the ORG 2766 
co-treated group. EP was significantly lower in the first days after the threshold
shift but had completely recovered at 28 days. Both CM threshold and ampli-
tude at 16 kHz decreased dramatically over the course of cisplatin treatment
and remained very low afterwards, indicating severe loss of OHC function in
the basal turn, although there was some recovery in both α−MSH and ORG
2766 co-treated animals. Histological analysis confirmed that OHC loss was
most severe in the basal turn of saline treated animals. These data suggest that
the cisplatin-induced acute threshold shift might be due to reversible strial fail-
ure, whereas subsequent OHC survival determines the final degree of func-
tional recovery. 
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Introduction
Cisplatin (cis-diamminedichloroplatinum-II) is one of the most potent anti-
tumor agents available, but its use is hampered by severe toxic side effects,
including ototoxicity and peripheral neuropathy. The main pathological finding
in the inner ear is the degeneration of the outer hair cells (OHCs), with those
in the first row and basal turn being most severely affected (Nakai et al., 1982;
Laurell and Bagger-Sjöbäck, 1991b; De Groot et al., 1997). Loss of OHCs dra-
matically affects both hearing thresholds and the ability to discriminate
between different frequencies. Clinically, cisplatin-induced hearing loss is usu-
ally irreversible, although evidence of recovery has been reported in both
humans (De Oliveira, 1989; Laurell and Jungnelius, 1990) and experimental
animals (Stengs et al., 1997; Klis et al., 2000, 2002). 
Although cisplatin is one of the most potent OHC toxins known (Anniko and
Sobin, 1986), it may also cause hearing loss by affecting other inner ear struc-
tures, such as spiral ganglion cells (Alam et al., 2000; Cardinaal et al., 2000b)
and the stria vascularis (Nakai et al., 1982; Tange and Vuzevski, 1984; Kohn et
al., 1988; Saito and Aran, 1994b; Zheng and Gao, 1996; Kohn et al., 1997;
Meech et al., 1998; Cardinaal et al., 2000a, b; Watanabe et al., 2002). Indeed, a
major decrease in the endocochlear potential, implying strial vascularis dys-
function, has been observed early after the occurrence of cisplatin-induced
threshold shifts (Klis et al., 2000, 2002; Tsukasaki et al., 2000).
Several strategies have been shown to protect against cisplatin-induced neuro-
and ototoxicity. One group of protective compounds is a class of neuropep-
tides known as the melanocortins. Melanocortins are compounds related to
the mother compounds α−Melanocyte Stimulating Hormone (α−MSH) and
AdrenoCorticoTropic Hormone (ACTH). α−MSH and the ACTH(4-9) analog ORG
2766 have been shown to enhance recovery after peripheral nerve trauma at
both histological and functional level (Bijlsma et al., 1984; De Koning et al.,
1986; Van der Zee et al., 1991), and ORG 2766 specifically has been shown to
prevent the development of cisplatin-induced neuropathy in animals 
(De Koning et al., 1987; Hamers et al., 1993a) and in humans (Gerritsen Van
der Hoop et al., 1990). Previous work from our laboratory has shown that co-
treatment with neuroprotective doses of the ACTH(4-9) analog ORG 2766
(Hamers et al., 1994; Stengs et al., 1998b; Cardinaal et al., 2000c) and α−MSH
(Heijmen et al., 1999) protects against cisplatin-induced hearing loss in guinea
pigs. Both peptides either completely protected against loss of auditory 
thresholds and OHCs, or thresholds were decreased similar to the placebo co-
treated animals. However, OHC counts in these ‘non-responders’ to ORG 2766
were significantly higher than in the saline-treated animals (De Groot et al.,
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1997; Cardinaal et al., 2000c). In longitudinal studies spontaneous recovery of
cochlear function from cisplatin-induced ototoxicity was observed (Klis et al.,
2000, 2002). The longitudinal studies also demonstrated that threshold shifts
initially develop slowly, followed by an abrupt threshold shift at 8 kHz between
one cisplatin injection and the next (30-50 dB loss within 24 hours). On the
basis of these data, we hypothesized that a slight delay in the onset of hearing
loss might explain the dichotomy between either complete protection or
severe hearing loss observed in our original protection studies in which we
administered the drugs on a fixed number of days (Hamers et al., 1994; Stengs
et al., 1998b, Heijmen et al., 1999). Furthermore, we also expected recovery to
be faster and more complete in animals co-treated with ORG 2766 or α−MSH,
since animals with severe threshold shifts, despite the fact that they were co-
treated with ORG 2766, exhibited significantly less severe OHC loss than place-
bo-treated ones (De Groot et al., 1997; Cardinaal 2000c).
In the present study, we show that in guinea pigs α−MSH and ORG 2766 modu-
late the response of the cochlea to cisplatin and that they also enhance subse-
quent recovery of auditory thresholds and auditory nerve function.
Materials and methods
Animals and experimental design
Thirty-four female albino guinea pigs (strain: Dunkin-Hartley, Harlan
Laboratories, Horst, The Netherlands; weight 330-560 g), equipped with a per-
manent round window electrode, were treated with cisplatin and one of three
co-treatments. These co-treatments consisted of either ORG 2766, α−MSH or
approximately equal volumes of saline. The animals were housed, four togeth-
er, in macrolon cages and had free access to food and water. They were main-
tained on a 12:12 h dark/light cycle. After the stability of the cochlear
responses was tested on at least 5 subsequent days, animals that displayed
baseline Compound Action Potential (CAP) thresholds, defined as the sound
level required to evoke a CAP of 3 µV at sound pressures of less than 25 dB
SPL at 8 kHz, were given a daily intraperitoneal injection of cisplatin. This
injection was immediately followed by a subcutaneous injection of the rele-
vant co-treatment until the electrocochleograms showed a 40 dB suppression
of CAP threshold at 8 kHz stimulation. One day after the 40 dB suppression
was reached (day 0), an additional last dose of ORG 2766, α−MSH or saline
was given without administration of cisplatin. Thereafter, electrocochleogra-
phy was continued either for 1-2 days or for four weeks, followed by measure-
ment of the endocochlear potential (EP) and harvesting of the cochleas for
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histology. Animals were randomized to early (n=5/experimental group) or late
(n=6/experimental group) EP measurements.  
The care and use of the animals reported in this study were approved by the
Animal Care and Use Committee of the University of Utrecht (DEC-UMC #
91035).
Drugs
Cisplatin (Platosin®; Pharmachemie B.V., Haarlem, The Netherlands) was
diluted with saline (pH 7.4) to a final concentration of 0.1 mg/ml. It was admin-
istered intraperitoneally at a daily dose of 1.5 mg/kg body weight. This dose
was based upon the previous experiments with cisplatin by Stengs et al.
(1998a, b) and Heijmen et al. (1999). The high dilution was chosen to stimu-
late diuresis and thus to minimize renal effects. The cisplatin injection was
immediately followed by a subcutaneous injection of either 60 µg/ml α−MSH
(Bachem, Heidelberg, Germany) (75 µg/kg; n=11), 60 µg/ml ORG 2766
(Organon, Oss, The Netherlands) (75 µg/kg; n=12) or saline (n=11). The dose
of 75 µg/kg α−MSH or ORG 2766 was based on experiments with a positive out-
come performed previously by Heijmen et al. (1999).  
Surgical techniques
Prior to surgery the animals were injected with an antibiotic (chloramphenicol
sodium succinate; 60 mg/kg) and then anaesthetized with 50 mg/kg ketamine
(Parke Davis, Hoofddorp, The Netherlands) and 1 ml/kg thalamonal (a mixture
of fentanyl and droperidol: 0.05/2.5 mg/ml; Janssen Pharmaceutica, Tilburg,
The Netherlands). Local anaesthetic (lidocaine 1%; Adrenaline 1:100.000; 0.3
ml) was used in areas to be incised. Under sterile conditions the bulla of the
right ear was opened retro-aurically and the skull was exposed around the
bregma. The round window electrode was made of insulated stainless-steel
wire (diameter 0.175 mm including teflon insulation; Advent, Halesworth, UK)
with a 0.5 mm diameter gold ball micro-welded (Unitek 80F; Unitek
Equipment, Monrovia, CA) to the exposed and flattened tip. The wire was sol-
dered to a Berg 22-26 gold terminal that fitted into a Berg 2x3 mini-latch hous-
ing (Farnell, Maarssen, The Netherlands). Stainless-steel screws were inserted
through the skull and connected to the mini-latch housing via two silver wires
also connected to a gold terminal. The electrode was positioned on the round
window and secured to the bulla with polymaleinate glass-ionomer cement
(Ketac-Cem Aplicap, ESPE dental supplies, Utrecht, The Netherlands). The
mini-latch housing was connected to the skull with dental acrylic cement,
which also covered and insulated the stainless-steel screws and the elec-
trodes. The wound was closed in two layers with vicryl.
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Electrocochleography
Measurements were performed differentially with the round window elec-
trode as the active electrode and two screws on the skull as reference and
ground electrode, respectively. Trains of tone bursts of 2, 4, 8, 11.3 (8√2), and
16 kHz were used as stimuli. The tone bursts were constructed with cosine-
shaped rise-and-fall times of 1 ms (1.5 ms at 2 kHz) and had a duration of 8
ms. The sound stimuli were produced in an open field configuration with a
Fame tweeter (Staffhorst Electronics, Utrecht, The Netherlands) positioned at
10 cm from the pinna. Consecutive tone bursts were presented with alternat-
ing polarity at 99 ms intervals in order to avoid synchronization with the mains
frequency of 50 Hz. The responses were amplified (EG&G Instruments model
5113 amplifier, Te Lintelo Systems, Zevenaar, The Netherlands), bandpass fil-
tered between 1 Hz and 30 kHz, AD converted and stored on disk for off-line
analysis. CAP and Summating Potentials (SP) were obtained by adding the
responses evoked by tone bursts of opposite polarity, Cochlear Microphonics
(CM) by subtracting these responses (Fig. 1). The CAP was measured relative
to the SP and not relative to the baseline of the recording since, in principle,
the CAP is superimposed on the SP. The CM was measured as the peak-to-
peak amplitude in the middle of the sinusoidal response. Complete input-out-
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Figure 1: Principles of an ECochG measurement. All recordings were performed at the round window. Traces
obtained on stimuli with 180o phase difference are averaged separately. Adding these averages cancels CM so
that CAP and SP are clearly distinguished. Subtracting these averages removes CAP and SP while the CM
remains. SP is measured relative to baseline, whereas CAP is the difference between N1 and SP.
put curves were produced at 10 dB resolution until no CAP or CM could be dis-
cerned in up to 128 stimulus pairs. Maximum sound pressure was between 80-
90 dB SPL in order to prevent noise-induced hearing damage.
Electrocochleography was continued either for 1-2 days or for four weeks
(daily for the first 3-5 days, every other day for the next week, and bi-weekly
thereafter), followed by measurement of the EP.
Measurements of the EP
The endocochlear potential was measured as described by Van Emst et al.
(1997). Under halothane anesthesia (1.5% in N2O/O2) preceded by a thalamo-
nal injection (1 ml/kg, i.m.) a tracheostomy was performed. During further sur-
gery and experimental procedures the animals were anaesthetized by artificial
ventilation through a tracheal cannula with a gas-mixture containing 33% O2,
66% N2O and 1% halothane. Heart frequency was monitored and body temper-
ature was kept at 38°C. The cochlea was exposed using the ventrolateral
approach. A small hole was shaven in the bony wall of the cochlea overlying
the scala media of the second turn.  A glass microelectrode filled with 150 mM
KCl was placed just above the hole in the scala media. An Ag/AgCl pellet-con-
taining microelectrode holder was connected to an Electro 705 preamplifier
(WPI, New Haven, CT, USA). The EP was measured relatively to another
Ag/AgCl pellet placed in the neck musculature. Using a micro-manipulator
(Narishige, Tokyo, Japan), the microelectrode was advanced into the scala
media while the EP was recorded. The recording potential was zeroed when
the microelectrode came into contact with fluids just lateral to the stria vascu-
laris. Then the microelectrode was  advanced in small steps and a sudden
positive voltage was measured when the electrode entered the scala media.
On withdrawal of the electrode from the scala media the measured potential
rapidly returned to zero. 
Histological techniques
After the measurement of the EP the animal was deeply anaesthetized, tempo-
ral bones were removed, and the cochleas were fixed by intralabyrinthine per-
fusion with a tri-aldehyde fixative consisting of 3% glutaraldehyde, 2%
formaldehyde, 1% acrolein, 2,5% dimethylsulfoxide in 0.1 M sodium cacody-
late buffer (pH 7.4) followed by immersion in the same fixative for 3 h at room
temperature. The cochleas were further processed according to the routine
method for guinea pigs (De Groot et al., 1987). Semithin (1 µm) midmodiolar
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sections were cut and stained with 1% methylene blue and 1% azur II in 1%
sodium tetraborate.  In the midmodiolar sections the organ of Corti was exam-
ined at seven (2 basal, 2 middle and 3 apical) locations, separated by a half
turn spacing, and the number of OHCs present at each location was counted
in 8-10 sequential 1 µm sections. If a hair cell was not seen in 8-10 sections, it
was assumed to be absent. OHC counts from the right and left ears of each
animal were averaged. All OHC counts were performed by two investigators,
independently of one another, in a single-blind fashion (cf., De Groot et al.,
1997; Cardinaal et al., 2000a). An estimate was made of the characteristic fre-
quencies of the locations along the basilar membrane at which the OHCs
were counted (Fig. 2).
Turn  c.f. (kHz)  
b1 Lower basal turn 26.2  
b2 Upper basal turn 10.4 
m1 Lower middle turn 5.1  
m2 Upper middle turn 2.7  
a1 Lower apical turn 1.3  
a2 Middle apical turn 0.7  
a3 Upper apical turn 0.3  
Figure 2: Midmodiolar section of the cochlea. Two transections each for basal (b1 and b2) and middle turns (m1
and m2), three transections for the apical turn (a1, a2 and a3). The characteristic frequency (c.f.) in kHz is comput-
ed based upon the frequency map by Greenwood (1990).
Data analysis and statistics
Animals that did not have a normal threshold at 8 kHz (defined as a threshold
at less than 25 dB SPL stimulus level) or that showed signs of otitis media at
the moment of EP measurement were discarded from the analysis. In addi-
tion, we discarded data from cochleas that were damaged during histological
processing. Each electrocochleographic (ECochG) measurement consisted of
complete input-output curves at 10 dB resolution for 2, 4, 8, 11.3 (8√2), and 16
kHz tone bursts. Thresholds (3 µV iso-response levels) were computed by lin-
early extrapolating the sound pressure at which the line connecting the two
lowest sound pressures yielding responses larger than 3 µV crossed the 3 µV
level. For assessment of recovery, all threshold shifts were expressed as the
percentage difference from baseline (with threshold at criterion defined at
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100%). This enabled comparison of differences in recovery between different
frequencies (e.g., the absolute 16 kHz threshold shifts were significantly larger
than observed at 2 kHz). Differences in the number of cisplatin injections
needed to generate the criterion threshold shift were analyzed by a one-way
analysis of variance (ANOVA). Differences in acute threshold shift, EP and OHC
counts were also evaluated by ANOVA, followed by Student-Newman-Keuls
test if ANOVA produced evidence of group differences. Return of CAP and CM
thresholds towards baseline were tested within each treatment group by
paired t-tests at days 2 (early) and 14 (late) after criterion threshold shift was
reached. Group differences in maximum CAP amplitude were analyzed by
repeated measures ANOVA, followed by Student-Newman-Keuls test at 14
days. Differences were considered statistically significant if P<0.05.
Results
Number of days to rapid threshold deterioration
All saline co-treated animals displayed a sudden CAP threshold shift at 8 kHz
after 7 to 9 daily doses of cisplatin. As expected, the development of hearing
loss was delayed substantially (up to 14 injections needed) in several ORG
2766- and α−MSH-treated animals. However, in others the development of
hearing loss was accelerated by 1 or 2 days. The mean cumulative cisplatin
dose needed to cause hearing loss did not differ between the groups
(F(2,31)=0.809, ns), but the variance in the α−MSH- (Levine’s test, P<0.049) and
especially in the ORG 2766- (Levine’s test, P<0.035) treated group was signifi-
cantly higher than in the saline-treated group (Fig. 3).
Cisplatin effects on CAP and CM thresholds in relation to co-treatment.
The criterion to stop treatment was a CAP threshold shift of at least 40 dB at 8
kHz. The absolute CAP threshold shift at this criterion did not differ between
the groups at any of the tested frequencies. As expected, the largest shifts
were observed at 16 kHz (Fig. 4). The electrical activity of all OHCs with char-
acteristic frequencies above the probe frequency contributes to the CM signal.
Because the basal OHCs are affected most by cisplatin, we only analyzed the
CM elicited by 16 kHz tone. Similarly to the CAP, CM threshold shifts (3 µV iso-
response levels) were equal in the three groups (Fig. 4).
Because the cumulative cisplatin dose needed to cause hearing loss differed
widely between animals, especially in the α-MSH and ORG 2766 groups, and
hearing loss became evident after as few as 5 doses in one case, we plotted
the threshold shifts relative to baseline from 4 days before the sudden increase
in CAP threshold.
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Figure 3: Number of animals reaching the criterion threshold shift (≥ 40 dB at 8 kHz compared to baseline) at a
given day. White bar: Saline; Grey bar: α-MSH; Black bar: ORG 2766
Moreover, as absolute threshold shifts did not differ between experimental
groups, but did differ between tone burst frequencies, the threshold shift at the
day the threshold criterion was reached was normalized to 100% (per animal).
The absolute threshold shift on the day criterion was reached at 8 kHz was
about 50 dB compared with pre-treatment (cf., Fig. 4). The larger part of this
threshold shift developed within 24 hours after the last cisplatin injection 
(Fig. 5). A slight threshold shift was already present at day -1. 
For all five frequencies tested, this threshold shift tended to be smaller in the
α−MSH (but not ORG 2766) group than in the saline co-treated group (t-tests
α−MSH versus saline: 2, 4 kHz, ns; 8 kHz, P<0.05; 11.313 kHz, P<0.03; 16 kHz,
P<0.004).
CAP thresholds in relation to time
For the first 3 to 5 days of hearing loss, the ECochG was recorded daily.
Thereafter, the ECochG was not recorded in all animals on the same recovery
days. To facilitate visualization and statistical analysis, thresholds were linearly
interpolated to give daily values. At 2 and 4 kHz, the relative CAP threshold loss
increased even further after the criterion had been reached, even though no
further cisplatin injections were given. This deterioration tended to be less
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severe in the peptide-treated groups. Ultimately, slight (16 kHz) to major 
(2 kHz) recovery of the CAP threshold was observed (Fig. 5). Recovery pro-
gressed most rapidly in the α−MSH-treated animals, but eventually became
similar in all groups, except at 11.3 and 16 kHz. At these high frequencies, the
CAP threshold did not recover significantly in the saline-treated animals (88%
and 92% residual loss at 14 days, respectively), whereas slight recovery was
seen in ORG 2766-treated animals (76% and 83% residual loss at 14 days) and
even more so in α−MSH-treated animals (45% and 61% residual loss at 14
days). The power to detect significant group differences was small due to the
fact that half the animals were used for EP measurements between day 0 and
day 2 and because some remaining animals developed problems with the
round window electrode hereafter. As such, ANOVA indicates group differ-
ences at 2 days for 8 and 11.3 kHz only (F(2,17)=3.46, P<0.048, and F(2,17)=3.74,
P<0.045 respectively; Student-Newman-Keuls: α−MSH differed from saline at
the 5% level). Paired t-tests, which can be used to look for significant recovery
from the original threshold shift, however, indicated that statistically significant
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Figure 4: Mean 3 µV iso-response levels (dB SPL ± SEM) before the start of treatment (baseline), after reaching the
criterion threshold shift at 8 kHz (after loss) and the difference between these (absolute threshold shift) for CAP at
respectively 2, 4, 8, 11.3, and 16 kHz and CM at 16 kHz. White bar: Saline; Grey bar: α−MSH; Black bar: ORG 2766.
recovery of the CAP threshold was present in the saline-treated animals only at
2 and 4 kHz,  in the ORG 2766-treated animals only at 4 kHz, but in the α−MSH-
treated animals at 8, 11.3, and 16 kHz (Table 1).
To exclude the possibility that higher cumulative cisplatin doses impair the
ability to recover, we tested for correlations between the cumulative dose and
recovery 14 days after discontinuation of cisplatin treatment. No significant
correlation was found (data not shown). A similar picture as for the CAP
threshold emerged for the CM threshold. In the saline co-treated animals the 3
µV iso-response level of the CM at 16 kHz increased even further in the follow-
ing 2 weeks, whereas it recovered in the α−MSH and ORG 2766 co-treated ani-
mals (14 days, ANOVA F(2,10)=4.87, P<0.033; Student-Newman-Keuls: both
α−MSH and ORG 2766 differed from saline at the 5% level) (Fig. 5).
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Figure 5: Normalized shifts in 3 µV iso-response levels for the CAP threshold shift at respectively 2, 4, 8, 11.3, and 16
kHz and the CM threshold shift at 16 kHz as function of time (% ± SEM). Day 0 is the day the criterion threshold
shift (≥ 40 dB at 8 kHz, compared to pre-treatment) was observed. Threshold shift at the day criterion has been
reached has been set to 100%. Note that because animals were used for EP measurements, the number of animals
that contributed to the graph was halved between days 0 and 2. , Saline; , α−MSH; , ORG 2766.
Table 1: The presence or absence of significant recovery of CAP thresholds in individual treatment groups was test-
ed by paired t-tests, comparing the threshold shifts at day 0 (criterion threshold shift reached) with those at days 2
and 14 for Saline, α−MSH and ORG 2766 co-treated animals. P-values are summarized in this table: P-values < 0.05
have been indicated in bold. 
Saline α−MSH ORG 2766  
Probe (kHz) d0-d2 d0-d14 d0-d2 d0-d14 d0-d2 d0-d14  
2 0.111 0.015 0.243 0.178 0.312 0.100  
4 0.526 0.035 0.685 0.078 0.069 0.040  
8 0.316 0.108 0.003 0.010 0.301 0.057  
11.313 0.450 0.415 0.012 0.027 0.637 0.077  
16 0.243 0.370 0.034 0.018 0.567 0.456  
Number of animals 6 6 5 5 6 4  
CAP amplitude in relation to co-treatment
The CAP amplitude, measured at high sound pressures (between 80-90 dB
SPL), recovered differently than the CAP thresholds (Fig. 6). 
During drug administration the CAP amplitude initially decreased to a similar
extent in all three groups, even before significant changes in the CAP threshold
occurred. Whereas saline-treated animals showed slight recovery to pretreat-
ment levels, α−MSH treatment evoked a modest, and ORG 2766 treatment an
almost complete recovery of the CAP amplitude (ANOVA for repeated 
measurements days 0-10: 2 kHz: F(2,10)=5.12, P<0.029; 4 kHz: F(2,10)=5.71,
P<0.022; 8 kHz: F(2,12)=3.10, P<0.082; 11.313 kHz: F(2,11)=1.74, P<0.221; 16
kHz: F(2,11)=5.27, P<0.025; Student-Newmans-Keuls test at day 10: 2 and 8
kHz: ORG 2766 differed from α−MSH and saline; 8 and 16 kHz: ORG 2766 dif-
fered from saline, α−MSH differed from neither ORG 2766 nor saline).
CM amplitude in relation to co-treatment
The maximum obtainable CM amplitude at 16 kHz decreased dramatically
over the course of cisplatin treatment and remained at a very low level after-
wards (Fig. 6), indicating severe loss of outer hair cell function in the basal
turn. Although there was some recovery in both the α−MSH- and ORG 2766-
treated groups, this recovery was significant only at day 2 after cessation of cis-
platin, at which point the α−MSH-treated group differed significantly from the
ORG 2766- and saline-treated groups (ANOVA F(2,17)=5.25, P<0.015).
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Endocochlear potential measurements
Since longitudinal measurement of the EP is technically not feasible, EP was
measured in half the animals between 0 and 2 days after the criterion was
reached and in the remaining animals about 26-28 days later. In the first days
after discontinuation of the cisplatin treatment, there was a severe reduction
in EP (range 35-65 mV). Small group differences existed (ANOVA: F(2,12)=4.32,
P<0.04), with the EP after ORG 2766 co-treatment being slightly lower com-
pared with saline or α−MSH co-treatment. The EP and absolute CAP or CM
threshold shifts were not correlated. The EP was back to normal values
(mean: 80 mV, range 72-87 mV) after 28 days in all three treatment groups.
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Figure 6: Maximum CAP and CM amplitudes obtained at high stimulus levels (80-90 dB SPL, exact level depending
on tone burst frequency) (µV - SEM). Note that CAP amplitudes are expressed as negative voltages (measured
against SP) so they go up as they deteriorate, in contrast to CM that goes down upon deterioration.  Saline; 
, α−MSH; , ORG 2766.
OHC counts
The presence of OHCs was evaluated on midmodiolar sections through both
left and right cochleas, and counts from the left and right ears of a given ani-
mal were averaged. The number of OHCs did not correlate with the cumula-
tive cisplatin dose, nor was there a difference between OHC counts in the
animals killed early versus late (i.e., there was no evidence for either further
degeneration or regeneration during the 4 weeks following discontinuation of
cisplatin treatment, see also Klis et al. (2000)). Thus, the OHC counts from all
animals were pooled over all survival times. 
In cross-sections the normal number of OHCs is 3 and the most severe loss of
these cells was observed in the basal turn of the saline co-treated animals
(1.04 ± 0.21 (mean ± SEM) OHCs remaining). Both α−MSH and ORG 2766 co-
treatment improved the survival of OHCs (1.86 ± 0.23 and 1.69 ± 0.20 OHCs
remaining, respectively; ANOVA F(2,28)=3.76, P<0.038). OHC loss in the middle
and apical turn was less severe. Again, less OHCs remained in these turns in
the saline-treated animals than in the α−MSH and ORG 2766-treated ones, but
differences were not statistically significant (Fig. 7). There was no IHC loss.
Figure 7: Number of OHCs remaining in the basal, middle and apical turns. As there were no differences in OHC
counts between animals sacrificed early (0-2 days after reaching criterion threshold shift) versus late (> 22 days)
data from all animals were pooled. Bars represent the mean OHC counts in the 2 basal, 2 middle and 3 apical sec-
tions. White bar: Saline; Grey bar: α−MSH; Black bar: ORG 2766.
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Discussion
Cisplatin ototoxicity 
This study demonstrates that cisplatin-induced ototoxicity is partly reversible at
a functional level (Klis et al., 2000, 2002) and that co-treatment with α-MSH and
ORG 2766 positively affects OHC survival and function. Neither peptide consis-
tently delayed the occurrence of ototoxicity, but recovery from ototoxicity was
faster and more extensive in peptide-treated animals. Moreover, cisplatin
affected cochlear function at two levels, the stria vascularis and the OHCs. The
EP, which is generated by the stria vascularis and critical for sound transduc-
tion, initially decreased in all three experimental groups but recovered com-
pletely. The initial decrease in the EP can explain both the observed losses of
CM and the CAP threshold shift. However, whereas the EP recovered com-
pletely, the CAP threshold did not. Recovery was especially poor after saline
co-treatment and at the highest frequencies, probably because of the severe
OHC loss observed in the basal turn. The finding that no statistically significant
recovery of the CAP threshold was observed at 4 and 8 kHz might seem to
contradict earlier observations (Klis et al., 2000), but is probably caused by the
low number of animals monitored over an extended period in this study, as
compared to the previous one, diminishing statistical power. The strong
decrease in CAP amplitude at high sound pressures indicates either disruption
of the transduction machinery (IHC to afferent axon), neuropathy of the
cochlear ganglion, or both. Because quantitative measures indicated that cis-
platin adversely affected the morphology of spiral ganglion cells (Alam et al.,
2000; Cardinaal et al., 2000b), we suggest that cisplatin also causes neuropathy
of the auditory nerve, analogous to the peripheral sensory neuropathy caused
by the drug (Hamers et al., 1991b). 
Pharmacological intervention with both ORG 2766 and α−MSH provided partial
protection against most of the adverse effects of cisplatin. Both OHC survival
and recovery of the CAP threshold were significantly enhanced by both pep-
tides. The recovery of CAP amplitude at high sound pressures was enhanced
by both ORG 2766 and α−MSH. Unexpectedly, neither of the peptides consis-
tently delayed the occurrence of hearing loss. Although in several animals oto-
toxicity was considerably delayed (up to 14 doses needed instead of 9), in
other animals it occurred earlier (5 doses instead of 7). It should be noted that
there is no clear relationship between the cumulative cisplatin dose and oto-
toxic symptoms in either humans (Black et al., 2001) or experimental animals,
and that in the latter the amount of cisplatin needed to elicit pathology may
vary widely between experiments (Klis et al., 2002). Nonetheless, the observa-
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tions in this study demonstrate that the peptides do affect the response of the
cochlea to cisplatin. The findings also help to explain the results of previous
studies in which fixed cumulative cisplatin doses were used. Major threshold
shifts were observed in all saline but not all ORG 2766 co-treated animals after
8 (2.0 mg/kg/day) (Hamers et al., 1994) or 10 (1.6 mg/kg/day, Hamers and Klis:
unpublished observations) doses. In view of the present data, we suppose that
in these previous studies the cumulative cisplatin dose sufficed to affect all
saline- but not all peptide-treated animals. The ‘non-responders’ to ORG 2766
tended to have slightly worse CAP input-output curves than the saline co-treat-
ed ones, but OHC survival was significantly better in these ‘non-responders’
than in saline-treated controls (De Groot et al., 1997). Similar observations
were reported by Stengs et al. (1998b): 8 doses of 1.0 mg cisplatin/kg induced
significant CAP threshold shifts in only 1 of 6 of saline co-treated animals,
whereas it did so in 3 of 6 ORG 2766 co-treated animals. In contrast, 8 injec-
tions with 1.5 mg cisplatin/kg led to severe threshold shifts in 6 of 6 saline co-
treated animals but only in 3/6 ORG 2766 co-treated animals. These results
suggest that, as in the current study, co-treatment with ORG 2766 might both
sensitize and desensitize animals for cisplatin-induced hearing loss.
Little is known about the sub-cellular mechanism by which cisplatin exerts its
side effects. Cisplatin easily crosses the cell membrane, but once within the
cell it is hydrated and platinates proteins and nucleic acids; its antineoplastic
activity is due to intra-strand DNA cross-linking inside the tumor cells.
Transplatin, the isomer of cisplatin, does not cause intra-strand DNA/RNA
cross-links and does not display anti-tumor activity or any of the other side
effects (Saito et al., 1997b). Therefore, it is likely that the anti-tumor efficacy
and the side effects have a similar background. Actively dividing cells with cis-
platin-caused DNA damage eventually proceed into apoptosis, but the ques-
tion remains why terminally differentiated cells such as OHCs or neurons are
killed by cisplatin-induced genomic DNA damage. One reason may be that the
drug negatively affects transcription (by DNA cross-linking and inhibition of
rRNA synthesis (Jordan and Carmo-Fonseca, 2000)) and translation. Another
reason is that mitochondrial DNA is especially vulnerable to cisplatin because
it lacks efficient repair mechanisms (Olivero et al., 1995). Indeed, 
mitochondrial damage is an early event in cisplatin nephrotoxicity (Brady et
al., 1990). Caspase-9 (mitochondrial apoptosis pathway) is activated in an 
in vitro model of cisplatin-induced cochlear hair cell damage (Devarajan et al.,
2002), and severe swelling of mitochondria can sometimes be observed in 
spiral ganglion cells of animals treated with cisplatin (Cardinaal and De Groot,
unpublished observations). Cisplatin also affects mitochondrial function by
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directly inhibiting the respiratory chain (Kruidering et al., 1997). In kidney prox-
imal tubular cells, inhibition of mitochondrial function precedes cell death.
Mitochondrial dysfunction can increase free radical production (and so 
promote cell damage) on the one hand and initiate apoptosis through release
of cytochrome-c on the other (Li et al., 1997), as reported in the stria vascularis
(Watanabe et al., 2001). The former may explain why radical scavengers can
prevent at least some of the cisplatin-induced damage (Hamers et al., 1993b,
Kamimura et al., 1999, Huang et al., 2000, Feghali et al., 2001), and the latter
explains why the same holds true for trophic compounds such as α−MSH and
ORG 2766 but also classical neurotrophic substances such as NGF (Apfel et al.,
1992), which in general enhance the ability of cells to counter a-specific
insults. 
On the basis of these and earlier data (Hamers et al., 1994; De Groot et al.,
1997; Klis et al., 2000), we suggest that cisplatin toxicity in the inner ear first
occurs in the stria vascularis because this structure is more exposed to cis-
platin than the OHCs (Laurell et al., 1995). Interference with mitochondrial
function in the stria vascularis eventually impairs its electrogenic activity, lead-
ing to a precipitous drop of the EP and a strong increase in CAP thresholds.
Until then, OHCs function relatively normal and no OHC loss occurs (De Groot
et al., 1997). Further strial failure, due to either the decrease in the EP or the
release of toxins in the endolymph, then causes the death of the most active
(i.e., basal) OHCs, even though OHC intracellular levels of cisplatin are not
high enough to cause damage per se. Discontinuation of cisplatin treatment
enables the stria vascularis and thus the EP to recover, with concomitant CAP
threshold recovery, provided that a sufficient number of OHCs have survived
and are functional.
According to this hypothesis, the peptides affect the ability of the stria vascu-
laris to withstand the toxicity of cisplatin, although this effect is not consistent
among individuals. The peptides also consistently protect against OHC death
once strial failure has developed. In principle, α−MSH might modulate strial
function because the intermediate cells necessary for normal strial function
are melanocytes (Motohashi et al., 1994). ORG 2766, however, has no melano-
trophic or corticotrophic activity (Greven and De Wied, 1973) and is known for
sure not to activate any of the five currently known melanocortin (MC) recep-
tor subtypes (Adan et al., 1994, 1996). As both peptides have similar trophic
activity in models of mechanical peripheral nerve damage (Bijlsma et al.,
1984; Van der Zee et al., 1991) and ototoxicity (Hamers et al., 1994; De Groot et
al., 1997; Stengs et al., 1998b; Heijmen et al., 1999), it is conceivable that there
is an as yet unidentified receptor for ORG 2766 that can also be activated by α−
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MSH, though less efficiently, because α−MSH and the potent MC1 and MC4
agonist MT-II seem to be less effective than ORG 2766 in preventing peripheral
neuropathies (Hamers and Ter Laak, unpublished observations).
ORG 2766 and α−MSH also differed in their efficacy to protect against cisplatin-
induced cochlear damage. Both provided comparable protection against OHC
loss, but whereas α−MSH produced a robust recovery of the CAP threshold,
ORG 2766 most strongly affected recovery of the CAP amplitude, or auditory
nerve function. So, co-treatment with ORG 2766 might reverse the cochlear
neuropathy, similar to its action in peripheral sensory neuropathy in both ani-
mals (De Koning et al., 1987; Hamers et al., 1991a, 1993a) and humans
(Gerritsen Van der Hoop et al., 1990). However, to date, little evidence for the
involvement of the auditory nerve in cisplatin-induced hearing loss has been
published, although an animal study (Cardinaal et al., 2000b) and a human
study of post-mortem temporal bone material (Hinojosa et al., 1995) described
morphological damage to the spiral ganglion in addition to OHC and strial
damage. 
Conclusion
This study shows that cisplatin causes profound damage to the cochlea, affect-
ing OHCs, stria vascularis and spiral ganglion neurons. α−MSH and ORG 2766
significantly prevent OHC loss and ameliorate other signs and symptoms of
cisplatin-induced ototoxicity. The fact that co-treatment with these peptides
did not consistently delay the occurrence of ototoxicity will probably limit its
clinical use. Nonetheless, these peptides remain interesting tools to further
investigate the cellular processes that determine susceptibility and resistance
to cisplatin ototoxicity and perhaps also other types of hearing loss.
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Summary
It has previously been demonstrated that systemic administration of cisplatin
induces severe ototoxic effects such as an increase of the compound action
potential (CAP) threshold, a reduction in CAP amplitude at high stimulus lev-
els, cochlear microphonics (CM) and the endocochlear potential (EP).
Concomitant administration of α−melanocyte stimulating hormone (α−MSH)
has shown to stimulate recovery of both CAP threshold and CM. The objective
of the present study was to investigate whether this recovery co-varies with
the recovery of EP within the first three days after cessation of cisplatin treat-
ment. Albino guinea pigs, equipped with a permanent round window elec-
trode, which allowed daily monitoring of the cochlear potentials, were treated
daily with a bolus injection of 1.5 mg/kg cisplatin (i.p.) and an injection of 75
µg/kg α−MSH (s.c.) or saline until the electrocochleogram showed a persistent
decrease in CAP amplitude (≥ 40 dB threshold shift at 8 kHz). Then, cisplatin
treatment was stopped, but α−MSH and saline treatment were continued for
one extra day. Either one, two, or three days after cessation of the cisplatin
treatment the EP was measured. The EP was depressed when measured one
day after cessation of cisplatin and showed no tendency to recover in the sub-
sequent two days. Co-treatment with α−MSH did not prevent nor stimulate
recovery of the EP within this time-window. Nevertheless, recovery of the CAP
threshold at 2 kHz was observed in both saline and α−MSH treated animals.
Since no recovery of EP was observed in the measured time-window, the
ameliorating effect of α−MSH in cisplatin-induced ototoxicity might be more
complex than previously thought; α−MSH might exert its effect at levels other
than the stria vascularis. 
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Introduction
Cisplatin is an important antineoplastic drug, effective in the treatment of solid
epithelial tumors. Unfortunately, treatment with cisplatin evokes severe side
effects. One of these side effects is ototoxicity, which usually presents itself in
humans as a high-frequency hearing loss accompanied with tinnitus
(Schweitzer, 1993). Animal studies have shown that chronic cisplatin adminis-
tration results in degeneration of the outer hair cells (OHCs), predominantly in
the basal turn of the cochlea. In addition to the toxic effect upon the hair cells,
there is growing evidence for an effect on the stria vascularis (Nakai et al.,
1982; Tange and Vuzevski, 1984; Kohn et al., 1988; Saito and Aran, 1994b;
Zheng and Gao, 1996; Kohn et al., 1997; Meech et al., 1998; Cardinaal et al.,
2000a, b; Watanabe et al., 2002). The damage of the stria vascularis consists of
blebbing and vacuolation of the marginal cells and atrophy of the intermediate
cells. Degeneration of these tissues is associated with a decrease in the endo-
cochlear potential (EP) (Laurell and Engstrom, 1989; Tsukasaki et al., 2000; Klis
et al., 2000, 2002; O’Leary and Klis, 2002). Since the EP provides the main driv-
ing force for hair cell transduction processes within the cochlea and, there-
fore, for normal auditory function (Wangemann and Schacht, 1996), the
decrease of the EP in turn raises auditory thresholds. Previous experiments,
performed by Klis et al. (2000, 2002), showed that both EP and auditory thresh-
olds partially recover within 4 weeks after cisplatin treatment, while OHC
counts do not improve in time. Another study, by O’Leary and Klis (2002),
showed that in cisplatin-deafened albino guinea pigs the EP returns to normal
within 5 to 7 days. Finally, some studies (Alam et al., 2000; Cardinaal et al.,
2000b) suggest that cisplatin also affects the spiral ganglion cells. These find-
ings raise the question whether cisplatin affects all three target-structures 
separately or that degeneration of one target-structure is related to the other. 
Previous work within our group has shown that the melanocortin 
α−melanocyte stimulating hormone (α−MSH) may stimulate recovery
(Hamers et al., 2003). Since epidermal melanocytes have shown to be primary
targets for α−MSH and melanocytes are also present within the stria vascularis
as intermediate cells (Hilding and Ginzberg, 1977), it seems likely that this is
the site of action of the putative protective effect of α−MSH.
The purpose of this study is to further investigate whether recovery of auditory
thresholds and EP are related and whether these two indicators of cochlear
health are affected to the same extent by co-treatment with α−MSH. 
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Materials and Methods
Animals and experimental design
Fifty female albino guinea pigs (strain: Dunkin-Hartley, Harlan Laboratories,
Horst, The Netherlands; weight 240-560 g), equipped with a permanent round
window electrode were treated with cisplatin (i.p.) and one of two co-treat-
ments (s.c.). These co-treatments consisted of either α−MSH or approximately
equal volumes of saline. The animals were housed, five together, in macrolon
cages and had free access to food and water. They were maintained on a
12:12 h dark/light cycle. The animals were treated daily with cisplatin and the
relevant co-treatment until electrocochleograms showed at least 40 dB
increase in the compound action potential (CAP) threshold at 8 kHz. This
threshold was defined as the sound level required to evoke a CAP amplitude
of 3 µV. One day after the 40 dB criterion was reached, an additional last dose
of α−MSH or saline was given, but no cisplatin. After the end of the treatment
electrocochleography was continued for one, two, or three days (cf., Table 1)
to evaluate possible effects of α−MSH on recovery, followed by measurement
of the endocochlear potential (EP). The care and use of the animals reported
in this study were approved by the Animal Care and Use Committee of the
University of Utrecht (DEC-UMC # 91035).
Drugs
Cisplatin (1 mg/ml; Platosin®; Pharmachemie BV, Haarlem, The Netherlands)
was diluted with physiological saline (pH 7.4) to a final concentration of 0.1
mg/ml. It was administered intraperitoneally at a daily dose of 1.5 mg/kg body
weight. This dose was based upon the previous experiments of Stengs et al.
(1998a, b) and Heijmen et al. (1999). The high dilution was chosen to stimu-
late diuresis and thus to minimize renal effects. The cisplatin injection was
immediately followed by a subcutaneous injection of either 75 µg/kg α−MSH
(Bachem, Heidelberg, Germany) or saline. The α−MSH dose of 75 µg/kg/day
was based upon experiments with a positive outcome performed previously
by Heijmen et al. (1999) and Hamers et al. (2003).
Surgical techniques
Prior to the operation the animals were injected with chloramphenicol sodium
succinate (30 mg/kg i.m.) and then anaesthetized with 40 mg/kg ketamine and
10 mg/kg xylazine (i.m.). Local anaesthetic (1% lidocaine, 0.50 ml) was used in
areas to be incised. A mid-line incision was made on the dorsal surface of the
head starting 2.5 cm anterior of bregma and continued post-auricularly to the
base of the pinna. Under sterile conditions the bulla of the left ear was opened
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retro-aurically and the skull was exposed around the bregma. The round win-
dow electrode, made of insulated stainless-steel wire (diameter 0.175 mm
including teflon insulation; Advent, Halesworth, UK) with a 0.5 mm diameter
gold ball micro-welded (Unitek 80F; Unitek Equipment, Monrovia, CA, USA) to
the exposed and flattened tip, was positioned on the round window and
secured to the bulla with carboxylate cement (Durelon, ESPE dental supplies,
Utrecht, The Netherlands). The wire was soldered to a Berg 22-26 gold termi-
nal that fitted into a Berg 2x3 mini-latch housing (Farnell, Maarssen, The
Netherlands). Stainless-steel screws were inserted through the skull and con-
nected to the mini-latch housing via two silver wires connected to a gold ter-
minal. The mini-latch housing was connected to the skull with dental acrylic
cement, which also covered and insulated the stainless-steel screws and the
electrodes. The wound was closed in two layers with vicryl.
Electrocochleography
Measurements were performed differentially with the round window elec-
trode as the active electrode and two screws on the skull as reference and
ground electrode, respectively. 
Animals that did not have a normal threshold at 8 kHz (defined as a threshold
at less than 25 dB SPL stimulus level) to begin with or that showed signs of oti-
tis media at the moment of EP measurement were excluded from further
analysis. Trains of tone bursts of 2, 4, 8, and 16 kHz were used as stimuli. The
tone bursts were constructed with cosine-shaped rise-and-fall times of 1 ms
(1.5 ms at 2 kHz) and had a duration of 8 ms. The sound stimuli were pro-
duced in an open-field configuration with a Fame tweeter (Staffhorst
Electronics, Utrecht, The Netherlands) positioned at 10 cm from the pinna.
Consecutive tone bursts were presented with alternating polarity at 99 ms
intervals in order to avoid synchronization with the mains frequency of 50 Hz.
The responses were amplified (EG&G Instruments model 5113 amplifier, Te
Lintelo Systems, Zevenaar, The Netherlands), bandpass filtered between 1 Hz
and 30 kHz, AD converted, and stored on disk for off-line analysis. The animals
were lightly restrained, but remained awake during all measurements, avoid-
ing the disadvantages of repeatedly having to anaesthetize the animals.
CAPs were obtained by adding the responses evoked by tone bursts of oppo-
site polarity; Cochlear Microphonics (CM) by subtracting these responses. The
CAP was measured relative to the positive summating potential (SP) and not
relative to the baseline of the recording since, in principle, the CAP is superim-
posed upon the SP. The CM was measured as the peak-to-peak amplitude in
the middle of the sinusoidal response. Complete input-output curves were
produced at 10 dB resolution until no CAP or CM could be discerned in up to
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128 stimulus pairs. Maximum sound pressure was between 80-90 dB SPL in
order to prevent noise-induced hearing damage. Electrocochleography was
continued either for one, two or three days followed by measurement of the
endocochlear potential.
Statistical analysis was performed by means of analysis of variance (ANOVA),
using STATISTICA software. 
Measurement of the endocochlear potential
The endocochlear potential was measured as described in Van Emst et al.
(1997). Under halothane anesthesia (1.5% in N2O/O2), preceded by a hypnorm
injection (0.1 mg/kg, i.m.), a tracheostomy was performed. During further sur-
gery and experimental procedures the animals were anaesthetized by artificial
ventilation through a tracheal cannula with a gas-mixture containing 33% O2,
66% N2O and 1% halothane. Heart frequency was monitored and body temper-
ature was kept at 38°C. The cochlea was exposed using the ventrolateral
approach. A small hole was shaven in the bony wall of the cochlea overlying
the scala media of the second turn. A glass microelectrode filled with 150 mM
KCl was placed just above the hole in the scala media. An Ag/AgCl pellet-con-
taining microelectrode holder was connected to an Electro 705 preamplifier
(WPI, New Haven, CT, USA). The EP was measured relatively to another
Ag/AgCl pellet placed in the neck musculature. Using a micromanipulator
(Narishige, Tokyo, Japan), the microelectrode was advanced into the scala
media while the EP was recorded. The recording potential was zeroed when
the microelectrode came into contact with fluids just lateral to the stria vascu-
laris. Then the microelectrode was advanced in small steps and a sudden pos-
itive voltage was measured when the electrode entered the scala media. On
withdrawal of the electrode from the scala media the measured potential rap-
idly returned to zero. 
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Results 
General findings
Eighteen of the 50 operated animals showed an abnormal threshold at 8 kHz
directly after surgery or showed infections upon inspection of the left (opera-
ted) ear at the moment of EP measurement. These animals were excluded
from the experiment. Table 1 shows the distribution of the remaining animals
(n=32) over the six experimental groups.
Table 1: Distribution of the animals over the experimental groups
Time of EP measurement Co-treatment 
(days after threshold shift) Saline α−MSH
Day 1 4 5  
Day 2 5 6  
Day 3 6 6  
Number of days to rapid threshold deterioration
Figure 1 shows the time required to reach the criterion threshold shift of ≥ 40
dB at 8 kHz. It took the saline co-treated animals 5 to 10 days of cisplatin to
evoke the criterion threshold loss, which corresponds to earlier findings (Klis
et al., 2000; Hamers et al., 2003).
Figure 1 suggests that the development of hearing loss was not delayed in the
α−MSH-treated animals. It took these animals 4 to 10 injections of cisplatin. A t-
test confirmed this lack of effect of co-treatment (P=0.790). 
Maximum threshold shift in dB as a function of frequency at the day cisplatin
treatment was stopped is shown in Figure 2 for both co-treatments. The hear-
ing loss occurred in a broad frequency range, although it tended to increase at
higher stimulus frequencies. ANOVA showed a significant main effect of fre-
quency (F(3,90)=33.88, P<0.001), but not of co-treatment (F(1,30)=0.053,
P=0.819). We also analyzed the CM elicited by a 16 kHz tone (data not
shown). Similar to the observed CAP threshold shifts, CM threshold shifts (3 µV
iso-response levels) were equal in the two groups (ANOVA; F(1,30)=1.338,
P=0.256). 
74
Chapter 4
Figure 1: The time necessary to evoke a hearing loss of ≥ 40 dB in the 3 µV iso-response level (CAP threshold) at 8
kHz for the saline (white bar) and the 75 µg/kg/day α−MSH (black bar) co-treated animals.
Figure 2: Maximal CAP threshold shift (± SEM) at the day the cisplatin treatment was stopped as a function of 
frequency for the saline () and the 75 µg/kg/day α−MSH () co-treated animals.
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Effects on EP in relation to recovery time and co-treatment.
Both the saline and the α−MSH co-treated animals were divided into three
separate groups in which the EP was measured 1, 2, or 3 days after cessation
of the cisplatin treatment. Since the EP measurement is highly invasive, we
used each day another group of animals. Figure 3 shows the results of the
recording of the EP in the second turn of the cochlea. 
For the CM thresholds (data not shown) no recovery was observed within the
measured time-period in any of the co-treated groups.
Figure 3: The endocochlear potential (± SEM) plotted at 1, 2 and 3 days following the last dose of cisplatin for the
saline (white bar) and the 75 µg/kg/day α−MSH (black bar) co-treated animals.
At day 1 the EP has decreased from its normal value between 75 and 85 mV
(Gill and Salt, 1997; Klis et al., 2002; O’Leary and Klis, 2002) to a value of 57.8 ±
2.9 mV (mean ± SEM). No recovery of the EP is observed at day 2 and 3
(F(2,12)=0.175, P=0.842). Furthermore, co-treatment with α−MSH did not affect
the decrease of EP nor its behavior in time. 
Normalized recovery of CAP and CM thresholds in relation to stimulus frequency and
co-treatment.
To facilitate comparisons across animals and across frequencies, threshold
shifts and recovery were normalized by setting the threshold shift at the day
cisplatin treatment was stopped to 0% and baseline values to 100%. Figure 4 
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Figure 4: Recovery at 2, 4, 8, and 16 kHz (% ± SEM) of the CAP threshold for the saline () and the 75 µg/kg/day 
α−MSH () co-treated animals. Each day a group of animals was withdrawn to undergo EP measurements so the
number of animals contributing decreased each subsequent day (cf., Table 1).
shows the percentage recovery of CAP threshold during the first three days of
recovery. 
On days 2 and 3 after cessation of the cisplatin treatment a slight recovery of
the CAP thresholds was observed. ANOVA showed a significant main effect of
time (recovery) at 2 kHz (F(2,20)=5.25, P=0.015), but no effect of co-treatment
(F(1,10)=0.165, P=0.693). At the other frequencies no significant recovery was
observed. Neither of both co-treatments showed a significant correlation
between the EP and the recovery of the CAP threshold at 2 kHz in the individ-
ual animals measured at day 2 and 3 (Fig. 5) (saline: r=0.577, P=0.063; 
α−MSH: r=-0.052, P=0.873).
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Figure 5: Recovery (%) of the CAP threshold at 2 kHz on day 2 () and 3 () after cessation of the cisplatin treat-
ment as a function of EP (mV) for the individual saline (white) and the 75 µg/kg/day α−MSH (black) co-treated 
animals.
Recovery of CAP and CM amplitudes in relation to stimulus frequency and co-treatment
The CAP amplitude at high stimulus levels recovers differently from CAP
thresholds in the sense that recovery is usually faster at higher stimulus levels
(Klis et al., 2002). Figure 6 shows the (remaining) CAP amplitude, measured at
high sound pressures (between 80-90 dB SPL), on the three days after the cri-
terion threshold loss occurred. In contrast to the recovery of the CAP thresh-
old, no recovery was observed for the CAP amplitude in any frequency in the
studied time-window (ANOVA; F(2,18)=0.604, P=0.577). However, after close
inspection of the graphs a t-test was performed for day 3. This test showed a
significantly higher CAP amplitude at 2 kHz for the α−MSH co-treated group
(P=0.040).
The CM amplitude at 16 kHz (data not shown) also decreased dramatically
over the course of cisplatin treatment. However, no recovery and no effect of
co-treatment were found.
Figure 6: Remaining CAP amplitude (78-86 dB SPL) at 2, 4, 8, and 16 kHz (± SEM) plotted at 0, 1, 2, or 3 days fol-
lowing the last cisplatin treatment for the saline () and the 75 µg/kg/day α−MSH () co-treated animals. 
Day 0 represents the day that the cisplatin treatment was stopped. Each day a group of animals was withdrawn to
undergo EP measurements so the number of animals contributing decreased each subsequent day (cf., Table 1).
Discussion
The recovery of cochlear sensitivity and its relation to recovery of EP 
Previously, several of our animal studies have shown statistically significant
recovery of the auditory sensitivity after cisplatin-induced hearing loss (Stengs
et al., 1997; Klis et al., 2000, 2002; O’Leary and Klis, 2002; Hamers et al., 2003).
Recovery has also been reported in other experimental animal studies
(Stadnicki et al., 1975; Nakai et al., 1982) and anecdotically in humans
(Aguilar-Markulis et al., 1981; Vermorken et al., 1983; Melamed et al., 1985;
Laurell and Jungnelius, 1990). An important issue is how to explain this recov-
ery. Klis et al. (2002) showed that deteriorating CAP thresholds occurred in a
broad frequency range, though the OHC loss was limited to the basal turn.
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There was also no relation between recovery and OHC loss, i.e. OHC counts
did not improve in time. So, the above findings suggested that a more global
determinant of cochlear sensitivity had to be involved in the recovery of
cochlear potentials. Klis et al. (2000, 2002) and O’Leary and Klis (2002)
showed a depression of EP at the moment CAP threshold was increased, fol-
lowed by a recovery of both EP and auditory sensitivity after cessation of the
cisplatin treatment. Therefore, it was suggested that recovery of the cochlear
sensitivity proceeds together with recovery of the EP up to a point determined
by permanent OHC loss (Klis et al., 2002). O’Leary and Klis (2002) and Hamers
et al. (2003) also proposed that both strial and hair cell injuries contribute to
ototoxicity over a wide range of cisplatin doses, and that the effects upon both
are temporally related. The present (preliminary) study suggests that cisplatin
ototoxicity and subsequent recovery might be based on more complex
processes. Our study concentrated on the recovery of the auditory thresholds
within the first three days after cessation of the cisplatin treatment. In this
time-window we only observed significant recovery of the CAP threshold at 2
kHz. However, in contrast to the other studies, in which also recovery of the EP
was observed, we found a stable, but still decreased, EP value within this
time-window. This observation seems to contradict the hypothesis that CAP
threshold recovery and EP recovery are related. However, also in contrast with
the previous studies, which used longer observation periods, recovery of CAP
thresholds is only observed at 2 kHz and even at that frequency recovery is
small. Furthermore, no recovery is observed in the CAP amplitudes at high
stimulus levels. Since recovery was only observed occasionally in CAP thresh-
old, CAP amplitude and EP, it was almost impossible to establish a correlation
between the recovery of CAP and EP.
In other words, we may have missed an essential part of the recovery process
by limiting our time-window to 3 days after cessation of cisplatin.
Nevertheless, we cannot rule out a mechanism other than EP recovery that
might contribute to recovery of cochlear sensitivity. Klis et al. (2002) have
demonstrated that the OHCs do not contribute to the threshold recovery. Of
course sub-cellular damage and subsequent repair of OHCs cannot be ruled
out. Further, a morphological study by Cardinaal et al. (2000b) showed that cis-
platin induced vacuolation of the spiral ganglion cells besides OHC loss and
strial dysfunction. Another morphological study (van Ruijven et al., personal
communication) showed severe shrinkage of spiral ganglion cells and a CAP
threshold shift of 30-40 dB at 8 kHz after cisplatin treatment, even before any
OHC loss was observed. Together these results suggest that recovery of the
spiral ganglion cell function might be related to recovery of the CAP threshold
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and CAP amplitude within the first days after cessation of cisplatin. Further
research into the mechanism(s) of recovery, particularly expanding the time-
window of analysis, will be necessary to settle this matter. 
α−MSH treatment in relation to recovery of EP, CAP threshold and CAP amplitude.
In previous studies it was shown that α−MSH is not only able to postpone the
ototoxic effects of cisplatin (Heijmen et al., 1999), but also to enhance recov-
ery. A recent study performed by Hamers et al. (2003) showed that α−MSH
provided partial protection against most of the adverse effects of cisplatin;
OHC survival, recovery of the CAP threshold and recovery of the CAP ampli-
tude at high sound pressures were significantly enhanced. Significant recovery
of the CAP threshold at 8 kHz already revealed itself within two days after ces-
sation of the cisplatin treatment, which is remarkably different from the situa-
tion in the present study. The recovery of the CAP amplitude at high sound
pressures, observed especially in the low frequencies, was already enhanced
by α−MSH three days after the end of the cisplatin administration similar to
what was found here. Hamers et al. (2003) suggested that α−MSH enhanced
recovery by affecting the ability of the stria vascularis to withstand the toxicity
of cisplatin and therefore for the EP to recover faster. Since EP was only meas-
ured directly after cessation of the cisplatin administration or 28 days there-
after this supposedly faster recovery of EP as a result of α−MSH co-treatment
could not be characterized. The results from the present study showed a sig-
nificant recovery of the CAP threshold at 2 kHz within the first three days after
cessation of cisplatin, but no ameliorating effect of α−MSH. Also EP did not
show an enhanced recovery as result of the α−MSH treatment. We might con-
clude, as before, that the time-window in this experiment was too narrow to
find α−MSH-enhanced recovery. 
Furthermore, as concluded before when we discussed the relation between
CAP recovery and EP recovery, we must conclude that the situation might be
more complex than previously thought and that α−MSH might work also at lev-
els other than the stria vascularis. Given the histological evidence for ganglion
cell disruption (Cardinaal et al., 2000b; Hamers et al., 2003) we suggest that α−
MSH might work at this level (too), similar to its action in peripheral sensory
neuropathy in experimental animals (Bär et al., 1993; Windebank et al., 1994).
The small recovery we found on day 3 in the CAP amplitude at 2 kHz of the α−
MSH treated animals, in absence of any effect on the EP, might be due to these
α−MSH effects on the eight nerve. 
81
Effect of α−MSH on recovery of EP
82
Chapter 4
Acknowledgements
This study was supported by the Dutch Cancer Society. The contributions of
H.J. Mansvelt Beck and R. van Vossen (electrode design) and J. W. Sepmeijer
(EP measurements) are gratefully acknowledged.
83
Effect of α−MSH on recovery of EP

Systemic co-treatment with 
α−melanocyte stimulating hormone 
delays hearing loss caused by local
cisplatin administration in guinea pigs
Francisca L.C. Wolters 
Sjaak F.L. Klis 
John C.M.J. de Groot 
Frank P.T. Hamers 
Diane M. Prieskorn
Josef M. Miller
Guido F. Smoorenburg
Hearing Research 2003; 179:53-61.
Chapter 5
86
Chapter 5
Summary 
It has previously been demonstrated that ototoxicity induced by systemic
administration of cisplatin is reduced by concomitant administration of
melanocortins, like α−melanocyte stimulating hormone (α−MSH). However,
these experiments were hampered by large interanimal variability. Therefore,
we re-investigated the effects of systemically administered α−MSH during local
(intracochlear) administration of cisplatin. Guinea pigs, implanted with a
round window electrode, allowing daily monitoring of the compound action
potentials (CAP), and a mini-osmotic pump, pumping either 0.5 µl/h physio-
logical saline or cisplatin solution (15 µg/ml), were co-treated daily with a sub-
cutaneous bolus injection of either α−MSH (75 µg/kg) or physiological saline
for one week or until the electrocochleogram showed a persistent decrease in
CAP amplitude (40 dB threshold shift at 8 kHz). Next, the animals were sacri-
ficed and the cochleas were processed for histology. After 2 to 3 days, cisplatin
alone caused a threshold shift at all frequencies (2-16 kHz). Co-administration
with α−MSH consistently delayed the criterion threshold shift by 1 day. When
the 40 dB criterion had been reached, similar OHC losses in both the
cisplatin/α−MSH and cisplatin/saline treated groups were observed. 
This experiment confirms that direct administration of cisplatin into the
cochlea results in considerably less interanimal variability than systemic
administration and that co-treatment with α−MSH delays cisplatin ototoxicity.
Since cisplatin was delivered directly to the cochlea, the ameliorating effect of
α−MSH probably involves a cochlear target.
87
Intracochlear cisplatin and systemic α−MSH
Introduction
Cisplatin (cis-diamminedichloroplatinum (II)) is a widely used antineoplastic
drug, effective in the treatment of solid epithelial tumors. Unfortunately, the
therapeutic efficacy of cisplatin is limited because of its side effects, which
include nephrotoxicity, peripheral neuropathy, and ototoxicity. In humans, the
ototoxic effect usually presents itself as a high-frequency hearing loss accom-
panied by tinnitus (Schweitzer, 1993). Animal studies have shown that chronic
cisplatin administration leads to loss of outer hair cells (OHCs), with those in
the basal turn more severely affected than the OHCs in the medial and apical
turn. At high doses or prolonged exposure, loss of inner hair cells (IHCs) has
also been observed (Tange, 1984; Hoeve et al., 1988; Saito and Aran, 1994b;
Cardinaal et al., 2000a). The ototoxic effects of cisplatin are not limited to the
auditory hair cells; also the stria vascularis and spiral ganglion cells are affected
(Tange and Vuzevski, 1984; Kohn et al., 1988; Zheng and Gao, 1996; Kohn et al.,
1997; Meech et al., 1998; Cardinaal et al., 2000a,b). 
During the past decade, a variety of compounds have been investigated in
order to prevent or reduce the ototoxic effect of cisplatin without affecting its
antineoplastic action. Compounds that are known for their nephro-, and neuro-
protective actions, when administered together with cisplatin, also protect the
inner ear from cisplatin toxicity. A well-investigated class of compounds are the
anti-oxidants (Rybak et al., 1995, 1999a; Reser et al., 1999; Campbell et al.,
1999; Li et al., 2001, 2002). The use of anti-oxidants is based upon the assump-
tion that reactive oxygen species, generated in the cochlea after administration
of cisplatin, are responsible for the ototoxic damage (Clerici et al., 1996; Kopke
et al., 1997). However, excessive amounts of these anti-oxidants are necessary
to realize a protective effect against cisplatin ototoxicity and most of these
drugs probably bind directly to cisplatin, potentially inhibiting its anti-tumor
action. Ekborn et al. (2002) showed that protection from cisplatin ototoxicity by
systemic treatment with the anti-oxidant D-methionine could be explained by a
decreased serum concentration of cisplatin. 
Another class of compounds that ameliorates cisplatin ototoxicity is the group
of melanocortins, such as the AdrenoCorticoTropic Hormone (ACTH)(4-9)
-analog ORG 2766 and α−melanocyte stimulating hormone (α−MSH) (Hamers
et al., 1994; De Groot et al., 1997; Stengs et al., 1998b; Heijmen et al., 1999;
Smoorenburg et al., 1999; Cardinaal et al., 2000c). With both peptides, admini-
stered separately, either complete protection from cisplatin ototoxicity (normal
electrophysiological auditory thresholds and OHC counts) was observed or
thresholds were increased similar to those in saline co-treated animals
(Hamers et al., 1994; Stengs et al., 1998b; Heijmen et al., 1999). Thus, a clear
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dichotomy was found in the co-treated animals. Furthermore, a large inter-
animal variability was found in the animals treated with cisplatin alone, 
hampering an effective comparison with those co-treated with ORG 2766 or 
α−MSH (Heijmen et al., 1999). Therefore, in the present study, a longitudinal
model was used to study cisplatin ototoxicity. This model involved intra-
cochlear administration of cisplatin into the scala tympani via a mini-osmotic
pump system, while the protective compound (i.e., α−MSH) was administered
through a systemic route. Daily recordings of the compound action potential
(CAP) were made from a permanent round window electrode. 
It has been demonstrated that the use of this longitudinal model with local 
cisplatin treatment results in less interanimal variability (O’Leary et al., 2001)
than observed with systemic application of cisplatin (Stengs et al., 1998b;
Heijmen et al., 1999; Smoorenburg et al., 1999), thus allowing a better evalua-
tion of possibly protective compounds. Another advantage of this approach is
that if a protective effect is found, it cannot be due to accelerated clearance of
cisplatin from the body resulting in a decrease in the amount of cisplatin reach-
ing the cochlea (Ekborn et al., 2002).
Materials and Methods
Animals and experimental design
Thirty female albino guinea pigs (strain: Dunkin-Hartley, Harlan Laboratories,
Indianapolis, IN, USA; weight 225-325 g) were implanted with a permanent
round window electrode and a mini-osmotic pump containing either cisplatin
solution or physiological saline (0.9% NaCl). The animals also received a daily
injection of co-treatment, starting on the day of surgery, consisting of a subcu-
taneous injection of either α−MSH or equal volumes of physiological saline
(cf., Table 1). The animals were housed individually in micro-isolator cages
and had free access to food and water. They were maintained on a 12:12 h
dark/light cycle. Continuous intracochlear perfusion of both cisplatin and phys-
iological saline continued for one week or less if electrocochleograms showed
≥ 40 dB suppression of the CAP threshold at 8 kHz stimulation. When the
threshold shift was reached or when one week had passed, the animals were
sacrificed and the ears were fixed and processed for histology.
The University of Michigan is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care International
(AAALAC International). The animal protocol for this study was approved by
the University Committee on Use and Care of Animals of the University of
Michigan. 
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Preparation of cisplatin and α−MSH solutions
A stock cisplatin solution (American Pharmaceutical Partners Inc., Los
Angeles, CA, USA) with a concentration of 1 mg/ml was diluted with physiolog-
ical saline to a final concentration of 15 µg/ml. This concentration was chosen
after interpolation of data obtained by O’Leary et al. (2001). These data sug-
gested that after intracochlear application of 15 µg/ml cisplatin (pump rate 0.5
µl/h; 0.18 µg/day) it would take approximately 4 days to reach the criterion of
40 dB threshold shift at 8 kHz. It was assumed that within this time-window
differences would become apparent between both co-treatments. The Alzet
mini-osmotic pump (model #2002, Alza Corp., Palo Alto, CA, USA) was filled
with either the cisplatin solution or physiological saline and placed in a saline
bath (37ºC) for 4 hours or more, using a sterile container. The cannula (length:
7.4 cm) was filled with 29 µl physiological saline. Given the cannula length and
the flow rate of the pump, we calculated that it would take approximately 58 h
after surgery before the saline in the cannula was completely replaced by cis-
platin from the pump and, hence, for cisplatin to enter the cochlea. α−MSH
(Sigma Chemical Co., St Louis, MO, USA) was dissolved in physiological saline
at a final concentration of 60 µg/ml and administered subcutaneously, always
in the morning, at a daily dose of 75 µg/kg. The first injection was given imme-
diately after the surgery. The α−MSH dose of 75 µg/kg/day was based on exper-
iments with a positive outcome performed previously by Heijmen et al. (1999).  
Surgical techniques
Surgical implantation of the mini-osmotic pump and further techniques were
performed according to the method described by Prieskorn and Miller (2000).
Prior to the operation the animals were injected with chloramphenicol sodium
succinate (30 mg/kg i.m.) and then anaesthetized with 40 mg/kg ketamine and
10 mg/kg xylazine (i.m.). Local anaesthetic (1% lidocaine, 0.75 ml) was used in
areas to be incised and over the midline of the back (where the pump-pocket
would be located). A mid-line incision was made on the surface of the head
starting 2.5 cm anterior of bregma and continued post-auricularly to the base
of the pinna. A superficial subcutaneous pocket was made in the back
between the scapulae of the animal to accommodate the pump. Two stain-
less-steel screws were placed on the skull, the first 1 cm posterior to bregma
to anchor the cannula and the other 2 cm anterior of bregma, which served as
the ground electrode for the CAP measurements. Under sterile conditions the
bulla of the left ear was opened. The round window electrode was made of
insulated stainless-steel wire (diameter 0.175 mm including teflon insulation;
Advent, Halesworth, UK) with a 0.5 mm diameter gold ball micro-welded
(Unitek 80F; Unitek Equipment, Monrovia, CA, USA) to the exposed and 
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flattened tip. The wire was soldered to a connector (Samtec, New Albany, IN,
USA), which was attached to the skull with methyl-methacrylate cement
(Lang Jet Acrylic, Lang Dental MFG Co., Wheeling, IL, USA). The electrode was
positioned on the round window and secured to the bulla with carboxylate
cement (Durelon, ESPE Premier Sales Corp., Norristown, PA, USA). A small
hole was made at the base of the cochlea, approximately 0.5 mm below the
round window. The cannula tip was placed into the hole until a silicone ball,
0.5 mm from the tip, was seated against the cochlea, to prevent leakage.
Carboxylate cement was used to cover the bulla defect and to secure the can-
nula in place. The pump was removed from the water-bath and attached to
the cannula. Subsequently, the pump was placed in the subcutaneous pocket,
the cannula was fixed to the skull, and the subcuticular layer was closed with
a continuous absorbable suture; the skin was closed with nylon using inter-
rupted sutures. The animals recovered overnight from surgery under a heating
lamp. 
Electrocochleography
Measurements were performed single-endedly with the round window elec-
trode as the active electrode and the screw on the skull (2 cm anterior of breg-
ma) as the ground electrode. Animals were excluded that did not have a
normal threshold at 8 kHz (defined as a threshold at less than 30 dB SPL stimu-
lus level) at the day after surgery or had a displaced cannula or signs of otitis
media at sacrifice. Stimulus generation and data acquisition were performed
with a TDT-II system (Tucker Davis, Gainesville, FL, USA) under control of cus-
tom-designed software. Trains of tone bursts of 2, 4, 8, and 16 kHz were used
as stimuli. The tone bursts were constructed with cosine-shaped rise-and-fall
times of 1 ms (1.5 ms at 2 kHz) and had a duration of 8 ms. The sound stimuli
were produced in an open-field configuration with a speaker (Model GTO302,
JBL, Woodbury, NY, USA), positioned at 10 cm from the pinna, driven by a
Parasound Zamp/Zone amplifier (Parasound Products, San Francisco, CA,
USA). Consecutive tone bursts were presented with alternating polarity at 99
ms. The responses were amplified (TDT DB4 bioamp system with HS4 head
stage; Tucker Davis, Gainesville, FL, USA) at 300 Hz to 3 kHz bandwidth, AD
converted, averaged and stored on disk for off-line analysis. The animals were
lightly restrained, but remained awake during measurements, avoiding the dis-
advantages of repeatedly anaesthetizing the animals. The CAP (N1), measured
relative to the P1 (first positive peak in the signal), was obtained by adding the
responses evoked by tone bursts of opposite polarity. Cochlear Microphonics
(CM) at 2 kHz were obtained by subtracting these responses. ANOVA was per-
formed with co-treatment as a between-subject factor and frequency and level
of stimulation as within-subject factors.
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Histological techniques
One week after surgery or on the day the animals showed a 40 dB threshold
shift at 8 kHz, the animal was deeply anaesthetised, temporal bones were
removed, and the cochleas were fixed by intralabyrinthine perfusion with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) followed by immer-
sion in the same fixative for 3 h at 4°C. After several rinses (2 x 15 min.) in 0.1
M sodium cacodylate buffer, the cochleas were stored in buffer at 4°C. The
cochleas were further processed according to the routine method for guinea
pigs (De Groot et al., 1987). Semi-thin (1 µm) midmodiolar sections were cut
and stained with 1% methylene blue and 1% azur II in 1% sodiumtetraborate.
In the midmodiolar sections of the left cochleas the organ of Corti was exam-
ined at 7 locations, separated by a half turn spacing. OHC loss was expressed
as the percentage of remaining OHCs per cross sectioned half turn, relative to
the expected 3 OHCs per transection. All OHC counts were performed by two
investigators, independently of one another, in a blinded fashion (cf., De Groot
et al., 1997; Cardinaal et al., 2000a; Cappaert et al., 2001). ANOVA was used for
statistical evaluation of the OHC counts. Co-treatment was a between-subjects
factor and cochlear location a within-subject factor. 
Results
General findings
Seven out of 30 animals were excluded from the study because they did not
have a normal threshold at 8 kHz the day after surgery or showed a displaced
cannula or signs of otitis media upon inspection of the left (operated) bulla
when the animals were sacrificed. Two animals that developed the 40 dB cri-
terion threshold shift at 8 kHz within the first 3 days after surgery were also
excluded, since we assume that in those cases hearing loss was due to post-
operative complications (arrival time of cisplatin was estimated at 58 h post-
surgery). The remaining 21 animals were used in the experiment. Table 1
shows their distribution among the four experimental groups.
CAP thresholds as a function of time 
Figure 1 shows CAP thresholds at 8 kHz, based on a 3 µV criterion, of all 21
individual animals as a function of time. 
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Table 1: Distribution of the animals over the experimental groups
Co-treatment (s.c. injection)  
Pump filling Physiological saline α−MSH  
Cisplatin 15 µg/ml 7 8  
Physiological saline 2 4
Figure 1: Development of CAP thresholds at 8 kHz stimulation during one week after the implantation of an osmot-
ic pump (Alzet 2002; 0.5 µl/hr) at day 0. Each curve represents one individual animal. A: The pump was loaded
with physiological saline. Co-treatment consisted of systemic physiological saline injections (interrupted lines) or
α−MSH injections (75 µg/kg/day; continuous lines); B: The pump was loaded with cisplatin (15 µg/ml). Co-treat-
ment consisted of physiological saline injections; C: The pump was loaded with cisplatin (15 µg/ml). Co-treatment
consisted of α−MSH injections (75 µg/kg/day).
Figure 1A represents the animals that were treated with physiological saline in
the pump (n=6). For this group, regardless of co-treatment (physiological
saline, n=2 or α−MSH, n=4) the animals showed a stable CAP threshold dur-
ing the observation period, which lasted 7 days. No significant differences
were found between the two co-treatments in these animals at any frequency
(F(1,3)=0.65, P=0.48). Therefore the animals treated with saline in the pump
were considered as one group (control group). Animals treated with 15 µg/ml
cisplatin in the pump and physiological saline co-treatment (n=7) (Fig. 1B)
showed thresholds equal to the control group during the first three days of
treatment. This can be explained by the fact that it took approximately 58
hours for the saline in the cannula to be completely replaced by the cisplatin
from the pump, which gave the animals time to recover from surgery.
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Between day 3 and 4 after surgery a rapid deterioration of the threshold devel-
oped. The group of animals that received 15 µg/ml cisplatin in the pump and
α−MSH as co-treatment (n=8) (Fig. 1C) also showed a stable baseline during
the first three days after surgery followed by a rapid deterioration of the thresh-
old between day 4 and 5 after surgery. 
Number of days to rapid threshold deterioration
Cochlear susceptibility to perilymphatic administration of cisplatin can be
expressed in terms of the number of days necessary to reach an ototoxic
effect. Figure 2 shows the time necessary to reach a threshold shift of ≥ 40 dB
at 8 kHz. 
Figure 2: Number of animals reaching the CAP criterion threshold shift (≥ 40 dB at 8 kHz) at a given day. The
arrow points to the calculated moment cisplatin from the pump enters the cochlea.
Since cisplatin arrived in the cochlea approximately 58 hours after surgery, this
corresponds to 45 hours of intracochlear cisplatin infusion. For those animals
co-treated with cisplatin/α−MSH it took significantly longer to reach the criteri-
on threshold shift (t-test; P=0.017), on average 123 hours (5-6 days) after 
surgery, corresponding to 65 hours of cisplatin infusion. Thus, α−MSH co-treat-
ment delayed the ototoxic effect of cisplatin by approximately 20 hours (44%). 
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CAP threshold shift as a function of frequency
The first animals reached the criterion threshold shift on the fourth day after
surgery (Fig. 1). This was the last day a CAP measurement for all 21 animals
was available. Figure 3 shows the CAP threshold in dB SPL as a function of fre-
quency on day 4 for the three groups (cisplatin/α−MSH n=8; cisplatin/saline
n=7; control (pooling the two groups that had physiological saline in the
pump) n=6). 
Figure 3: CAP threshold at 8 kHz (3 µV criterion) as a function of frequency at day 4 after the implantation of a mini-
osmotic pump in the three groups of animals. Pumps were loaded with physiological saline (continuous line;
saline/saline and saline/α−MSH treated groups were pooled) or cisplatin 15 µg/ml in combination with saline s.c.
injections (dotted line) or α−MSH s.c. injections (interrupted line). The individual data are also shown; asterisk:
pooled saline in pump groups; open circle: cisplatin/saline treated group; filled circle: cisplatin/α−MSH treated
group.
On average, the threshold shift in the cisplatin/saline group is much larger than
the shift in the cisplatin/α−MSH group, regardless of frequency. The animals in
the cisplatin/α−MSH group show a similar CAP threshold in the low frequen-
cies as compared to the control animals, although a threshold shift is apparent
at the higher frequencies (8 and 16 kHz). Individual data are also depicted to
illustrate the variation within the three groups. ANOVA showed a significant
main effect of frequency (F(2,18)=22.43, P<0.001) and treatment (F(3,54)=6.29,
P=0.008) and an interaction between both factors (F(6,54)=8.27, P<0.001).
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Post-hoc analysis (Tukey HSD) on treatment showed a significant difference
between the cisplatin/saline group and the control group (P=0.01) for all fre-
quencies, but not between the cisplatin/α−MSH group and the control group
(P=0.47). The difference between the cisplatin/saline and cisplatin/α−MSH
groups did not quite reach significance (P=0.08), which did not change when
the analysis was done for each frequency separately.
Figure 4: CAP threshold shift ± SEM at the time criterion threshold shift for 8 kHz was exceeded (≥ 40 dB) or after
7 days if this criterion was not reached (exclusively animals with saline in pump). Asterisk: pooled saline in pump
groups; open circle: cisplatin/saline treated group; filled circle: cisplatin/α−MSH treated group.
Figure 4 shows the threshold shift in dB as a function of frequency on the day
the animals were sacrificed, i.e., on the day they passed criterion threshold
shift (40 dB) at 8 kHz, or after 7 days if they did not pass this criterion (control
animals only). The threshold shift was calculated for each animal separately,
by subtracting the threshold measured on the last day from the threshold
measured the day after surgery. 
No threshold shift was observed in animals treated with physiological saline in
the pump (cf., Fig. 1A). The animals that received cisplatin in the pump dis-
played a threshold shift at all frequencies, although the higher frequencies
were clearly most affected. ANOVA, comparing the cisplatin/saline and the cis-
platin/α−MSH groups, showed a significant main effect of frequency
(F(3,39)=17.55, P<0.001), but no significant effect of co-treatment (F(1,13)=1.78,
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P=0.20). From one respect these data are partially trivial, because we used a
criterion loss of ≥ 40 dB at 8 kHz to determine the day at which these meas-
urements were made. Nevertheless, these data demonstrate that, regardless
of co-treatment, hearing loss occurs over a broad frequency range.
CAP input-output curves
Figure 5 shows input-output curves for the CAP at 8 kHz stimulation on day 4
(the last day all 21 animals were still in the experiment). There is a large differ-
ence in CAP amplitudes between the control group (pooled) and the
cisplatin/α−MSH group on the one hand and the cisplatin/saline group on the
other hand, especially at low levels of stimulation. 
ANOVA was performed on the logarithmically transformed CAP data to
improve homogeneity of variance. Only the moderate-level stimuli (45-85 dB
SPL) were tested in order to avoid floor effects and because of the recruit-
ment-like shape of the input-output curves. Statistical analysis confirmed an
effect of stimulus level (trivial) and treatment (F(2, 18)=2.72, P=0.006) and a
strong interaction between both factors (F(8, 72)=9.03, P<0.001). A separate
analysis of the difference between the cisplatin/α−MSH treated animals and
the cisplatin/saline treated animals revealed a pronounced effect of α−MSH
co-treatment (F(1, 13)=5.97, P=0.03).
Figure 5: CAP growth curves at 8 kHz stimulation as a function of sound level obtained on day 4 after pump
implantation. Asterisk: pooled saline in pump groups; open circle: cisplatin/saline treated group; filled circle: cis-
platin/α−MSH treated group. Error bars represent SEM.
97
Intracochlear cisplatin and systemic α−MSH
98
Chapter 5
CM
A correlation was found between shifts in CAP threshold at 16 kHz and shifts in
CM threshold at 2 kHz (r=0.80), also defined as the 3 µV iso-response level.
Figure 6 illustrates that this correlation is not influenced by α−MSH co-treat-
ment. The cisplatin/α−MSH treated animals required, on average, about 1 day
of cisplatin treatment extra, but reached the same shift as the cisplatin/saline
treated animals, both with regard to the CAP threshold shift as well as the CM
threshold shift.
Figure 6: CAP threshold shifts at 16 kHz compared to CM threshold shifts at 2 kHz. Both shifts are expressed relative
to their respective thresholds at day 0, when the pump was implanted. Each data-point represents the threshold
shifts for one animal at the last day of treatment. Asterisk: pooled saline in pump groups; open circle:
cisplatin/saline treated group; filled circle: cisplatin/α−MSH treated group.
OHC counts
Outer hair cells counts (i.e., the percentage of remaining OHCs) of the three
groups of animals are presented in Figure 7. The degree of OHC loss is pre-
sented for 7 different transections (at a half-turn spacing) along the basilar
membrane. The control group, which was treated with physiological saline in
the pump, showed almost no OHC loss. In animals treated with cisplatin in the
pump both co-treatments (physiological saline and α−MSH) showed most pro-
nounced OHC loss in the basal turn, 51% remaining OHCs versus 93% in the
medial and 97% in the apical turn. Statistical analysis by means of ANOVA
showed main effects of treatment (F(2,18)=6.75, P=0.007) and location
(F(6,108)=33.29, P<0.001) and a significant interaction between both factors
(F(12,108)=5.9, P<0.001). Thus, an analysis of the effects of co-treatment was
performed for each relevant transection separately. A significant effect of treat-
ment (= less OHC loss) was found only in b1, the lower basal turn
(F(2,18)=16.19, P<0.001). Post-hoc analysis (Tukey HSD) on treatment showed
that both cisplatin/saline and cisplatin/α−MSH treated groups were significant-
ly different from the control group (α−MSH co-treatment, P<0.001; saline co-
treatment, P<0.001). No significant difference was found between both
co-treated groups (P=0.89). Thus, α−MSH co-treatment does delay, but not
prevent the loss of OHCs caused by cisplatin treatment. Inner hair cell loss was
not seen in this study.
Figure 7: Outer hair cell counts (represented as percentage of remaining OHCs) as a function of cochlear position
along the basilar membrane (b1, b2: basal turns; m1, m2: middle turns; a1, a2, a3: apical turns). Hatched bar:
pooled saline in pump groups; open bar: cisplatin/saline treated group; filled bar: cisplatin/α−MSH treated group.
The estimated characteristic frequencies (c.f.) according to the Greenwood (1996) frequency map are indicated
above the graph. Error bars represent SEM.
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Discussion
Perilymphatic cisplatin exerts an ototoxic effect
This study shows that intracochlear cisplatin application with a mini-osmotic
pump (0.18 µg/day; 15 µg/ml in pump) results in loss of auditory sensitivity
after 2-3 days of continuous perilymphatic infusion (Figs. 1-2). In comparison,
O’Leary et al. (2001) demonstrated that local administration of cisplatin in the
perilymph at a somewhat higher dose (0.36 µg/day; 30 µg/ml in pump) also
resulted in a loss of auditory sensitivity after 2-3 days of continuous application
with the same mini-osmotic pump system. They also found that at a lower
concentration (0.036 µg/day; 3 µg/ml in pump) borderline loss of sensitivity
occurs, whereas profound hearing loss is observed within 1 day in most of the
animals treated with a higher concentration (3.60 µg/day; 300 µg/ml in pump).
Our results are in general agreement with the results of O’Leary et al. (2001),
although the concentration used (15 µg/ml in pump) did not result in the
longer symptoms-free interval we desired. Our results also confirm that direct
administration of cisplatin into the cochlea results in considerably less interan-
imal variability than systemic administration (cf., Heijmen et al., 1999; Klis et
al., 2000, 2002). This feature, together with the avoidance of systemic cisplatin
toxicity, makes this animal model ideally suited for studies on potentially pro-
tective compounds.
α−MSH delays cisplatin ototoxicity
The most salient result in this study is that systemic co-treatment with α−MSH
significantly alters the course of effects during perilymphatic application of cis-
platin; co-treatment delays, but does not prevent, cisplatin ototoxicity. Thus, at
the chosen endpoint (40 dB threshold shift at 8 kHz stimulation) similar fre-
quency-dependent threshold shifts and position-dependent OHC losses were
observed in both cisplatin/α−MSH and cisplatin/saline groups, but the thresh-
old loss was found at a later time in the cisplatin/α−MSH treated group. Several
recent studies, both morphologically and electrophysiologically, have shown
that α−MSH reduces cisplatin ototoxicity. Heijmen et al. (1999) have demon-
strated that treatment of albino guinea pigs with daily injections of cisplatin (2
mg/kg/day i.p. for 8 days) and concomitant injections of α−MSH (75 µg/kg/day
s.c. for 9 days) resulted in a considerable number of animals with preserved
hearing after cessation of cisplatin treatment. This was not found in the cis-
platin/saline treated group. Hamers et al. (personal communication) have con-
firmed that α−MSH significantly enhances recovery of CAP thresholds and
OHC survival after systemic cisplatin treatment. However, in the latter experi-
ment the number of days necessary to reach criterion threshold shift (≥ 40 dB
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at 8 kHz) did not differ in a statistically significant way between the cisplatin/α−
MSH treated group and the cisplatin alone group. This discrepancy with our
experiment might be explained by the higher interanimal variability, which is
usually associated with systemic application of cisplatin.
An important issue is the mechanism of protection by α−MSH, which cannot
be considered separately from the mechanism of cisplatin ototoxicity itself.
Morphological effects of cisplatin upon OHCs (Komune et al., 1981; De Groot
et al., 1997; Cardinaal et al., 2000a, 2000b), spiral ganglion cells (Cardinaal et
al., 2000b; Zheng and Gao, 1996) and the stria vascularis (Nakai et al, 1982;
Tange and Vuzevski, 1984; Kohn et al., 1988, 1997; Meech et al., 1998; Cardinaal
et al., 2000a) have been described, but it is not known whether these effects
are independent or causally related. Several recent studies emphasize that cis-
platin affects the stria vascularis, both morphologically (Meech et al., 1998;
Cardinaal et al., 2000a) and functionally, as reflected by a decrease in the
endocochlear potential (EP), which is generated by the stria vascularis (Klis et
al., 2000; Tsukasaki et al., 2000; O’Leary et al., 2001; Klis et al., 2002). One
might surmise that damage to the stria vascularis impairs the maintenance of
the EP, which leads to increases in the CAP and CM thresholds. The intermedi-
ate cells in the stria vascularis, which are actually melanocytes (Hilding and
Ginzberg, 1977) are necessary for normal strial function (Motohashi et al.,
1994). Meyer zum Gottesberge (2000) has suggested that melanocytes in the
cochlea are under α−MSH control. The ameliorating effects of α−MSH on cis-
platin ototoxicity might be linked to the activity of strial melanocytes. Although
the possibility of direct involvement of strial melanocytes needs to be investi-
gated further, it is nevertheless clear from our experiments that α−MSH seems
to act through a cochlear target, as cisplatin was delivered directly to the
cochlea. In other words, systemic effects of α−MSH on cisplatin pharmacody-
namics, or other absorption- or transport-factors can be excluded by our
approach.
Conclusion
The present study confirms the previously reported results with regard to oto-
toxic effects of cisplatin after local administration into the perilymphatic com-
partment. The ototoxic effects were significantly delayed when the animals
were co-treated with systemically administered α−MSH. This delay (an
increase of 44% in time to toxicity) might be of clinical significance. Since cis-
platin was delivered directly to the cochlea, the ameliorating effect of α−MSH
probably involves a cochlear target, possibly the strial melanocytes. Thus, the
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α−MSH peptide remains interesting. Further research with this peptide could
reveal matters relating to the mechanism of cisplatin ototoxicity and the regu-
lation of strial activity, as well as an effective clinical strategy to attenuate cis-
platin ototoxicity.
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Summary  
It has previously been demonstrated that ototoxicity induced by systemic
administration of cisplatin is reduced by concomitant systemic administration
of α−melanocyte stimulating hormone (α−MSH). In this study we investigated
the effects of cochlear, perilymphatic application of α−MSH during intraperi-
toneal administration of cisplatin. Guinea pigs, implanted with a round win-
dow electrode, allowing daily monitoring of the compound action potential
(CAP), and a mini-osmotic pump, pumping at a rate of 0.25 µl/h either physio-
logical saline or α−MSH solution (0.02, 2, 20 µg/ml), were treated daily with a
bolus injection of cisplatin (2 mg/kg) until the electrocochleogram showed an
increase in CAP threshold of 40 dB at 8 kHz. Then, cisplatin treatment was
stopped, but intracochlear perfusion of α−MSH or physiological saline was
continued for 10 days to evaluate possible effects of α−MSH on the expected
recovery. On day 10, the animals were sacrificed and the cochleas were fixed
and processed for histological analysis. All groups required an average of 6 to 7
days of cisplatin to reach the criterion CAP threshold shift. Ten days after ces-
sation of the cisplatin treatment, recovery of the CAP was observed in all
groups and at all frequencies, although it was more pronounced at the low fre-
quencies. With respect to recovery, small statistically significant differences
were found between the saline and the α−MSH co-treated groups. Histological
results showed significantly less outer hair cell (OHC) loss in the group co-
treated with 2 µg/ml α−MSH as compared to the group co-treated with saline.
Thus, since α−MSH was delivered directly into the cochlea, the ameliorating
effect of α−MSH on OHC survival is exerted by means of a cochlear target and
not through interaction with a systemic factor. 
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Introduction
Cisplatin is a widely used antineoplastic drug, which is effective in the treat-
ment of different types of epithelial tumors. However, in humans, chronic
treatment with cisplatin may result in ototoxic side effects such as high-fre-
quency hearing loss and tinnitus (Schweitzer, 1993). Animal studies have
shown that chronic cisplatin administration leads to loss of outer hair cells
(OHCs) in the cochlea, with the hair cells in the basal turn being more severely
affected than those in the middle and apical turns (Tange, 1984; Hoeve et al.,
1988; Saito and Aran, 1994; Cardinaal et al., 2000a). The ototoxic effects of cis-
platin are not limited to the auditory hair cells; the stria vascularis (Tange and
Vuzevski, 1984; Kohn et al., 1988; Zheng and Gao, 1996; Kohn et al., 1997;
Meech et al., 1998; Cardinaal et al., 2000a,b) and spiral ganglion cells
(Cardinaal et al., 2000b; Hamers et al., 2003) are also affected. These ototoxic
limitations can be (partially) overcome with the application of compounds
that are known for their neuroprotective effects in cisplatin-induced sensory
neuropathies. A family of compounds that have distinct neuroprotective prop-
erties are the melanocortins (Gispen, 1990). Previous work in our laboratory
has shown that systemic administration of some of these melanocortins, e.g.
the AdrenoCorticoTropic Hormone (ACTH)-analog ORG 2766 and the naturally
occurring ACTH fragment α−melanocyte stimulating hormone (α−MSH), pro-
tect the cochlea from cisplatin-induced damage (Hamers et al., 1994; De Groot
et al., 1997; Stengs et al., 1998; Heijmen et al., 1999; Smoorenburg et al., 1999;
Cardinaal et al., 2000c; Wolters et al., 2003; Hamers et al., 2003). However, the
systemic concomitant administration of ORG 2766 or α−MSH resulted in a
clear dichotomy; individual animals were either completely protected from
cisplatin ototoxicity with normal auditory thresholds and no OHC loss or
demonstrated increased thresholds similar to animals treated with cisplatin
alone (Hamers et al., 1994; Stengs et al., 1998; Heijmen et al., 1999). Therefore,
further quantitative characterization of the interaction between melanocortin
effects and cisplatin-induced ototoxicity was needed. Introduction of a longitu-
dinal animal model allowed us to monitor the cochlear sensitivity and the ben-
eficial effects of α−MSH and ORG 2766, via a permanent round window
electrode, on a day-to-day basis (Hamers et al., 2003). Neither of the co-treat-
ments affected the mean number of cisplatin injections necessary to reach the
criterion threshold shift (≥ 40 dB at 8 kHz). Nevertheless, both α−MSH and
ORG 2766 enhanced recovery of CAP thresholds and CAP amplitudes at high
sound pressure levels. Furthermore, hair cell loss was significantly lower in the
melanocortin co-treated groups. On the one hand, the beneficial effects of α−
MSH and ORG 2766 could be evoked through a target within the inner ear. On
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the other hand, systemically applied melanocortins may exert their effects
indirectly, e.g. by accelerating renal clearance of cisplatin from the body,
resulting in decreased amounts of cisplatin that can reach the cochlea. This
latter explanation has been found to be the basic mechanism by which the
sulphur-containing amino acid D-methionine acts as an otoprotective agent
(Ekborn et al., 2002).
The present study was designed to investigate the issue of the primary target
for α−MSH. A way to prevent the systemic effect of the protective compound is
to apply the protective agent exclusively and directly to the cochlea. To accom-
plish this, a new longitudinal model was used, which involved administration
of α−MSH directly into the scala tympani via a mini-osmotic pump system,
while cisplatin was administered intraperitoneally. Daily recordings of the
compound action potentials (CAPs) as a function of frequency and level were
made from a permanent round window electrode. This study complements a
similar study with a mirrored experimental design: cisplatin was applied
directly into the scala tympani, whereas α−MSH was administered subcuta-
neously, in combination with permanent recordings (Wolters et al., 2003). In
that study a clear ameliorating effect of α−MSH was found. It should be kept in
mind, however, that positive results in this study would not completely rule out
a systemic component, but positive results from the combination of the two
studies would make that possibility extremely unlikely.
The experimental approach used in the present study has the additional
advantage that since cisplatin is administered systemically, treatment can be
terminated easily in contrast to an approach in which cisplatin is delivered
directly into the cochlea through a mini-osmotic pump system. This allows for
a better analysis of the role that α−MSH plays in recovery from cisplatin ototox-
icity, especially since there are indications that α−MSH accelerates recovery
(Hamers et al., 2003).
Materials and Methods
Animals and experimental design
Fifty-eight female albino guinea pigs (strain: Dunkin-Hartley, Harlan
Laboratories, Horst, the Netherlands; weight 275-380 g) were implanted with a
permanent round window electrode and equipped with a mini-osmotic pump
containing sterile solutions of either α−MSH in saline or plain saline (0.9%
NaCl). The pump fed these solutions directly into the scala tympani. The ani-
mals were housed, four together, in macrolon cages and had free access to
food and water. They were maintained on a 12:12 h dark/light cycle. The ani-
109
Intracochlear α−MSH and systemic cisplatin
mals were treated with a continuous perilymphatic perfusion of α−MSH or
physiological saline, starting directly after surgery, and a daily injection of cis-
platin, starting 3 days after surgery, until electrocochleograms showed ≥ 40 dB
shift of the threshold at 8 kHz stimulation. When the criterion threshold shift
was reached, cisplatin administration was stopped, but perilymphatic perfu-
sion with α−MSH or physiological saline was continued for 10 days to evaluate
possible effects of α−MSH on the expected recovery. During this period all ani-
mals were daily monitored by means of electrocochleography using the per-
manent round window electrode. On day 10, the animals were sacrificed and
the ears were fixed and processed for histology. 
The animals were allotted at random to the different experimental groups. 
The care and use of the animals reported in this study were approved by the
Animal Care and Use Committee of the University of Utrecht (DEC-UMC #
91035).
Preparation of pump, cisplatin and α−MSH solutions
A stock solution of cisplatin (1 mg/ml; Platosin®; Pharmachemie B.V.,
Haarlem, the Netherlands) was diluted with physiological saline to a final con-
centration of 0.1 mg/ml. It was administered intraperitoneally at a daily dose of
2.0 mg/kg body weight. The first injection was given 3 days after surgery. The
dose was chosen based upon the previous experiments of Stengs et al. (1998)
and Heijmen et al. (1999). The high dilution was chosen to stimulate diuresis
and, thus, to minimize renal effects. 
α−MSH (Bachem, Bubendorf, Switzerland) was dissolved in HCl (1 mM) con-
taining 0.02% BSA (bovine serum albumin; BDH Chemicals Ltd., Poole, UK) at
a concentration of 2 mg/ml (stock). This stock was further diluted with physio-
logical saline containing 0.02% BSA to obtain the final concentrations used in
this study (20, 2, and 0.02 µg/ml). The Alzet mini-osmotic pump (model #2004,
Alza Corp., Palo Alto, CA, USA) was filled with either one of the three α−MSH
solutions or 0.02% BSA containing saline and placed in a saline bath (37°C) for
40 hours or more before surgery, using a sterile container. After this, according
to the manufacturers specifications, the pump worked immediately at a con-
stant rate of 0.25 µl/h for 4 weeks.
Surgical techniques
Surgical implantation of the mini-osmotic pump and further techniques were
performed according to the method described by Prieskorn and Miller (2000).
The animals were anaesthetized with a mixture of ketamine and xylazine. The
cannula (length: 7.4 cm) was filled with the same α−MSH solution as the
pump. A mid-line incision was made on the dorsal surface of the head starting
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2.5 cm anterior of bregma and continued post-auricularly to the base of the
pinna. A superficial subcutaneous pocket was made in the back between the
scapulae of the animal to accommodate the pump. Under sterile conditions
the bulla of the left ear was opened retro-aurically and the skull was exposed
around bregma. A small hole was made at the base of the cochlea, approxi-
mately 0.5 mm below the round window. The cannula tip was placed into the
hole until the silicone ball, 0.5 mm from the tip, was seated against the
cochlea to prevent leakage. The round window electrode, made of insulated
stainless-steel wire (diameter 0.175 mm including teflon insulation; Advent,
Halesworth, UK) with an 0.5 mm diameter gold ball micro-welded (Unitek 80F;
Unitek Equipment, Monrovia, CA, USA) to the exposed and flattened tip, was
positioned on the round window and secured to the bulla with carboxylate
cement (Durelon, ESPE dental supplies, Utrecht, The Netherlands). The wire
was soldered to a Berg 22-26 gold terminal that fitted into a Berg 2x3 mini-latch
housing (Farnell, Maarssen, The Netherlands). Stainless-steel screws were
inserted through the skull and connected to the mini-latch housing via two sil-
ver wires connected to a gold terminal. The mini-latch housing was connected
to the skull with dental acrylic cement, which also covered and insulated the
stainless-steel screws and the electrodes. The pump was removed from the
water-bath and attached to the cannula. Subsequently, the pump was placed
in the subcutaneous pocket, the cannula was fixed to the skull, and the subcu-
ticular layer was closed with a continuous vicryl suture; the skin was closed
with vicryl using interrupted sutures. 
Electrocochleography
Measurements were performed differentially with the round window elec-
trode as the active electrode and two screws on the skull as reference and
ground electrode, respectively. 
Animals that did not have a normal threshold at 8 kHz (defined as a threshold
at less than 25 dB SPL stimulus level) at the day after surgery or that showed a
displaced cannula or signs of otitis media when sacrificed were excluded from
further analysis. Trains of tone bursts of 2, 4, 8, and 16 kHz were used as stim-
uli. The tone bursts were constructed with cosine-shaped rise-and-fall times of
1 ms (1.5 ms at 2 kHz) and had a duration of 8 ms. The sound stimuli were
produced in an open-field configuration with a Fame tweeter (Staffhorst
Electronics, Utrecht, The Netherlands) positioned at 10 cm from the pinna.
Consecutive tone bursts were presented with alternating polarity at 99 ms
intervals in order to avoid synchronization with the mains frequency of 50 Hz.
The responses were amplified (EG&G Instruments model 5113 amplifier, Te
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Lintelo Systems, Zevenaar, The Netherlands), bandpass filtered between 1 Hz
and 30 kHz, AD converted at 33 kHz, and stored on disk for off-line analysis.
The animals were lightly restrained, but remained awake during all measure-
ments, avoiding the disadvantages of repeatedly having to anaesthetize the
animals. CAPs were obtained by adding the responses evoked by tone bursts
of opposite polarity; Cochlear Microphonics (CM) by subtracting these
responses. The CAP was measured relative to the positive summating poten-
tial (SP) and not relative to the baseline of the recording since, in principle, the
CAP is superimposed upon the SP. The CM was measured as the peak-to-peak
amplitude in the middle of the sinusoidal response. Electrocochleography was
continued for 10 days following the cessation of cisplatin treatment.
ANOVA was performed on thresholds (3 µV iso-response levels) and ampli-
tudes of CAPs and CM. Co-treatment was a between-subjects factor; time and
stimulation frequency and level were within-subject factors. STATISTICA soft-
ware was used.
Histological techniques
Ten days after the cessation of cisplatin administration the cochleas were fixed
by intralabyrinthine perfusion with a tri-aldehyde fixative consisting of 3% glu-
taraldehyde, 2% formaldehyde, 1% acrolein, 2.5% dimethylsulfoxide in 0.1 M
sodium cacodylate buffer (pH 7.4) followed by immersion in the same fixative
for 3 h at room temperature. The cochleas were further processed according
to the routine method for guinea pigs (De Groot et al., 1987). Semithin (1 µm)
midmodiolar sections were cut and stained with 1% methylene blue and 1%
azur II in 1% sodium tetraborate. In the midmodiolar sections the organ of
Corti was examined at seven locations, separated by a half-turn spacing, and
the number of OHCs present at each location was counted. OHC loss was
expressed as the percentage of remaining OHCs per cross-sectioned half turn
(2 transections each for the basal and middle turns; 3 transections for the api-
cal turn), relative to the number of OHCs found in non-treated cochleas. All
OHC counts were performed by two investigators, independently of one
another, in a single-blind fashion (cf., De Groot et al., 1997; Cardinaal et al.,
2000a; Wolters et al., 2003). ANOVA was used for statistical evaluation of the
OHC counts. Co-treatment was a between-subjects factor and cochlear loca-
tion a within-subject factor. 
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Results
General findings
Sixteen of the 58 operated animals showed an abnormal threshold at 8 kHz
directly after surgery and fourteen animals demonstrated a displaced cannula
or infections upon inspection of the left (operated) bulla when sacrificed.
These animals were excluded from the experiment. Table 1 shows the distri-
bution of the remaining animals (n=28) over the four experimental groups.
Table 1: Distribution of the animals over the experimental groups
Pump filling Number of animals 
α−MSH (20 µg/ml) 6  
α−MSH (2 µg/ml) 8 
α−MSH (0.02 µg/ml) 8  
Physiological saline 6  
Effects of cisplatin on CAP thresholds in relation to co-treatment
During the first days of cisplatin treatment only small random changes in CAP
threshold were observed. At some moment between day 5 and day 11 after
the start of cisplatin administration, the animals showed a sudden deteriora-
tion of the CAP threshold. This was reported before when a similar experimen-
tal design was applied (Klis et al., 2000; Wolters et al., 2002; Hamers et al.,
2003). Figure 1 shows the time required to reach the criterion threshold shift of
≥ 40 dB at 8 kHz. 
Saline co-treated animals reached this criterion threshold shift after an aver-
age of 6.8 days. Animals that received the lowest concentration of α−MSH
(0.02 µg/ml in the pump) reached the criterion threshold shift almost one day
earlier (6 days) and also showed significantly less variability (Levene’s test,
P<0.026). Animals receiving higher concentrations of α−MSH (2 or 20 µg/ml in
the pump) reached the criterion threshold shift after 7.3 and 6.7 days of cis-
platin administration, respectively. ANOVA showed that the mean number of
days of cisplatin administration necessary to cause hearing loss did not differ
between the four groups in a statistically significant way (F(3,24)= 0.719,
P=0.55). 
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Figure 1: The time required to induce a hearing loss of ≥ 40 dB in the 3 µV CAP iso-response level (threshold) at 8
kHz for the four different groups.
Figure 2: Maximum shift in CAP threshold (3 µV criterion) at the day cisplatin administration was terminated or
shortly thereafter, as a function of stimulus frequency for the four different groups.
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CAP thresholds
Maximum CAP threshold shifts occurred either at the day cisplatin administra-
tion was terminated or 1 to 2 days later. After the maximum CAP threshold
shift was reached, the threshold recovered in 50% of the animals (cf., Fig. 3).
Maximum threshold shift in dB as a function of frequency is shown in Figure 2
for all groups. 
Although the hearing loss occurred within a broad frequency range, it clearly
increased as a function of frequency. ANOVA showed a significant main effect
of frequency (F(3,72)=112.8, P<0.001) but no main effect of co-treatment
(F(3,24)=2.07, P=0.13). Although only a small significant interaction between
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Figure 3: Build-up and recovery of the CAP threshold shift at 2, 4, 8, and 16 kHz (± S.E.M.) as a function of time for
the 4 different groups. The horizontal black bar represents the last 6 days of cisplatin administration. Day 0 repre-
sents the day that cisplatin administration was discontinued. CAP threshold baseline values between day -6 and day
-2 before cessation of cisplatin administration were averaged for each individual animal and set to zero. These val-
ues were taken as the reference “normal hearing level” (nHL).
both factors (F(9,72)=1.97, P=0.055) was found, we performed an analysis of
the effect of α−MSH co-treatment for each frequency separately. Animals co-
treated with 2 µg/ml α−MSH showed a significantly smaller threshold shift than
animals treated with saline at 2 and 4 kHz (F(1,12)=9.60, P=0.009 and
F(1,12)=16.90, P=0.001, respectively), but not at 8 and 16 kHz (F(1,12)=0.98,
P=0.343 and F(1,12)=0.185, P=0.67, respectively). 
Figure 3 shows CAP thresholds at 2, 4, 8, and 16 kHz, based on the 3 µV
response amplitude criterion as a function of time. Since baseline threshold
values varied between animals, the CAP threshold baseline values between
day -6 and day -2 before cessation of cisplatin administration were averaged
for each individual animal and set to zero. These values were taken as the ref-
erence “normal hearing level” (nHL). As mentioned before, pronounced
recovery of the CAP threshold was observed in all groups after cessation of
cisplatin administration and it was observed at all frequencies, although it was
more prominent at the lower frequencies. Statistical analysis (ANOVA for
repeated measurements) of the data starting at day 0 showed a significant
effect of time (recovery) at all frequencies (2 kHz: F(9,216)=44.13, P<0.001; 4
kHz: F(9,216)=20.67, P<0.001; 8 kHz: F(9,216)=10.88, P<0.001; 16 kHz:
F(9,216)=5.59, P<0.001). Animals co-treated with either 0.02 or 2 µg/ml α−MSH
showed significantly lower CAP thresholds, between day 0 and day 9, than
those receiving saline co-treatment at 2 kHz (0.02 µg/ml: F(1,12)=5.77, P=0.033;
2 µg/ml: F(1,12)=6.82, P=0.023) and 4 kHz (0.02 µg/ml: F(1,12)=4.22, P= 0.062; 2
µg/ml: F(1,12)= 7.21, P=0.020), but not at 8 and 16 kHz, although a similar trend
is present at these latter frequencies. 
CM thresholds
Figure 4 shows the CM thresholds at 16 kHz, based on a 3 µV criterion. As the
cochlear electrode was positioned at the round window, the CM generated in
the basal turn contributed most to the signal, and hence only the CM elicited at
16 kHz stimulation was analyzed. CM threshold baseline values between day 
-6 and day -2 before cessation of cisplatin administration were averaged for
each individual animal and set to zero. The CM thresholds at 16 kHz did not
show significant recovery (F(9,216)=1.34, P=0.215). Still, animals treated with
0.02 µg/ml α−MSH showed a significantly lower CM threshold shift, between
day 0 and day 9, than those co-treated with saline (F(1,12)= 7.88, P= 0.016).
The higher concentrations of α−MSH did not show any significant effect at all. 
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Figure 4: Build-up and recovery of the CM threshold shift at 16 kHz (± S.E.M.) for the 4 different groups. The hori-
zontal black bar represents the last 6 days of cisplatin administration. Day 0 represents the day that cisplatin admin-
istration was discontinued. 
CAP and CM amplitudes in relation to recovery and treatment
In addition to threshold measurements it is informative to study the effect at
higher stimulus levels. Figure 5 shows the CAP amplitudes obtained at stimu-
lus levels of 78 to 87 dB SPL during and after cisplatin administration. Local
perfusion with α−MSH resulted in less CAP amplitude reduction, especially at
the lower frequencies. ANOVA from day 0 to day 9, performed on the logarith-
mically transformed CAP amplitudes, demonstrated main effects of frequency
(F(3,72)=19.49, P<0.001) and time (F(9,216)=20.39, P<0.001) and a strong inter-
action between both factors (F(27, 648)=3.30, P<0.001). A separate analysis per
frequency revealed a pronounced effect of co-treatment with 2 µg/ml α−MSH
at 2 kHz (F(1, 12)= 9.34, P=0.010). At the other frequencies there was only a
main effect of time (recovery). Analysis of CM amplitudes at 16 kHz, 78 dB SPL
(data not shown), starting at day 0, did not show an effect of co-treatment
(F(3,24)=1.03, P=0.40), nor of time (F(9,216)=1.66, P=0.10). 
117
Intracochlear α−MSH and systemic cisplatin
118
Chapter 6
Figure 5: Collapse and recovery at 2, 4, 8, and 16 kHz (± S.E.M.) of the CAP amplitude at 78-86 dB SPL stimulus
level for the four different groups. The horizontal black bar represents the last 6 days of cisplatin administration.
Day 0 represents the day that cisplatin administration was terminated.
OHC loss in relation to co-treatment
OHC counts for the right and left (implanted) ears of the four groups of ani-
mals are presented in Fig. 6. OHC losses were observed in the basal and mid-
dle turns of both left and right cochleas. OHC losses in the basal turns were
more severe than in the middle ones. Remarkably, OHC loss in the left ears
(with saline co-treatment) was more severe (10-15% remaining OHCs) than
those in the right ears without cannula (50% remaining OHCs) (F(1,23)=5.20,
P=0.032). This finding is in line with observations in chickens of Roberson et
al. (2000). They found that cannula implantation itself may cause OHC death
and can also cause potentiation of hair cell death induced by systemic gen-
tamicin administration. 
Since the cannula implantation itself seems to have a negative effect on hair
cell survival, the effect of α−MSH co-treatment could only be compared within
the left (implanted) ears. Statistical analysis showed a significant effect of
treatment in the basal turn of the ears co-treated with 2 µg/ml α−MSH as com-
pared to the ears co-treated with saline (F(1,11)=6.05, P=0.032). Co-treatment
with the lowest (0.02 µg/ml) and highest (20 µg/ml) concentration of α−MSH
did not reach statistical significance (F(1,12)=3.94, P=0.071; F(1,10)=2.65,
P=0.135, respectively). 
Figure 6: Outer hair cell counts (percentage remaining OHCs) for the left (implanted) and right ear, as a function of
position in the cochlear turns. Co-treatments: Open bar: saline; light-gray bar: 0.02 µg/ml α−MSH; dark-gray bar: 2
µg/ml α−MSH; black bar: 20 µg/ml α−MSH. Error bars represent S.E.M.
Discussion
α−MSH has a dose-dependent ameliorating effect on cisplatin intoxication
The first issue in this study was whether ameliorating effects of α−MSH on cis-
platin ototoxicity, which were seen in previous studies (Heijmen et al., 1999;
Wolters et al., 2003; Hamers et al., 2003), remain when α−MSH is applied
exclusively perilymphatically as opposed to systemically. This study shows that
intracochlear administration of 2 µg/ml α−MSH, with a mini-osmotic pump,
indeed has an ameliorating effect on cisplatin-induced threshold shifts and the
recovery in time (Figs. 2, 3) and also protects against OHC loss (Fig. 6). The
group that received 0.02 µg/ml α−MSH showed small effects on both CAP and
CM threshold shifts (Figs. 3, 4). With 20 µg/ml α−MSH in the pump, no statisti-
cally significant effects were found. Thus, the intermediate concentration (2
µg/ml in the pump) was the most optimal concentration in this study.
Surprisingly and in contrast to the mirror experiment in which cisplatin was
applied locally and α−MSH systemically (Wolters et al., 2003), we did not find
an increase in the number of injections (days) necessary to evoke ototoxic
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effects at any α−MSH concentration. This discrepancy can probably be
explained by the large inter-animal variability associated with systemic cis-
platin application (Klis et al., 2002) in combination with the relatively small
size of the effect.
However, how can we explain that the highest concentration α−MSH applied
in this study (20 µg/ml in the pump) is not effective while lower concentrations
are? De Koning et al. (1986) found that the ACTH(4-9) analog ORG 2766 has an
ameliorating effect on peripheral nerve regeneration with an inverted U-
shaped dose-effect curve, i.e., low and high doses of ORG 2766 were inactive
and only intermediate doses resulted in enhanced peripheral nerve recovery.
We hypothesize that α−MSH, also an ACTH fragment, has a similar dose-effect
curve for its ameliorating effects on cisplatin ototoxicity and that the highest
dose results in a perilymphatic concentration that is well above the effective
range. A point of concern with this hypothesis is that we do not know the
validity of the comparison between both melanocortins, since we do not know
the (sub)cellular mechanism by which both compounds exert their effects,
neither with respect to enhancing peripheral nerve regeneration by ORG 2766,
nor with respect to ameliorating cisplatin ototoxicity by α−MSH. Nevertheless,
the present study has brought new information about the target of α−MSH.
α−MSH exerts its ameliorating effects on cisplatin-induced ototoxicity through 
a cochlear target 
The most salient result in this study is that the positive effects we found with
α−MSH, applied directly and exclusively to the cochlea, can almost only be
explained by postulating a cochlear target for the compound. Especially in
combination with the mirror study (Wolters et al., 2003), the possibility seems
extremely unlikely that α−MSH works through interaction with a systemic fac-
tor or target. Given the strong possibility of a cochlear target, the question is of
course which target? This is intimately related with the question about the tar-
get for cisplatin in the cochlea. On the basis of earlier data (Hamers et al.,
1994; De Groot et al., 1997; Klis et al., 2000, 2002; O’Leary and Klis, 2002), we
hypothesize that cisplatin toxicity in the cochlea first occurs in the stria vascu-
laris. Interference with strial function leads to a drop in EP (Klis et al., 2000,
2002; O’Leary and Klis, 2002) and subsequently to a large increase of the CAP
threshold. In a causally and yet unknown manner, these events might be relat-
ed to OHC loss, progressing apically from the basal turn. Further, evidence is
accumulating that suggests involvement of spiral ganglion cells (Zheng and
Gao, 1996; Cardinaal et al., 2000b; Alam et al., 2000; Hamers et al., 2003), once
again in an unknown relation to the strial and OHC effects described above. All
these targets for cisplatin need to be considered as cochlear components with
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which α−MSH might interfere.
α−MSH may exert its otoprotective effect by affecting the potency of the stria
vascularis to counteract the effects of cisplatin. In principle, α−MSH might
exert its protective action through activation of the melanocortin-1 receptor,
which is commonly found in epidermal melanocytes. Intermediate cells,
which are necessary for normal strial function and are involved in the genera-
tion of EP, have been identified as melanocytes (Motohashi et al., 1994). Also, it
has been suggested that cochlear melanocytes are under α−MSH control
(Meyer zum Gottesberge, 2000). 
Since melanocortins have shown to exert neuroprotective effects in the
peripheral sensory nerve system after cisplatin administration (De Koning et
al., 1987; Hamers et al., 1993; Ter Laak et al., 2003), the otoprotective effect of
the melanocortin α−MSH might also be related to interference with ganglion
cells or the Schwann cells (Hol et al., 1994). Such an interference would
explain the significantly smaller decrease in CAP amplitude at high sound lev-
els in the 2 µg/ml α−MSH group (Fig. 5). Since the CAP at high stimulus levels is
shown to depend on the viability of the ganglion cells, not so much on the via-
bility of the OHCs (Hall, 1990; Schmiedt et al., 2002).
A direct effect of α−MSH on OHCs is, for lack of data about interference of
melanocortins with hair cells, at present a purely hypothetical possibility. 
Conclusion
The present study provides further evidence for the previously reported protec-
tive effect of α−MSH in cisplatin ototoxicity. The ototoxic effects of cisplatin
were significantly reduced when the animals were co-treated with perilym-
phatically applied α−MSH. This preventive effect was dose-dependent and
rather small, perhaps too small for clinical relevance. Since α−MSH was deliv-
ered directly to the cochlea, it is plausible that the ameliorating effect of α−
MSH involves a cochlear target, possibly the strial melanocytes or the spiral
ganglion cells. 
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Melanocortins, peptides derived from AdrenoCorticoTropic Hormone (ACTH),
such as α−MSH, and derivatives thereof, such as ORG 2766 and melanotan-II
(MT-II), have been shown to protect against cisplatin-induced peripheral neu-
ropathy. Previous experiments performed by our group have also shown 
protective effects of some of these peptides against cisplatin-induced ototoxic-
ity. Based on these results, the aim of this thesis was to further characterize the
protection efficacy of co-treatment with these neurotrophic peptides in 
relation to cisplatin-induced ototoxicity and, subsequently, to analyze the
mechanisms involved. The studies performed were based on the following
questions: 
1) Do ORG 2766, α−MSH and MT-II delay the action of cisplatin? 
2) Do the melanocortins enhance recovery after cisplatin treatment, 
and how? 
3) Is there a neural component in cisplatin ototoxicity or is the effect 
confined to hair cells and stria vascularis? 
4) Is the protective effect a direct local effect of the peptides or does the
effect depend upon a systemic (intermediate) effect? 
5) Can these melanocortin(-like) peptides be used in the clinic as otopro-
tective agents? 
1) Do ORG 2766, α-MSH and MT-II delay the action of cisplatin?
Previous studies, in which a fixed number of injections of 1.5 or 2 mg/kg cis-
platin was administered daily in combination with 75 µg/kg ORG 2766
(Hamers et al., 1994; Stengs et al., 1998b) or 75 µg/kg α−MSH (Heijmen et al.,
1999), demonstrated a considerable number of co-treated animals that dis-
played preserved hearing after cessation of cisplatin and melanocortin treat-
ment. This was not found in the cisplatin/saline controls. In the longitudinal
animal model used in chapters 2, 3, and 4 of this thesis all animals were treat-
ed with cisplatin until a pronounced (criterion of ≥ 40 dB loss at 8 kHz) hear-
ing loss occurred. Following the dichotomous results in the co-treated groups
with the fixed dose experiments, we hypothesized that in the experiments
with the longitudinal model the animals co-treated with ORG 2766 or α−MSH
would require more injections of cisplatin than the saline co-treated animals
to evoke the criterion threshold loss. Unexpectedly, neither α−MSH nor ORG
2766 consistently increased the mean number of cisplatin-injections (1.5
mg/kg/day) necessary to evoke this threshold loss. Also, the melanocortin MT-
II (chapter 2) did not delay cisplatin ototoxicity. This can be explained by the
large variability seen with cisplatin treatment in combination with a relatively
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small effect. In the experiments described in this thesis, the most susceptible
animals required 5 injections of cisplatin before reaching criterion threshold
loss while the most resistant animal required 18 injections (without co-treat-
ment). In such a noisy background only large delays can be proven to be sta-
tistically significant. Nevertheless, in several co-treated animals the onset of
the ototoxic reactions seemed considerably delayed; the animals that required
the highest cumulative dose of cisplatin were usually the co-treated ones,
which might be an explanation of the dichotomy observed by Hamers et al.
(1994), Stengs et al. (1998b), and Heijmen et al. (1999). These studies showed
animals that were completely protected from cisplatin ototoxicity with normal
auditory thresholds and no OHC loss but also animals that demonstrated
increased thresholds similar to the animals treated with cisplatin alone.
In an attempt to decrease the variability in susceptibility to cisplatin an alterna-
tive route of application was used in which we applied cisplatin directly into
the cochlea (chapter 5). With this approach systemic factors that might be
responsible for the large variability associated with systemic treatment could
be eliminated. This experiment indeed showed a statistically significant delay
in the group of animals that were systemically co-treated with α−MSH (75
µg/kg/day s.c.). However, when α−MSH was delivered directly into the cochlea
via an osmotic pump system and cisplatin systemically (chapter 6) again only
a trend was visible, which showed that some animals receiving the high dose
of α−MSH (2 or 20 µg/ml in the pump) required more injections of cisplatin (2
mg/kg/day) to reach the criterion threshold shift than the animals with pure
saline in the pump. Once again, we attribute this lack of effect of α−MSH to the
higher variability associated with systemic application of cisplatin. However,
we can not exclude causes associated with the different mode of application
of α−MSH (local versus systemic).
2) Do the melanocortins enhance recovery after cisplatin treatment,
and how?
Previous experiments by Klis et al. (2000, 2002) showed that when cisplatin
treatment is stopped after reaching the criterion threshold shift, a pronounced
recovery of hearing sensitivity occurs. This recovery reaches asymptotic levels
after 10 days and is better at lower than at higher frequencies. Co-treatment
with the melanocortin(-like) peptides ORG 2766 and α−MSH (chapter 3, 6) sig-
nificantly changed the recovery after cisplatin treatment. Recovery of CAP
threshold and CAP amplitude at high sound pressure levels was faster and
126
Chapter 7
more complete. Furthermore, hair cell loss was significantly lower in the pep-
tide co-treated groups. In contrast to the ameliorating effect of ORG 2766 and
α−MSH, co-treatment with MT-II did not show a significant effect on recovery
(chapter 2), although this compound is a more potent melanocortin-1 (MC1) 
and MC4-receptor agonist than α−MSH. 
Thus, since not all melanocortin(-like) peptides enhance recovery after cis-
platin-induced ototoxicity it is difficult to identify the cochlear target(s) and the
exact cellular mechanism involved in the otoprotective effects of the
melanocortin(-like) peptides. Cisplatin causes pronounced damage to and
even loss of OHCs (Komune et al., 1981; De Groot et al., 1997; Cardinaal et al.,
2000a, b) and spiral ganglion cells (Zheng and Gao, 1996; Cardinaal et al.,
2000b), and damage to the stria vascularis (Nakai et al., 1982; Kohn et al., 1988,
1997; Meech et al., 1998; Cardinaal et al., 2000a). Thus, one or more of these
cochlear components might be involved in the recovery-process. Further 
characterization of the melanocortin-enhanced recovery process might bring
us closer to the actual target of the melanocortins (and cisplatin itself) and
with that the mechanism involved in the otoprotective action of
melanocortins. 
Co-treatment with α−MSH, or its derivatives, might enhance recovery from cis-
platin-induced ototoxicity through activation of the MC1-receptor known to be
present in melanocytes, for instance in the stria vascularis (Hilding and
Ginzberg, 1977). The melanocytes in the stria, the so-called intermediate cells,
have been suggested to be under α−MSH control (Meyer zum Gottesberge,
2000). However, co-treatment with the more potent MC1-receptor agonist MT-
II did not show an enhancement of the recovery-process (chapter 2).
Furthermore, ORG 2766 has no melanotrophic or corticotrophic activity
(Greven and De Wied, 1973) and is known not to activate any of the five cur-
rently known MC-receptor subtypes (Adan et al., 1994, 1996). Since both 
α−MSH and ORG 2766 have similar protective and/or recovery enhancing
effects in models of mechanical peripheral nerve damage (Bijlsma et al., 1984;
Van der Zee et al., 1991) and ototoxicity (Hamers et al., 1994; De Groot et al.,
1997; Stengs et al., 1998b; Heijmen et al., 1999) the question arises whether or
not there is an as yet unidentified receptor for ORG 2766 that can also be 
activated by α−MSH.
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3) Is there a relevant neural component in cisplatin ototoxicity or is 
the effect confined to hair cells and stria vascularis?
On the basis of earlier data (Hamers et al., 1994; De Groot et al., 1997; Klis et
al., 2000), we hypothesized that cisplatin toxicity in the inner ear first occurs in
the stria vascularis, since the endocochlear potential (EP) was decreased early
in the process. Possibly, interference of cisplatin with strial function impairs its
electrogenic activity, leading to a precipitous drop of the EP and a strong
increase in CAP threshold (Hamers et al., 1994). In a causally and yet unknown
manner, these events might be related to OHC loss, progressing apically from
the basal turn. Discontinuation of cisplatin treatment enables the stria vas-
cularis and thus the EP to recover, with concomitant CAP threshold recovery,
provided that a sufficient number of OHCs have survived and are functional.
The preliminary data in chapter 4 of this thesis, however, showed that the 
relation between EP recovery and CAP recovery may not be as strong as sug-
gested above. The EP did not show recovery after 3 days, although significant
recovery of the CAP threshold at 2 kHz was observed. However, CAP 
amplitudes at higher frequencies and at high stimulus levels did not show sig-
nificant recovery in the limited time frame of chapter 4. In other words, we
may have missed an essential part of the recovery process by limiting our time
window to 3 days after cessation of the cisplatin treatment. We cannot rule out
that the melanocortin(-like) peptides might exert their effect through another
target than the stria. Both ORG 2766 (in vivo; Gerritsen van der Hoop et al.,
1988; Muller et al., 1990; Hamers et al., 1993a) and α−MSH (in vitro; Windebank
et al., 1994) have shown to protect from cisplatin-induced peripheral neuro-
pathy. Thus, we cannot exclude the possibility that these compounds (partial-
ly) induce their protective effect in cisplatin-induced ototoxicity through
modulation of a neural component. To date, some evidence for the involve-
ment of the auditory nerve in cisplatin-induced hearing loss has been pub-
lished. Both animal studies (Zheng and Gao, 1996; Alam et al., 2000; Cardinaal
et al., 2000b) and a human study of post-mortem temporal bone material
(Hinojosa et al., 1995) described morphological damage to the spiral ganglion
cells in addition to OHC and strial damage.
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4) Is the protective effect a direct local effect of the melanocortin-like 
peptides or does the effect depend upon a systemic (intermediate)  
effect?
So far we suggested that the melanocortin(-like) peptides ameliorate cisplatin-
induced ototoxicity through a local (cochlear) target. However, since both cis-
platin and the peptides were administered systemically in several studies
(chapters 3 and 4) their effect could also have been mediated through a sys-
temic effect. Such a systemic effect has been found earlier with the anti-oxi-
dants, a group of sulphur containing compounds that are also known to
prevent cisplatin-induced ototoxicity. The sulphur-groups in the anti-oxidants
are known to bind irreversibly to heavy metals such as platinum. When both
cisplatin and anti-oxidants are administered systemically, inactive sulphur-
platinum-complexes are formed which are quickly excreted. This may result in
a lowered systemic exposure to cisplatin, reducing its side effects but probably
also its anti-tumor effect. Indeed, such a reduction in the systemic cisplatin
concentration has been found when cisplatin was administered together with 
D-methionine (Ekborn et al., 2002). Since both ORG 2766 and α−MSH have
been administered in our studies in doses at least 20 times smaller than the
cisplatin dose, the protective effect of these peptides cannot be due to direct
chemical interaction between cisplatin and α−MSH or ORG 2766. 
Another possibility might be that melanocortin(-like) peptides exert their pro-
tective effect through enhancement of cisplatin clearance. The results in both
chapter 5 and chapter 6 invalidate this hypothesis. In chapter 5 it was found
that, despite the fact that cisplatin was administered locally through an 
osmotic pump system, systemic co-treatment with α−MSH significantly altered
the number of days necessary to reach the criterion threshold shift.
Furthermore, in chapter 6, in which α−MSH was administered directly into the
ear and cisplatin systemically, we found small but significant effects on CAP
threshold and OHC loss. Therefore, systemic effects of α−MSH on cisplatin
excretion, or other absorption or transport factors can be excluded. 
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5) Can α-MSH and ORG 2766 be used in the clinic as an 
otoprotective agent? 
With the results from this thesis we hoped to contribute to better understan-
ding of cisplatin ototoxicity, which in turn might provide a key to ameliorate
cisplatin ototoxicity in humans. With this knowledge we also hoped, eventual-
ly, to be able to generalize our results and find medical treatment for other
acute cochlear insults, like those due to carboplatin treatment, aminoglyco-
side antibiotic treatment or even noise-induced hearing loss. The first part of
this objective was reached. We showed that α−MSH does not delay the onset
of cisplatin effects when cisplatin is applied systemically, but it enhances
recovery and partly prevents OHC loss. The experiments with local application
of cisplatin or α−MSH showed that α−MSH does not cause its effect through
direct interaction with cisplatin or through stimulation of cisplatin excretion,
but that the ameliorating effect of α−MSH probably involves a cochlear target,
possibly the strial melanocytes or the spiral ganglion (nerve) cells. Thus, the
results from this thesis confirm that α−MSH may be used to reduce cisplatin-
induced ototoxicity. Also, the fact that α−MSH and its analogs show little side
effects in clinical studies (Gerritsen van der Hoop, 1990; Wessels et al., 2000)
pleads for introduction of the melanocortin-like peptides as a treatment for cis-
platin-induced ototoxicity. However, this thesis shows that the protective
effects of these peptides are rather small and that the effect varies consider-
ably between individuals. This seriously hampers the introduction of these
peptides as an otoprotective agent in patients. More research, especially about
the dose-effect relationship of the peptides, has to be performed. Furthermore,
the mechanism through which cisplatin exerts its ototoxic effects is such a
complicated process that further research, especially at the morphological and
molecular level, is necessary to reliably identify both the cochlear targets and
the exact cellular mechanism involved in the otoprotective effect of the
melanocortin(-like) peptides. The research performed within this thesis
brought us a step closer to the unraveling of the mechanism of cisplatin-
induced ototoxicity and ways and means to protect the ear against this highly
potent ototoxicant. 
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Cisplatine is een belangrijk geneesmiddel voor de behandeling van hoofd- en
halstumoren, longkanker en kanker aan de eierstokken of teelballen. Helaas
kan behandeling met cisplatine gepaard gaan met een aantal schadelijke
effecten, zoals schade aan de zenuwen (neurotoxiciteit) en verslechtering van
het gehoor (ototoxiciteit). Patiënten, die behandeld worden met cisplatine,
kunnen een gehoorverlies ontwikkelen dat wordt gekarakteriseerd door een
tweezijdig, meestal permanent verlies van de hoge tonen. Herstel van dit ver-
lies treedt sporadisch op en is meestal slechts gedeeltelijk. Uit experimenten
in proefdieren is gebleken dat een langdurige cisplatinebehandeling leidt tot
verlies van de buitenste haarcellen, voornamelijk in de basale winding van het
slakkenhuis (cochlea). Daarnaast kan cisplatine in het oor ook de cellen in de
stria vascularis (de bloedvoorziening) en de spirale ganglioncellen (zenuw-
cellen) beschadigen. Deze drie structuren in de cochlea zijn betrokken bij het
omzetten van de geluidsgolven in zenuwactiviteit. De buitenste haarcellen zor-
gen voor de versterking van de geluidsgolven. De stria vascularis is belangrijk
voor de handhaving van de elektrolytische compositie en de endocochleaire
potentiaal (EP) van de endolymfe (de vloeistof in de scala media), welke
noodzakelijk zijn om de elektrische signalen in de haarcellen op te kunnen
wekken. De spirale ganglioncellen zorgen voor de geleiding van de zenuwim-
pulsen naar de hersenen. Wanneer een of meer van de bovengenoemde
structuren beschadigd wordt, kan verlies van (een deel van) het gehoor 
optreden. 
Diverse pogingen zijn ondernomen om de bijwerkingen van cisplatine te ver-
minderen, o.a. door het doseringsschema te wijzigen, door de wijze van toe-
diening te veranderen of zelfs door cisplatine te vervangen door een minder
schadelijk antitumormiddel. Helaas hebben deze methoden tot op heden de
bijwerkingen slechts gering kunnen verminderen. Verschillende onderzoeks-
groepen zijn zich dan ook gaan concentreren op een andere methode om
gehoorschade te verminderen: namelijk de farmacologische interventie. Bij
deze methode wordt tegelijkertijd met cisplatine een andere stof toegediend
die de bijwerkingen moet verminderen, maar geen invloed mag hebben op de
antitumorwerking. Tegenwoordig bestaan er verschillende groepen stoffen die
de door cisplatine veroorzaakte gehoorschade kunnen verminderen of in som-
mige gevallen zelfs helemaal kunnen voorkomen. Voorbeelden daarvan zijn
de anti-oxidanten, de groeifactoren en de melanocortinen. Anti-oxidanten
moeten echter in grote hoeveelheden worden toegediend. Bovendien berust
hun werking waarschijnlijk op het wegvangen van cisplatine. Het laatst
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genoemde heeft tot gevolg dat er minder cisplatine beschikbaar is voor de
antitumorwerking. Bij de groeifactoren is bewezen dat ze in celsystemen een
beschermend effect hebben op de door cisplatine veroorzaakte haarcel-
schade. Echter, in proefdieren is een beschermende werking van deze stoffen
nog niet aangetoond. Onze onderzoeksgroep heeft zich daarom op de
beschermende eigenschappen van de melanocortinen gericht. 
De melano-cortinen zijn de van adrenocorticotroop hormoon (ACTH) afgelei-
de neuropeptiden, waarvan een aantal neuroprotectieve eigenschappen
heeft. Van zowel het lichaamseigen α−melanocyt stimulerend hormoon 
(α−MSH) als een synthetisch fragment daarvan (ORG 2766) is in het verleden
aangetoond dat ze zowel zenuwen kunnen beschermen als de schadelijke
effecten van cisplatine kunnen verminderen. Helaas liet bovengenoemde
studie zien dat er naast dieren die volledig beschermd waren tegen de
effecten van cisplatine er ook dieren waren die in het geheel niet beschermd
werden. Uit deze tweedeling blijkt dat de optimale balans tussen de dosis 
cisplatine en melanocortine nog niet gevonden is. Daarnaast is het
onderliggende mechanisme van zowel de ototoxische werking van cisplatine
als de beschermende werking van de melanocortinen hierop momenteel nog
niet duidelijk. Onze onderzoeksgroep vermoedt dat de neuropeptides in het
binnenoor een herstelmechanisme bevorderen.
Het doel van dit promotieonderzoek was om de mogelijk beschermende
werking van de melanocortinen op het binnenoor na behandeling met cispla-
tine nader te bestuderen. Daarbij is onderzocht of de melanocortinen ORG
2766, α−melanocyt stimulerend hormoon (α−MSH) en het cyclisch, van 
α−MSH afgeleide peptide melanotan-II (MT-II) in staat zijn om de ototoxische
bijwerkingen van cisplatine uit te stellen en is onderzocht of ze een her-
stelmechanisme kunnen bevorderen. Tevens werd bestudeerd of het effect
van de melanocortinen een lokaal effect in het binnenoor is of dat de
melanocortinen ergens anders in het lichaam processen beïnvloeden waar-
door cisplatine sneller uitgescheiden wordt. 
In het onderzoek is gebruik gemaakt van een longitudinaal diermodel. In dit
model werden cavia’s geïmplanteerd met een permanente elektrode op het
ronde venster van de cochlea. Met de electrode werd dagelijks de gevoe-
ligheid van het gehoororgaan voor geluid (piepjes), met afnemende geluids-
sterkte, in het frequentiegebied van 2 tot 16 kHz bepaald. Hierbij werd
gekeken naar de minimale geluidssterkte waarbij nog een reactie van de
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gehoorzenuw wordt waargenomen (CAP drempel) en de grootte van de
zenuwimpuls bij harde geluidsniveaus (CAP amplitude). Na het bereiken van
een bepaald criterium (40 dB drempelverlies bij 8 kHz) was het mogelijk om
de cisplatinebehandeling te staken en vervolgens de drempelbepalingen voort 
te zetten zodat een (mogelijk) herstel van de gehoordrempel vastgesteld kon
worden. 
In hoofdstuk 2 is aangegeven hoe met behulp van het longitudinale diermodel
het beschermend effect van het cyclisch, van α−MSH afgeleide peptide,
melanotan-II (MT-II) getest is. Van MT-II heeft men in het verleden laten zien
dat het beter bindt aan de melanocortine-receptor dan α−MSH en dat behan-
deling in ratten bescherming kan bieden tegen de door cisplatine veroorzaak-
te zenuwschade. In ons experiment werden cavia’s dagelijks geïnjecteerd met
1.5 mg/kg cisplatine en vervolgens met MT-II (3 of 30 µg/kg) of een zoutoplos-
sing (controle). Na 5 tot 13 dagen trad, onafhankelijk van de toegediende con-
centratie MT-II, bij alle cavia’s een gehoorverlies op. Daarna werd de
behandeling met cisplatine gestaakt en werd nog een extra injectie van MT-II
of zoutoplossing gegeven. De gehoordrempel werd nog gedurende 4 weken
gecontroleerd op een mogelijk herstel van het gehoorverlies. Het bleek dat
binnen 10 dagen nadat de cisplatinebehandeling was gestopt in alle drie de
groepen en bij alle frequenties een herstel van de gehoordrempel optrad. Dit
herstel was beter bij lage stimulus frequenties. Helaas werd in de dieren die
behandeld waren met één van de twee MT-II concentraties geen extra toe-
name van het herstel waargenomen. In tegenstelling tot de eerder gevonden
beschermende effecten van de andere melanocortinen en de beschermende
werking van MT-II bij cisplatine neurotoxiciteit laat MT-II geen beschermend
effect zien op de door cisplatine veroorzaakte gehoorschade.
In hoofdstuk 3 is beschreven hoe in hetzelfde longitudinale diermodel de
beschermende effecten van twee andere melanocortinen, te weten α−MSH en
ORG 2766, op de door cisplatine veroorzaakte gehoorschade zijn getest.
Wederom werden cavia’s dagelijks behandeld met 1.5 mg/kg cisplatine en 75
µg/kg α−MSH, 75 µg/kg ORG 2766 of een zoutoplossing totdat een gehoorver-
lies van 40 dB bij 8 kHz optrad. Vervolgens werden twee groepen gevormd. Bij
de eerste groep dieren werd 1 tot 2 dagen na het drempelverlies de endo-
cochleaire potentiaal (EP) gemeten. Na de EP meting werden de cochleas van
de cavia’s bewerkt voor de histologie, zodat de effecten van cisplatine ook op
cellulair niveau bekeken konden worden. Bij de overige dieren werd de EP 28
dagen na het beëindigen van de cisplatinebehandeling gemeten. Zowel de
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dieren die behandeld waren met α−MSH of ORG 2766 als de dieren die behan-
deld werden met zoutoplossing lieten na 5 tot 14 injecties cisplatine een drem-
pelverlies van 40 dB bij 8 kHz zien. Na beëindiging van de cisplatine-
behandeling trad in alle drie de groepen een herstel op van zowel de CAP
drempelwaardes als de CAP amplitude. Dit herstel bleek significant beter te
zijn bij dieren die behandeld waren met α−MSH of ORG 2766. Bovendien
lieten deze met melanocortine behandelde dieren ook minder haarcelverlies
zien in de basale winding dan de dieren die met de zoutoplossing waren
behandeld. Hieruit kan worden afgeleid dat zowel ORG 2766 als α−MSH een
beschermende werking blijken te hebben op door cisplatine veroorzaakte
gehoorschade. 
Het bovenstaande onderzoek met α−MSH en ORG 2766 liet zien dat, alhoewel
de endocochleaire potentiaal (EP) verlaagd was gedurende de eerste dagen
na het beëindigen van de cisplatinebehandeling, deze potentiaal na 28 dagen
weer volledig hersteld was. Dit deed vermoeden dat het herstel van de CAP en
het beschermend effect van de melanocortinen mogelijk gerelateerd zou kun-
nen zijn aan het herstel van de schade aan de stria vascularis en aan het her-
stel van de EP. Om dit verder te onderzoeken werd met behulp van het
longitudinale diermodel de aandacht gericht op de effecten van cisplatine,
met of zonder α−MSH, op het herstel van de EP (hoofdstuk 4). Cavia’s werden
behandeld met 1.5 mg/kg cisplatine tot het moment dat het gehoorverlies
optrad. Vervolgens werden de dieren in drie groepen verdeeld waarbij na 1, 2
of 3 dagen herstel de EP werd gemeten. Net als in de voorgaande studies had-
den de dieren 4 tot 10 dagen cisplatine nodig om het gehoorverlies te
bereiken. De EP bleek, bij het bereiken van een drempelverlies van 40 dB bij 8
kHz, van de normale waarde tussen 75 en 85 mV verlaagd te zijn tot een
waarde van gemiddeld 58 mV. Echter, anders dan verwacht was op basis van
de resultaten van hoofdstuk 3 liet de EP geen herstel zien binnen de twee
dagen na de beëindiging van de cisplatinebehandeling. Behandeling met 
α−MSH bleek noch effect te hebben op het verlies noch op het herstel van de
EP. Daar de CAP drempels toch een klein herstel lieten zien bij de lage fre-
quenties en de met α−MSH behandelde dieren op dag 3 een significant hogere
CAP amplitude lieten zien dan de controledieren, werd voorlopig gecon-
cludeerd dat α−MSH niet alleen een effect heeft op de stria vascularis, maar
dat de beschermende werking van deze stof mogelijk complexer is dan tot op
heden was aangenomen. 
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Om meer inzicht te krijgen via welk mechanisme α−MSH zijn beschermend
effect teweegbrengt, werd een nieuw diermodel geïntroduceerd, waarbij
naast de elektrode op het ronde venster ook een osmotisch pompje met de
cochlea van de cavia werd verbonden. Met behulp van dit osmotisch pomp-
systeem was het mogelijk om continu een (beschermende) stof direct in de
cochlea toe te dienen. Experimenten met deze osmotische pompjes hebben
in het verleden laten zien dat door deze methode door toediening de 
variabiliteit tussen de dieren verkleind kan worden, doordat de individuele
(systemische) effecten van de dieren, zoals bijv. de zuivering van de nieren of
de snelheid van uitscheiden, worden omzeild. 
Vervolgens is met behulp van dit nieuwe proefdiermodel een oplossing van 15
µg/ml cisplatine door middel van een osmotisch pompje continu met een
snelheid van 0.5 µl/uur in de cochlea gepompt (hoofdstuk 5). De canule tussen
de pomp en de cochlea werd gevuld met een zoutoplossing waardoor de
cavia’s nog anderhalve dag konden herstellen van de operatie voordat de cis-
platine het oor bereikte. Bovendien werden de cavia’s dagelijks behandeld
met een injectie van 75 µg/ml α−MSH of een zoutoplossing totdat een 40 dB
gehoorverlies bij 8 kHz optrad. Dit gehoorverlies werd in de zoutgroep na 2 tot
3 dagen intracochleaire toediening van cisplatine bereikt. Bij de dieren die
behandeld waren met α−MSH trad dit gehoorverlies een dag later op. De
haarceltellingen, welke gedaan werden op het moment dat de dieren de 40
dB drempelverlies bereikt hadden, lieten geen verschil zien tussen de beide
behandelingen. Dit duidt erop dat beide behandelde groepen hetzelfde eind-
punt bereikt hadden. Met andere woorden α−MSH is in dit nieuwe diermodel
in staat om de schadelijke effecten van cisplatine met 1 dag uit te stellen. Daar
cisplatine direct in de cochlea werd toegediend en α−MSH via een injectie,
kan uit deze studie geconcludeerd worden dat de beschermende werking van
α−MSH waarschijnlijk te maken heeft met een interactie met een van de cel-
structuren in de cochlea. 
Om de bovenstaande studie te completeren werd, zoals beschreven in hoofd-
stuk 6, een experiment met de omgekeerde opzet uitgevoerd. Cavia’s werden
geïmplanteerd met een permanente elektrode en een osmotisch pompje dat
met een snelheid van 0.25 µl/uur een zout-, of een α−MSH-oplossing (0.02, 2 of
20 µg/ml) in de cochlea pompte. Daarnaast werden de dieren dagelijks via
injecties behandeld met 2 mg/kg cisplatine totdat een drempelverlies van 40
dB bij 8 kHz optrad. Vervolgens werd de cisplatinebehandeling gestaakt, maar
de electrocochleografie en de intracochleaire toediening van α−MSH werden
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nog gedurende 10 dagen voortgezet om een eventueel herstel te kunnen
meten. De norm voor het gehoorverlies werd na 5 tot 11 dagen cisplatine-
behandeling bereikt, wat overeen komt met eerder gevonden resultaten. Uit
dit onderzoek bleek verder dat vooral de groep dieren met 2 µg/ml α−MSH in
de osmotische pomp minder verlies liet zien van de CAP drempelwaardes bij
lage frequenties. Ook het haarcelverlies in de basale winding was voor deze
groep dieren significant minder dan in de met zout behandelde dieren. De
dieren met 0.02 µg/ml of 20 µg/ml α−MSH lieten geen significant beter herstel
zien dan de met zout behandelde dieren. Kortom: de resultaten uit deze studie
laten wederom zien dat α−MSH een bescherming biedt tegen cisplatine
gehoorschade. Omdat α−MSH lokaal toegediend is kunnen we, overeenkom-
stig de eerder gevonden resultaten (hoofdstuk 5), ervan uitgaan dat de
beschermende werking van α−MSH bij cisplatine gehoorschade te maken
heeft met één van de cochleaire celstructuren, hoogstwaarschijnlijk de stria
vascularis of de spirale ganglioncellen.
Met de resultaten van dit promotieonderzoek hopen we een bijdrage te kun-
nen leveren aan een beter inzicht in de beschermende effecten van α−MSH op
de door cisplatine veroorzaakte gehoorschade, wat vervolgens weer een
handvat zou kunnen bieden om cisplatine-ototoxiciteit in mensen te behande-
len. Uiteindelijk zou deze kennis mogelijk ook van pas kunnen komen bij de
behandeling van gehoorschade veroorzaakt door behandeling met carbopla-
tine, aminoglycosides of zelfs bij de behandeling van gehoorschade veroor-
zaakt door lawaai. We hebben aangetoond dat α−MSH de door cisplatine
veroorzaakte gehoorschade niet in alle gevallen uitstelt, maar dat behandeling
wel een beter herstel van de gehoordrempel teweeg kan brengen en dat
behandeling met α−MSH gedeeltelijk kan beschermen tegen buitenste
haarcelverlies. Het experiment waarbij cisplatine lokaal aangeboden werd,
demonstreerde dat de beschermende werking van α−MSH niet veroorzaakt
wordt door een directe interactie met cisplatine of door bevordering van de
uitscheiding van cisplatine, maar dat de beschermende werking van α−MSH
waarschijnlijk te maken heeft met effecten op één van de celstructuren in de
cochlea, mogelijk de stria vascularis of de spirale ganglioncellen. De resultaten
van dit proefschrift bevestigen dat α−MSH gebruikt zou kunnen worden om de
door cisplatine veroorzaakte schadelijke bijwerkingen op het gehoor te behan-
delen. Ook het feit dat α−MSH en analoge stoffen weinig bijwerkingen laten
zien in klinische studies pleit voor de introductie van melanocortinen bij de
behandeling van cisplatine ototoxiciteit. Dit proefschrift laat echter ook zien
dat de beschermende effecten van de melanocortinen betrekkelijk klein zijn
en dat er veel variabiliteit is tussen de verschillende individuen. Dit staat de
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introductie van deze peptiden als otoprotectieve agentia bij patiënten in de
weg. Meer onderzoek, met name naar de dosis-effect relatie is nodig.
Bovendien blijkt het mechanisme waardoor cisplatine zijn schadelijke
effecten in het oor teweegbrengt zo complex dat ook op dit punt meer onder-
zoek nodig is. Zowel het cochleair doelorgaan als het precieze cellulaire
mechanisme dat betrokken is bij de beschermende effecten van de
melanocortinen zijn tot op heden nog niet bekend. Toch heeft het onderzoek,
beschreven in dit proefschrift, ons én een stap dichter bij het ontrafelen van
het mechanisme van door cisplatine veroorzaakte gehoorschade gebracht, én
bovendien dichter bij een middel om het oor tegen het sterk ototoxische cis-
platine te beschermen.
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Gedurende de afgelopen vier jaar heb ik in Utrecht met veel plezier aan mijn
promotieonderzoek gewerkt. De resultaten die ik met dit onderzoek verkregen
heb, mocht ik op een aantal belangrijke internationale congressen presen-
teren. Zo heb ik congressen bijgewoond in Uppsala (Zweden), Florida (USA),
Luik (België) en Dresden (Duitsland). Daarnaast heb ik gedurende 3 maanden
extra ervaring op kunnen doen in Ann Arbor (USA) op het gebied van het
implanteren van osmotische pompjes. Maar één van de hoogtepunten was de
avond van Wetenschap en Maatschappij in oktober 2001. Als vertegenwoordi-
ger van de belangenvereniging AIO’s/OIO’s Utrecht (BAU) mocht ik een diner
in de Ridderzaal bijwonen, waar een groot aantal prominenten uit zowel de
wetenschap, de politiek als de sport voor waren uitgenodigd. Gedurende deze
avond heb ik met een aantal bekende Nederlanders waaronder Z.K.H. Prins
Willem Alexander, Mevr. Hanja Maj-Weggen, Thom de Graaf en de directeuren
van Philips en Unilever van gedachten kunnen wisselen over de voor- en
nadelen van het promoveren. Een promotie heeft namelijk naast hele leuke
momenten toch ook moeilijke momenten. De beruchte “man met de hamer”
ben ik ook zeker tegengekomen. Maar dankzij het luisterend oor en de vele
motiverende opmerkingen van familie, vrienden en collega’s heb ik me
gelukkig ook door deze moeilijke periodes heen kunnen slaan.
Allereerst zou ik graag mijn promotor Professor Smoorenburg willen noemen.
Ondanks uw vaak drukke schema, was u er altijd op de momenten dat ik u
nodig had. De opbeurende en motiverende commentaren zorgden ervoor dat
ik na iedere werkbespreking weer nieuwe ideeën had voor mijn experi-
menten en artikelen. Ook mijn beide co-promotoren Sjaak Klis en Frank
Hamers zijn mij tot grote steun geweest. Niet alleen door hun positieve kri-
tieken over mijn artikelen, maar ook door hun hulp in de weekenden bij het
verrichten van experimenten. Naast de hulp bij het uitdenken en opzetten van
experimenten heb ik ook veel gehad aan de mensen die me vooral tijdens de
experimenten bij stonden. Rick Mansvelt Beck en Rene van Vossen wil ik van
harte bedanken voor de vele elektrodes die ze voor mij hebben gemaakt,
Henk te Biesebeek voor de ruim tweehonderd pompjes die hij heeft
aangepast en Ferry Hendriksen en John de Groot voor de werkzaamheden op
histologisch gebied. Maar ook de hulp bij de operaties van Jeroen Wijbenga en
Thijn de Vocht heb ik erg gewaardeerd.
Naast het werk moet er ook tijd zijn voor ontspanning. Met de collega’s van het
histolab heb ik heel wat uurtjes doorgebracht in de kantine. John, Marjolein,
Ferry en Frits bedankt dat ik bij jullie mijn hart kon luchten als niet alles ging
zoals ik dat wilde. Naast de vele KNO medewerkers, Helmholtz AIO’s en RMI
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AIO’s wil ik met name mijn collega AIO’s Marjolein, Rolph en Natalie en de
AIO’s van de BAU bedanken voor de prettige tijden en goede gesprekken over
de typische AIO-perikelen en de gezelligheid tijdens borrels, retraites en
congressen. I also want to thank Joe Miller, Diane Prieskorn and other 
co-workers of the Kresge Research Hearing Institute for their help and distrac-
tion during my stay in Ann Arbor. I especially want to thank Susan Blake, Marta
Dzaman and Woitek Lesniak for their company and excursions to parts of
Michigan I could not and would not have visited without them. 
Ook met mijn vrienden en vriendinnen, met name Cathalijn, Marieke
Kruijssen en mijn studiegenoten van Bio-Farmaceutische wetenschappen:
Aukje, Ine, Reshma, Marieke, Suzanne, Roos, Mascha, Heidi en hun partners
heb ik lief en leed kunnen delen tijdens onze etentjes en tijdens de treinreizen
van en naar Utrecht. 
Mijn ouders, maar ook mijn zus Yvette en broer Elwin, ben ik erg dankbaar
voor de steun, interesse en motivatie die ze me hebben gegeven waardoor ik
deze periode succesvol af heb kunnen sluiten.
Tot slot: Ad, jouw liefde, geduld, steun en begrip hebben me geholpen om vol
te houden en binnen de gestelde tijd dit proefschrift af te ronden.     
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